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Murine gammaherpesvirus 68 (MHV-68) is used as a model for the study of 
gammaherpesvirus infection and pathogenesis. In the left region of the genome 
MHV-68 encodes four unique genes, eight viral tRNA-like molecules (vtRNAs) and 
nine miRNAs. The vtRNAs have a predicted cloverleaf-like secondary structure like 
cellular tRNAs and are processed into mature tRNAs with the addition of 3’ CCA 
termini, but are not aminoacylated. Their function is unknown; however they have 
been found to be expressed at high levels during both lytic and latent infection and 
are packaged in the virion. The miRNAs are expressed from the vtRNA primary 
transcripts during latent infection. All herpesviruses examined to date have been 
found to express miRNAs. These are thought to aid the viruses in avoiding the host 
immune response and to establish and maintain latency. 
The aim of this project was to investigate the functions of the vtRNAs and miRNAs 
of MHV-68. MHV-76 is a natural deletant mutant lacking the unique genes, vtRNAs 
and miRNAs. This virus was previously used in our lab to construct two insertion 
viruses encoding vtRNAs1-5 and miRNAs1-6. The only difference between  
MHV-76 and the insertion viruses is therefore the vtRNAs and miRNAs. The B-cell 
line NS0 was latently infected with the various viruses and the infected cells 
characterised. In situ hybridisation and antibody staining showed that all viruses 
infect the same proportion of cells. The insertion viruses were confirmed to express 
the vtRNAs during latency by RT-PCR. In addition, using Northern blot analysis the 
insertion viruses were shown to express miRNA1 during lytic infection of fibroblast 
cells; however, not during latent infection of NS0 cells. The lack of miRNA1 
expression during latency was confirmed using qRT-PCR and miRNAs3-6 were 
found to be expressed at a lower level than in MHV-68 infected cells.  
Replication and reactivation kinetics of latently infected NS0 cells showed that 
introduction of vtRNAs and miRNAs into MHV-76 causes a reduction in 
reactivation and production of lytic virus. To determine if the reduction in 
reactivation was caused by the miRNAs, they were introduced into infected cells by 
transfection. Transfection of miRNAs1-6 into MHV-76 infected cells or miRNA1 
into insertion virus infected cells did not lead to an increase or decrease in 
 
 v
reactivation. It was confirmed by qRT-PCR that the transfection did result in miRNA 
levels higher than in insertion virus infected cells. Further, down-regulation of 
miRNAs using a siRNA against DICER did not lead to a reduction in reactivation. 
This supports the hypothesis that the vtRNAs rather than the miRNAs are 
responsible for the reduction of reactivation seen in insertion virus latently infected 
cells.  
To determine the effect of the non-coding RNAs on protein expression, NS0 cells 
latently infected with MHV-76 and insertion virus were analysed using cleavable 
ICAT and 1-D PAGE cleavable ICAT. In an ICAT analysis the proteins are labelled 
and the levels of individual proteins in two samples can be compared using mass 
spectrometry. These techniques were optimised and several proteins with differences 
in expression between the viruses were identified. It was, however, difficult to 
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1.1. Herpesviruses 
Herpes can be traced back to the ancient Greeks describing the lesions appearing to 
“creep or crawl” along the skin (Roizman and Whitley 2001). The order of 
Herpesvirales is a very large order of viruses containing approximately 135 members 
found to infect most animal species ranging from humans to frogs and oysters 
(Davison et al. 2009). The different members are diverse in terms of genomic 
sequence; however, they are all similar in terms of structure and genome 
organisation. There is large variation in the diseases caused by the viruses, e.g. 
encephalitis, chickenpox and cancer; however, they share several significant 
biological properties. They all encode a variety of enzymes involved in nucleic acid 
metabolism, DNA synthesis and protein processing. The genome replication and 
capsid assembly takes place in the nucleus, while the final processing of the virion 
takes place in the cytoplasm. Upon release of new virus particles the cell is 
destroyed. Another common feature among the members is the ability to remain 
latent in the host with the possibility of reactivation to a lytic infection at a later 
stage. During latency the viral genome is maintained as circularised DNA in an 
episome with very limited gene expression (Pellet and Roizman 2007).  
There are also differences in the biological properties of the viruses: some have very 
narrow host cell ranges and some wider, while replication cycles can be long or very 
short. The cell choice for latency also differs between viruses. Most animal species 
can be infected by at least one herpesvirus; however, few viruses infect more than 
one species (Pellet and Roizman 2007). There are eight herpesviruses associated with 
human disease (Table 1.1).  
1.1.1. Classification 
The herpesviruses were initially ordered under the Herpesviridae family into three 
subfamilies based on biological properties: the Alphaherpesvirinae, the 
Betaherpesvirinae, and the Gammaherpesvirinae. The viruses have further been 
classified using DNA sequence homology, similarities in genome sequence 
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Alphaherpesvirinae Simplexvirus Herpes simplex virus 1 and 2 Encephalitis, Genital herpes
Varicellovirus Varicella-zoster virus Chickenpox, Herpes zoster
Mardivirus Marek's disease virus
Iltovirus Pacheco's disease virus
Subfamily
Betaherpesvirinae Cytomegalovirus Human cytomegalovirus Mononucleosis
Muromegalovirus Mouse cytomegalovirus







Gammaherpesvirinae Lymphocryptovirus Epstein-Barr virus Infectious mononucleosis, 
Burkitt's lymphoma






Macavirus Malignant catarrhal fever virus
Percavirus Equine herpesvirus 2 and 5
Family
Alloherpesviridae Ictalurivirus Channel catfish virus
Family
Malacoherpesviridae Ostreavirus Oyster herpesvirus
 
Table 1.1 Classification of herpesviruses in the order of Herpesvirales, with examples of 
viruses for each genus. The eight human herpesviruses are in red. Adapted from 
Davison et al. 2009. 
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arrangement, and relatedness of important viral proteins (Pellet and Roizman 2007). 
Recently this led to a revision of the herpesvirus classification by the Herpesvirus 
Study Group of the International Committee on Taxonomy of Viruses (ICTV). A 
new order, the Herpesvirales, was established which includes three virus families 
(Table 1.1): the Herpesviridae (the herpesviruses of mammals, birds and reptiles, 
still under three subfamilies), the Alloherpesviridae (fish and frog viruses), and the 
Malacoherpesviridae (bivalve viruses) (Davison et al. 2009). Subsequent chapters 
will focus on the family Herpesviridae.  
1.1.1.1. Alphaherpesvirinae 
The alphaherpesvirus subfamily includes the genera Simplexvirus (e.g. Herpes 
simplex virus 1 and 2 (HSV-1 and HSV-2)), Varicellovirus (e.g. Varicella-zoster 
virus (VZV)), Mardivirus (e.g. Marek’s disease virus (MDV)) and Iltovirus  
(e.g. Pacheco’s disease virus (PDV)). The alphaherpesviruses have a variable host 
range and relatively short replication cycle with rapid spread in culture, leading to 
efficient destruction of the host cell. These viruses establish latency primarily but not 
exclusively in sensory ganglia (Pellet and Roizman 2007). MDV is different from the 
other alphaherpesviruses in that it establishes latency in T-cells and causes T-cell 
lymphoma (Osterrieder et al. 2006). 
1.1.1.2. Betaherpesvirinae 
The betaherpesvirus subfamily consists of genetically diverse viruses in the genera 
Cytomegalovirus (e.g. Human cytomegalovirus (HCMV)), Muromegalovirus  
(e.g. Mouse cytomegalovirus (MCMV)), Roseolovirus (Human herpesvirus 6 and 7 
(HHV-6 and HHV-7)), and Proboscivirus (Elephant endotheliotropic herpesvirus). 
These viruses exhibit restricted host range and have a long replication cycle and slow 
replication in cell culture. Infection of cells often leads to the characteristic 
cytomegalia, enlargement of the cell. The betaherpesviruses can persist in 
mononuclear cells, salivary glands, kidneys and other tissues (Mocarski et al. 2007).  
1.1.1.3. Gammaherpesvirinae 
The members of the gammaherpesvirus subfamily are characterised by having a 
narrow host range both in terms of the cell type and the host species they infect.  
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In vitro work is limited as the viruses have varied ability to replicate in cultured cells, 
with only some of the viruses being able to undergo lytic replication in epithelial and 
fibroblast cell lines. The gammaherpesviruses have slow replication cycles and 
establish latency in lymphocytes. These viruses are often associated with 
lymphoproliferative disease. This subfamily includes the genera Lymphocryptovirus 
(e.g. Epstein-Barr virus (EBV)), Rhadinovirus (e.g. Kaposi’s sarcoma-associated 
herpesvirus (KSHV), Murine gammaherpesvirus 68 (MHV-68) and Herpesvirus 
saimiri (HVS)), Macavirus (e.g. Malignant catarrhal fever virus) and Percavirus  
(e.g. Equine herpesvirus 2 and 5).  
1.1.2. Herpesvirus structure 
The herpesvirus virions consist of four distinct structures: the core, capsid, tegument 
and envelope (Figure 1.1). The core containing the linear double stranded (ds) DNA 
genome is found within an icosahedral (triangulation number T=16) capsid, 100nm 
in diameter, composed of 162 capsomeres (150 hexons and 12 pentons)  
(Pellet and Roizman 2007). The capsid consists of five conserved proteins: the major 
capsid protein, the triplex monomer and dimer proteins, the small capsomer-
interacting protein and the portal protein (Mettenleiter et al. 2006). The capsid is 
surrounded by the tegument, an amorphous layer consisting of several proteins both 
viral and cellular, that links the capsid and the envelope, the outer layer of the virion 
made up of host-cell derived lipid membranes containing viral proteins and 
glycoproteins of varying numbers. Herpesvirus virions vary in size from 120 to 
260nm; partly because of the variability of the thickness of the tegument  
(Pellet and Roizman 2007).  
The virions contain a varying number of viral and host proteins with between 14 and 
71 viral proteins and up to 71 host proteins identified. Several herpesvirus virions 
have also been reported to include viral and cellular messenger RNAs (mRNAs), 
both through apparent selective (Bechtel et al. 2005; Bresnahan and Shenk 2000; 
Cliffe et al. 2009b; Sciortino et al. 2001) and non-selective uptake (Greijer et al. 
2000; Terhune et al. 2004). In addition to mRNAs, non-coding RNAs have been 
found to be present in herpesvirus virions; the non-coding the polyadenylated nuclear 
(PAN) RNA in KSHV virions (Bechtel et al. 2005) and viral tRNAs (vtRNAs) in  





Figure 1.1 The structure of the KSHV virion, used as a representation of a typical 
herpesvirus virion. Showing the four distinct structures: the core, capsid, tegument and 
envelope. Taken from PRN Notebook; www.prn.org 
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MHV-68 virions (Cliffe et al. 2009b). The reason for the presence of viral and host 
proteins and RNAs in the virion is not clear. Packaging them in the virion would 
mean that they are available for the virus immediately following infection of the cell, 
facilitating the takeover of the cell. Alternatively, they may have a structural role in 
the virion, perhaps by forming the tegument. 
1.1.3. Herpesvirus genome 
Genomes of the Herpesviridae consist of large, linear, dsDNA ranging from 124 kbp 
(Simian VZV) to 241 kbp (Chimpanzee CMV); however, upon entry into the cell the 
DNA circularises forming an episome. The genomes also have great variation in 
nucleotide composition with the G+C content varying from 31% to 77%. The 
herpesvirus genomes can be divided into six groups based on the presence and 
localisation of internal and terminal repeat regions (A-F, Figure 1.2)  
(Pellet and Roizman 2007). The variation in genome lengths of the viruses is the 
result of varying copy numbers of the terminal and internal repeats. 
The majority of herpesvirus genomes encode between 70 and 200 open reading 
frames (ORFs). A typical ORF is flanked by 5’ and 3’ non-translated sequences of 30 
to 300 bp and 10 to 30 bp respectively, with a polyadenylation signal at the 3’ end. 
The transcription initiation site is 20 to 25 bp downstream of a TATA box, which is 
50 to 200 bp downstream of the promoter and regulatory sequences  
(Pellet and Roizman 2007). The majority of genes are transcribed by RNA 
polymerase II; however, a few genes such as the EBV encoded small RNAs (EBERs) 
of EBV are transcribed by RNA polymerase III. Most genes are not spliced and  
beta- and gammaherpesviruses have more intron-containing genes than 
alphaherpesviruses (McGeoch et al. 2006). 
The number of predicted ORFs is most likely an underestimation since the 
herpesvirus genomes are complex with alternative splicing, translational frame 
shifting, and antisense and overlapping ORFs. It is common for herpesvirus genomes 
to have clusters of genes overlapping at the 3’ end and sharing a polyadenylation site, 
leading to 3’ co-terminal transcripts. The coding regions of these genes usually do 
not overlap by more than a few codons (Pellet and Roizman 2007). The herpesvirus 
genomes also encode a great variety of non-coding RNAs, for example the 





Figure 1.2 The genome organisations for the different classes of herpesviruses (A-F). 
Group A viruses (e.g. HHV-6) have large sequences of terminal repeats at each end 
(LTR and RTR). Members of group B (e.g. HVS) also have two terminal repeats (TR); 
however, these have a varying copy number of repeats at each end. Group C viruses 
(e.g. EBV) have shorter terminal repeats, but also have internal repeats (IR1-IR4) in 
the unique region of the genome. In group D viruses (e.g. VZV) the terminal repeat is 
repeated in the reverse orientation within the unique region of the genome, dividing the 
genome into the unique long (UL) and unique short (US) region. The short region can 
invert relative to the large sequence, allowing for two different isomers. The terminuses 
of group E viruses (e.g. HSV and HCMV) consist of two parts. On one end there is a 
repeat sequence (a) of varying copy number next to a larger sequence (b). The other 
end has one copy of the a sequence next to a repeat sequence (c). These terminal ab and 
ca sequences are found inverted in the unique region (b'a'nc'), separating the genome 
into the unique long (UL) and unique short (US) regions. In group E viruses both the UL 
and US can be inverted, creating the possibility of four isomers of the virus. Group F 
viruses (e.g. tupaia herpesvirus) do not have any terminal or internal repeats. Adapted 




R4 R3 R2 R1 
TR TR 
TR TR 
UL USIR TR 






Chapter One  Introduction 
 9
latency-associated transcript (LAT) of HSV, EBERs of EBV, PAN RNA of KSHV 
and vtRNAs of MHV-68. In addition, all herpesviruses examined to date encode 
microRNAs (miRNAs).  
Most herpesvirus proteins have several different functions. They can be divided into 
structural proteins that make up the virion particle and non-structural proteins that 
are necessary for viral replication. There are 43 core genes that are conserved 
between the alpha-, beta- and gammaherpesviruses that make up seven core gene 
blocks containing two to 12 genes (Figure 1.3). Within each gene block the gene 
order and orientation is conserved (Pellet and Roizman 2007). Between the family 
members the order and orientations of the gene blocks vary; however, between 
members of the same subfamily it is usually conserved. Most of the core genes are 
involved in the lytic replication of the virus (McGeoch et al. 2006). Gene 
conservation also exists at the subfamily level; betaherpesviruses encode a block of 
14 genes that are unique to that subfamily. Herpesvirus genomes also contain cellular 
homologues captured from host DNA relatively recently; KSHV expresses at least 12 
cellular homologues (Choi et al. 2001). These proteins have either kept their cellular 
function, allowing the virus to produce it when needed, or have been modified to 
alter their function. Many of the captured genes are involved in regulation of host 
cell defences (McGeoch et al. 2006).  
1.1.4. Herpesvirus life cycle 
The viral life cycle involves two different stages: the lytic stage with viral replication 
and production of virions, and the latent stage where the viral DNA persists in the 
cell as an episome with no production of virions and expression of only a few genes. 
The lytic life cycle can be divided into four different stages: entry of the virus into 
the cell, viral gene expression, replication of viral DNA and assembly and egress of 
virus particles. The viral life cycle of HSV-1 is extensively studied and as such the 
herpesvirus life cycle is described below as it is known for HSV-1. 
1.1.4.1. Entry 
The first step of virus entry into the host cell, the attachment, involves a reversible 
binding of virion glycoproteins to a receptor, in most cases to cell surface  






Figure 1.3 The arrangement of core gene blocks of the three herpesvirus subfamilies. 
There are 43 core genes in seven gene blocks. The gene order and orientation within the 
gene blocks is conserved; however, between the different subfamilies the orientation 
and order of gene blocks vary. Within the same subfamily the order and orientation of 
gene blocks is usually conserved.  Abbreviations; Terminal repeats, TR; internal 
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glycosaminoglycans (GAGs). In the case of HSV-1 the virion glycoprotein C (gC) 
and/or gB bind to the heparin sulphate of the cell surface proteoglycans (HSPGs) 
(Herold et al. 1991; Herold et al. 1994; Shieh et al. 1992). This first attachment step 
does not seem to be necessary for infection; however, it leads to an increased 
efficiency (reviewed in Spear and Longnecker 2003).  
Following attachment the virions enter the cell by fusion of the virion envelope with 
a cell membrane, promoting uptake of the virion by fusion or endocytosis. Three 
glycoproteins seem to be essential for herpesvirus entry: gB, gH and gL; although 
additional virus specific receptor-binding glycoproteins may be necessary. HSV-1 
entry initiates with the irreversible binding of gD to one of three classes of receptors: 
nectins-1 or -2, herpesvirus entry mediator (HVEM) or heparin sulphate specifically 
modified by 3-0-sulfotransferases (3-OS-HS) (Geraghty et al. 1998; Montgomery et 
al. 1996; Shukla et al. 1999; Warner et al. 1998). The binding of gD to its receptor 
promotes a conformation change that allows gD binding to gB and gH/gL which is 
sufficient to enable fusion of the membranes (Pertel et al. 2001; Turner et al. 1998).  
Binding to different co-receptors enables the viruses to infect a variety of cell types 
and also allows the viruses to exhibit different cellular tropism during different 
stages of infection. A good example is EBV which only needs gB and gH/gL to 
infect epithelial cells, but requires glycoprotein 42 (gp42) binding to major 
histocompatibility complex (MHC) class II to allow entry into B-cells. Virions 
released by B-cells have very little gp42 which lead them to infect epithelial cells, 
while virions released by epithelial cells have more gp42 and infect B-cells 
(Heldwein and Krummenacher 2008).  
Following fusion with the plasma membrane and de-envelopment of the virion the 
HSV capsid and tegument are released into the cytoplasm. Some of the tegument 
proteins remain in the cytoplasm, such as virion host shut off protein which causes 
degradation of host mRNA. Other proteins, like VP1-2, follow the capsid to the 
nuclear pore; whereas VP16, which is involved in viral gene expression, localises to 
the nucleus on its own. The capsid is transported to the nucleus along microtubules 
where the viral DNA enters via nuclear pores, circularises, and localises to nuclear 
domain 10 (ND-10) sites (Roizman et al. 2007). 
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1.1.4.2. Gene expression 
The host RNA polymerase II transcribes the viral DNA in the nucleus with protein 
synthesis taking place in the cytoplasm. The expression of lytic viral genes takes 
place in a highly regulated cascade fashion, with the genes being classed as 
α/immediately-early, β/early or γ/late genes (Honess and Roizman 1974). The  
α genes are expressed very soon following infection in the absence of de novo viral 
protein synthesis. During HSV-1 infection the tegument protein VP16 acts as a 
transactivator of α genes and promotes active chromatin on the α gene promoters, 
enabling transcription of six α genes (ICP0, 4, 22, 27, 47 and US1.5) (Roizman et al. 
2007). Five of these proteins can promote β gene expression, which requires α gene 
expression but not viral DNA replication (Honess and Roizman 1974). The 
β proteins are involved in replication of viral DNA (e.g. DNA polymerase) and 
nucleotide metabolism (e.g. thymidine kinase), and can be further subgrouped into β1 
and β2 proteins depending on the time of their expression (Roizman et al. 2007). The 
γ proteins are dependent on viral protein expression and are either stimulated by  
(γ1 genes) or dependent on (γ2 genes) DNA replication (Roizman et al. 2007). These 
proteins are mainly structural proteins that make up the virion.  
1.1.4.3. Replication 
Several of the β proteins, the DNA replication proteins, localise with viral DNA near 
ND-10 sites and assemble DNA replication complexes in prereplicative sites 
(Roizman et al. 2007). DNA synthesis initiates on the circular molecule with the 
binding of the origin binding protein and the single stranded DNA (ssDNA) binding 
protein to the origin sequence, followed by the recruitment of the helicase-primase 
proteins and viral polymerase complex. Seven viral proteins are necessary for viral 
DNA synthesis. Even though the replication starts in the theta replicative form it 
soon switches to a rolling circle replication producing long continuous DNA, 
concatemeric molecules (reviewed in Boehmer and Lehman 1997). As replication 
progresses the prereplicative sites become replication compartments that enlarge and 
eventually fill the nucleus (Quinlan et al. 1984). The concatemeric DNA is cleaved 
Chapter One  Introduction 
 13
in genome length molecules and packaged into empty capsids (Boehmer and Lehman 
1997). 
1.1.4.4. Assembly and egress  
Following their synthesis in the cytoplasm the γ structural proteins localise to the 
nucleus where the capsid assembly takes place. The five conserved capsid proteins 
(section 1.1.2) are assembled around a scaffold which is cleaved and removed as the 
viral DNA is packaged through the portal complex. Proteins required for cleavage 
and encapsidation are also conserved among the herpesviruses  
(Mettenleiter et al. 2009).  
There are three models of how virion envelopment and egress takes place, as 
reviewed in Roizman et al. 2007. In the first model the capsids are enveloped at the 
inner nuclear membrane and transported to the plasma membrane in perinuclear 
vesicles which fuse with the membrane releasing the virions. The second model 
proposes that the capsid envelopes at the inner nuclear membrane, deenvelops 
through fusion with the outer nuclear membrane and reenvelopes at cytoplasmic 
membranes, possibly of the trans-Golgi network or endosomal, by budding into 
vesicles. The third model suggests that the majority of virions exit the nucleus 
through the nuclear pores and are enveloped at cytoplasmic membranes, while a 
minority of virus follow the route of the first model.  
The tegument is obtained through a complex network of protein-protein interactions 
forming an inner capsid-associated and an outer envelope-associated tegument. The 
enveloped virions exit the cell by transportation of the vesicle to the cell surface and 
fusion of the vesicle with the cell membranes, releasing the virions into the 
extracellular space (Mettenleiter et al. 2009).  
1.1.4.5. Latency 
Herpesviruses are able to remain latent in the host with the possibility of reactivation 
at a later stage. During latency the virus genome circularises and associates with 
nucleosomes; hence chromosome organisation is important for the establishment and 
maintenance of latency by determining which genes are active (Knipe and Cliffe 
2008; Tempera and Lieberman 2009). The different herpesviruses differ in their 
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preferred cell type for latency and the mechanisms for latency do not seem to be 
conserved, with no common pattern of gene expression. Some viruses have a very 
limited gene expression during latency; LAT is the only abundant transcript during 
HSV-1 latent infection (Stevens et al. 1987). In contrast EBV encodes several 
proteins during latency with various patterns of gene expression observed.  
1.2. Gammaherpesviruses 
Gammaherpesviruses undergo productive replication in epithelial cells and usually 
establish latency in lymphocytes. The latently infected lymphocytes have the ability 
to reactivate and infect nearby epithelial cells, allowing spread of the viruses to  
non-infected individuals (Pellet and Roizman 2007). The gammaherpesvirus 
subfamily includes the genera Lymphocryptovirus, Rhadinovirus, Macavirus and 
Percavirus (Table 1.1). The two human gammaherpesviruses, EBV and KSHV, 
belong to the Lymphocryptovirus and Rhadinovirus genera respectively. The 
Rhadinoviruses also include the well studied HVS, which causes T-cell lymphomas 
in new world primates, and MHV-68. The genus Macavirus includes the veterinary 
important Ovine herpesvirus 2 and Alcelaphine herpesvirus 1, which are  
non-pathogenic in their hosts, sheep and wildebeest respectively, but cause malignant 
catarrhal fever in other species (Davison et al. 2009).  
1.2.1. Epstein-Barr virus 
EBV was discovered in 1964 by Epstein, Achong and Barr, through electron 
microscopy of cultures from Burkitt’s lymphoma (BL) tissue (Epstein et al. 1964). 
Four years later EBV was identified as the causative agent of infectious 
mononucleosis (IM), a self-limiting lymphoproliferative disease (Henle et al. 1968). 
As the first candidate human tumour virus EBV has since been associated with 
several cancers, such as nasopharyngeal carcinoma (NPC), non-Hodgkin’s 
lymphoma, oral hairy leukoplakia, T-cell lymphomas and Hodgkin’s lymphoma 
(HL) (Cohen 2000; Weiss et al. 1987; Ziegler et al. 1982; zur Hausen et al. 1970). 
EBV is an ubiquitous virus infecting over 90% of the human adult population 
persisting for life, in most cases causing no disease (Rickinson and Kieff 2007). In 
the developing world the majority of infections occur within the first three years of 
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life. In the developed world 50% of children have not been infected by the age of 10, 
delaying the primary infection to adolescence (Rickinson and Kieff 2007), which 
leads to a 25% risk of developing IM (Crawford et al. 2006).  
The EBV genome is a 184 kbp long group C genome (Figure 1.2) with four internal 
repeats within the unique part of the genome, and encodes nearly 100 proteins. There 
are two subtypes of EBV, EBV-1 and EBV-2, which share extensive homology but 
differ in the regions encoding the EBV nuclear antigens (EBNAs)  
(Kieff and Rickinson 2007).  
EBV has a very restricted host range and efficient infection in vitro is restricted to 
primary human B lymphocytes. Infection of these cells leads to transformation of the 
cells resulting in lymphoblastoid cell lines. Lytic infection in vitro is usually studied 
by inducing latently infected B-cells to reactivate and allow lytic replication  
(Kieff and Rickinson 2007). 
1.2.1.1. EBV latency 
EBV expresses a restricted subset of genes during latent infection, with different 
patterns for gene expression observed (Table 1.2) (Kerr et al. 1992). These viral 
genes are six viral nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and –LP), three 
membrane proteins (LMP-1, -2A, -2B), the viral bcl-2 homologue (BHRF1), EBERs, 
several spliced transcripts from the BamA rightward transcripts (BARTs) and 
miRNAs (Kelly et al. 2009; Kieff and Rickinson 2007). These gene products work to 
maintain the latent infection and to immortalise the B-lymphocytes  
(Kieff and Rickinson 2007).  
The virus establishes latency in resting memory B-cells (Babcock et al. 1998; 
Miyashita et al. 1997). How it enters these cells is debated. In the main model EBV 
infects naïve tonsillar B-cells and drive the cells into memory cells by changing the 
gene expression pattern (program) to mimic physiologic antigen driven 
differentiation of the B-cell (Babcock et al. 2000). Thus, the infected naïve tonsillar 
B-cells express the growth program driving the cells to undergo proliferation, while a 
switch to the default program causes the cells to pass through germinal centres and 
mature into memory B-cells, at which point the cells shut down the protein 
expression and enter the latency program (Thorley-Lawson and Gross 2004). This is  
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Table 1.2 EBV gene expression pattern during latent infection and associated diseases. 
Abbreviations: EBNA, EBV-encoded nuclear antigen; LMP, Latent membrane 
protein; EBERs, EBV-encoded RNAs; BARTs, Bam A rightward transcripts. BHRF1 
encodes the vbcl-2. 
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supported by the findings that the only type of B-cell expressing the growth program 
in the tonsil is the naïve B-cell, while germinal-centre and tonsillar memory B-cells 
express the default program and peripheral memory cells the latency program 
(Babcock et al. 2000; Joseph et al. 2000). The memory B-cells circulate between the 
peripheral blood and the tonsils in the latency program, expressing EBNA-1 and 
possibly LMP2 during cells division (Young and Rickinson 2004). Since memory  
B-cells rarely die and viral protein production is at a minimal, avoiding detection by 
the immune response, the virus can persist for a long time. Occasionally the memory 
B-cell may receive plasma cell signals activating lytic virus production, allowing 
spread of virus to nearby epithelial cells in mucosal sites and cause shedding of virus 
(Rickinson and Kieff 2007). Other programmes of latency have also been described; 
around 15% of BLs express the Wp-restricted latency program, characterised by 
EBNA-1, -3A, -3B, -3C, -LP, and BHRF1 expression, with the genome lacking 
EBNA2 (Kelly et al. 2009). 
1.2.1.1.1. Latency transcripts 
The EBV-encoded nuclear antigens 
EBNA-1: EBNA-1 is essential for the maintenance and replication of the EBV 
episome in dividing cells, binding to the plasmid origin of replication, oriP  
(Rawlins et al. 1985; Yates et al. 1984). During cell division it tethers the episome to 
the chromosome ensuring even distribution of viral genomes (Kanda et al. 2001). 
EBNA-1 can also act as a transcriptional activator of the EBNAs and LMP-1  
(Young and Rickinson 2004). It avoids CD8+ T-cell recognition by inhibiting its own 
translation, through a glycine-alanine repeat sequence that is thought to delay 
translation initiation, but since it simultaneously blocks degradation the levels of 
EBNA-1 remain stable (Apcher et al. 2009; Yin et al. 2003). 
EBNA-2: EBNA-2 is essential for transformation of B-lymphocytes  
(Cohen et al. 1989). It up-regulates the viral latency genes, as well as several cellular 
proteins, through interactions with the DNA binding protein RBP-Jκ  
(Kieff and Rickinson 2007). 
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EBNA-3: The EBNA-3 family of proteins also regulate protein expression. They 
modulate the EBNA-2-mediated up-regulation of viral and cellular genes by 
competing with EBNA-2 for RBP-Jκ binding (Kieff and Rickinson 2007). 
EBNA-LP: EBNA-LP is transcribed with EBNA-2 at the start of infection and 
interacts with EBNA-2 to up-regulate viral and cellular genes  
(Harada and Kieff 1997). 
The EBV-encoded latent membrane proteins 
LMP-1: LMP-1 is the main EBV transforming protein, functioning as a 
constitutively activated member of the TNF receptor family (Mosialos et al. 1995). It 
activates several signalling pathways, including nuclear factor κB (NFκB), by 
mimicking the functions of the B-cell receptor CD40; thereby driving cell growth 
and differentiation (Uchida et al. 1999), and up-regulating cell-surface adhesion 
molecules, anti-apoptotic proteins and cytokines (Young and Rickinson 2004).  
LMP-2: LMP-2A inhibits EBV reactivation from latency in B-lymphocytes by 
blocking B-cell receptor signal transduction by interacting with the tyrosine kinases 
(Miller et al. 1994). It also provides survival signals by providing surrogate B-cell 
receptor signalling (Caldwell et al. 1998). LMP-2B is reported to negatively regulate 
the function of LMP-2A (Rechsteiner et al. 2008).  
BHRF1 
vbcl-2: The viral bcl-2 homologue was recently shown to be expressed during the 
growth programme of latency and the Wp-restricted latency found in around 15% of 
BLs (Kelly et al. 2009). This protein has anti-apoptotic properties and protects the 
BL cells from cell death (Watanabe et al. 2009). 
EBV-encoded RNAs 
EBERs: These non-polyadenylated small non-coding RNAs are the most abundant 
EBV RNAs in latently infected cells and have been found to interact with several 
proteins. These will be discussed further in section 1.4.1.2.1. 
Bam A rightward transcripts 
BARTs: The BARTs is a set of alternatively spliced transcripts expressed during 
both lytic and latent infection containing several possible ORFs; however, the protein 
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products have not been detected. The introns of BART encode miRNAs, which will 
be discussed in chapter 1.4.3. 
1.2.1.2. EBV infection and associated diseases 
EBV is spread by oral secretions and infects cells of the oropharynx of naïve 
individuals. Whether these cells are B-lymphocytes or epithelial cells is still debated; 
perhaps it is a co-operation where binding of EBV to the B-cell aids entry into 
epithelial cells (Rickinson and Kieff 2007). The virus enters the memory B-cell pool 
as previously described and the EBV infection is brought under control by humoral 
and cell mediated responses, with natural killer (NK) cells and CD4+ and CD8+ 
cytotoxic T-cells playing an important part (Cohen 2000).  
Whereas most EBV infections are asymptomatic some do cause diseases such as IM. 
IM is usually cleared by immunocompetent individuals after a few weeks; however, 
can cause severe problems in immunosuppressed individuals. In addition, EBV is 
associated with three lymphoid tumours of B-cell origin: B-lymphoproliferative 
disease in the immunocompromised hosts, Burkitt’s lymphoma and Hodgkin’s 
lymphoma; as well as other tumours such as nasopharyngeal carcinoma.  
Infectious mononucleosis 
IM usually occurs during primary EBV infection of young adults with 25% 
developing IM (Crawford et al. 2006). The reason for this age difference is not 
known; however, it may be related to the viral dose and the host immune response 
(Rickinson and Kieff 2007). The symptoms include fever, sore throat, swollen and 
enlarged lymph glands, and fatigue. IM is thought to be an immunopathological 
disease where the symptoms arise from an exaggerated CD8+ cytotoxic T-cell 
response that results in an increased cytokine release (Williams and Crawford 2006). 
Posttransplantation lymphoproliferative disease  
EBV can also cause disease in people with acquired T-cell deficiencies, for example 
people on immunosuppressant therapy following transplantations. Between 0.5% and 
30% of transplant recipients develop Posttransplantation lymphoproliferative disease 
(PTLD) as a result of immunosuppressive therapy (Thompson and Kurzrock 2004). 
This is a heterogeneous collection of disorders which results from an uncontrolled 
expansion of B-lymphocytes. The risk factors include the degree of 
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immunosuppressive therapy and primary EBV infection; those that undergo primary 
infection during the immunosuppression have a higher risk of PTLD  
(Crawford 2001). Around 90% of tumours are EBV infected and most cells express 
the growth program. The reason for development of PTLD is not clear; however, it is 
possible that the impaired T-cell response fails to eliminate EBV infected 
proliferating abnormal cells or directly infected memory cells (Thorley-Lawson and 
Gross 2004). 
Burkitt’s lymphoma 
BL first described by Burkitt in 1958 as a tumour in the jaw of children in equatorial 
Africa (Burkitt 1958) is the most common childhood cancer in this area. These 
endemic cases of BL are prevalent in areas of holoendemic malaria in Africa and 
New Guinea, and 96% are associated with EBV. The association of EBV with BL in 
other parts of the world (sporadic BL) is however lower, ranging from 50-70% in 
some parts of the world and around 20% in North America and Europe  
(Crawford 2001). BL is also common in human immunodeficiency virus (HIV) 
infected individuals where EBV is found in 30-40% of BL tumours (Rickinson and 
Kieff 2007).  
All BL tumours carry one of three chromosomal translocations that brings the c-myc 
oncogene under the influence of the immunoglobulin (Ig) heavy- or light-chain 
genes, leading to its dysregulation (Klein 1983). This over-expression of c-myc 
drives the cell to proliferate and inhibits its differentiation, and even though this 
over-expression is not sufficient for BL development it seems to be necessary 
(Bornkamm 2009). The majority of EBV-positive tumours are germinal centre cells 
that contain EBV clonal genomes expressing the latency program, indicating that 
EBV infection occurs prior to translocation (Bornkamm 2009; Thorley-Lawson and 
Gross 2004).  
In endemic BL at least three factors co-operate to cause BL, these include malaria, 
EBV and c-myc translocation (reviewed in Crawford 2001; Thompson and Kurzrock 
2004). EBV is thought to promote survival of the B-cell, perhaps by inhibiting 
apoptosis, and avoids detection by the immune system by only expressing EBNA-1 
(Bornkamm 2009).  
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Hodgkin’s lymphoma  
HL accounts for around 20% of all lymphomas in the western world. In these 
tumours the malignant cells, large mono- or multinuclear Reed-Sternberg cells 
(RBC) and Hodgkin’s cells, make up a minority of cells (1-2%) with a heavy 
inflammatory infiltrate of reactive mononuclear cells making up the rest of the 
tumour (Crawford 2001). Activation of the NFκB-signalling pathway has been 
suggested as a possible cause of HL (Staudt 2000).  
The association of EBV with HL was confirmed when clonal EBV DNA was 
detected in tumour cells (Weiss et al. 1987) and later also in RSCs (Wu et al. 1990). 
These EBV positive cells express the default program of latent gene expression 
(Table 1.2). The EBV association varies depending on the type of tumour, 
geographical location, and age; ranging from 40-50% in developed countries up to 
almost 100% in cases in South America (Crawford 2001).  
RSCs contain hypermutated Ig genes and are believed to be B-cells that have arrested 
at the centrocyte stage during B-cell differentiation in the germinal centre and do not 
express IgG molecules. These abnormal B-cells would normally be prone to 
apoptosis; however, it is possible that EBV provides survival signals keeping the 
cells alive and proliferating (Andersson 2006; Crawford 2001). LMP-1 mimics CD40 
replacing the T-cell signal needed during memory cell selection (Uchida et al. 1999), 
while LMP-2A mimics B-cell receptor signalling from surface Ig, replacing antigen 
binding (Caldwell et al. 1998). LMP-1 also activates NFκB (Hammarskjold and 
Simurda 1992), indicating that both EBV- positive and negative tumours may use the 
same pathway to induce HL. One hypothesis is that EBV associated HL occurs when 
a mutation in a germinal centre B-cell prevents its differentiation. If this cell is 
infected with EBV it will express LMP-1 and LMP-2, promoting survival and 
proliferation; thus enhancing tumour growth.  
Nasopharyngeal carcinoma 
NPC is a tumour of squamous epithelium of the post-nasal space common in 
southern China, south-east Asia, north Africa and among Inuits in Alaska and 
Greenland, but rare in the rest of the world. The tumour is more common in men than 
in women and in southern China it is the most common malignancy in men and 
second commonest in women (Crawford 2001). NPC can be divided into different 
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types depending on the level of differentiation of the tumour cells; 70% are classed 
as undifferentiated and 100% of these tumours are associated with EBV. These 
tumours are made up of undifferentiated carcinoma cells and a lymphocyte infiltrate, 
with clonal EBV genomes present only in the epithelial cells expressing the default 
latency program (Table 1.2) (Brooks et al. 1992; Young and Rickinson 2004). 
Nasopharyngeal epithelial cells do not usually contain EBV, which has led to a 
model where the genetic events of NCP occur early in the pathogenesis and makes 
the epithelial cells either more susceptible to EBV infection or more able to maintain 
the viral genome (Rickinson and Kieff 2007). EBV latent gene expression may then 
provide survival signals and promote tumour growth. The EBERs confer resistance 
to Fas-mediated apoptosis by blocking the double-stranded RNA-regulated protein 
kinase R (PKR) pathway in an human epithelial intestine cell line (Nanbo et al. 
2005) and may enhance growth of NPC cells by inducing expression of insulinlike 
growth factor 1 (IGF-1) (Iwakiri et al. 2005). LMP-2 promotes the growth of 
epithelial cells and enhance epithelial cell migration (Rickinson and Kieff 2007). In 
addition, NPC cells express high levels of BARTs which encode several miRNAs 
that could be involved in the pathogenesis of NPC (Cai et al. 2006).  
1.2.2. Kaposi’s sarcoma-associated herpesvirus 
KS was first described in 1872 by the Hungarian dermatologist Moritz Kaposi when 
he published the case histories of five patients with a rare idiopathic pigmentation of 
the skin (Kaposi 1872). Initially considered a non-aggressive disease of elderly men 
in the Mediterranean, it was given further attention during the emergence of the HIV 
pandemic in the 1980s, when KS became the most common neoplasm in patients 
with acquired immune deficiency syndrome (AIDS) (Beral et al. 1990). The finding 
that KS was more prevalent among patients that had acquired HIV by sexual contact 
than parentally suggested that KS was spread by a sexually transmitted infectious 
agent (Beral et al. 1990). In 1994 Chang et al. identified two short fragments from a 
new herpesvirus (KSHV) in AIDS associated KS tissues using representational 
difference analysis. These sequences were homologous to capsid and tegument genes 
of the gammaherpesviruses EBV and HVS (Chang et al. 1994).  
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1.2.2.1. KSHV genome 
Sequencing of the viral genome further revealed that KSHV was a Rhadinovirus with 
linear dsDNA of 165 to 170 kbp made up of a central unique region of 140.5 kbp 
flanked by a variable number of 801 bp terminal repeat sequences (Renne et al. 
1996; Russo et al. 1996). The unique region encodes at least 86 ORFs, with 66 
conserved herpesvirus genes involved in virus replication and structure grouped 
together in gene blocks interspersed with non-conserved genes (Russo et al. 1996). 
KSHV also encodes several homologues of cellular proteins involved in DNA 
synthesis, cell cycle regulation, and signalling; at least 12 of these were captured 
from the host. These include cell-cycle regulators (e.g. vcyclin), inhibitors of 
apoptosis (e.g. vbcl-2 and vFLIP) and immunomodulatory proteins (e.g. vIRF-1 and 
vIL-6) (Moore and Chang 2001; Russo et al. 1996). Most of the captured genes are 
functionally similar to cellular genes induced by EBV infection, indicating that the 
two viruses use different ways of achieving the same thing. The KSHV genome also 
encodes miRNAs and a lytic polyadenylated non-coding RNA, PAN, that localises to 
the nucleus. 
1.2.2.2. KSHV epidemiology 
Although KSHV is found all over the world the prevalence varies significantly by 
geographical region. In Europe, North America, and Asia the prevalence in the 
general population is low, ranging from 0%-15%, and the virus is mainly spread by 
sexual transmission, particularly among homosexual men. In Mediterranean and 
Eastern European countries, where KS is more common, there is a higher prevalence 
ranging from 4% to 24%, while there is a very high prevalence in African regions 
with rates over 50%. In the latter two cases the virus is thought to spread by both 
sexual contact and parentally thorough saliva with infection often starting in 
childhood (Ganem 2007; Jenson 2003). KSHV has been divided into subtypes based 
on the sequence of the ORF K1. These subtypes A-H show distinct geographical 
distributions suggesting that KSHV is an ancient human infection with the subtypes 
reflecting the migration of human populations out of Africa (Boshoff and Weiss 
2001; Hayward 1999).  
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1.2.2.3. KSHV latency 
KSHV infection in vivo is restricted to humans making it difficult to study viral 
infection in the host. Most of the knowledge of KSHV latent infection comes from 
cultivation of primary effusion lymphoma (PEL) cell lines derived from patients with 
advanced AIDS. These cells are latently infected with the KSHV genome maintained 
as a circular episome, but following cultivation 1% to 5% of cells produce virus. This 
can be enhanced by treatment with chemicals or viral replication and transcription 
activator (rta), and thus allows for production of viral stocks and study of gene 
expression. However, this will not entirely represent gene expression in vivo. KSHV 
can latently infect several cell lines such as human fibroblasts, endothelial, and 
epithelial cells. Fibroblasts and epithelial cells have not been found to be infected in 
vivo, while B-cells, which are the site of latency in vivo, have been very difficult to 
infect in vitro (Ganem 2007).  
During latent infection only a few of the viral genes are expressed. In PEL cells most 
latently expressed transcripts are expressed from a region at the far right end of the 
genome. Latency-associated nuclear antigen-1 (LANA-1), vcyclin and vFLIP are 
transcribed through a program of alternative splicing and internal translational 
initiation. The kaposin locus gives rise to a family of proteins; kaposin A, B, and C, 
as well as miRNAs (Ganem 2007). LANA-2 lies outside of this region and is a B-cell 
specific latency gene not expressed in KS tumours (Rivas et al. 2001).  
It is possible that the latency expression in PEL cells gives a restricted view of 
KSHV latency. EBV has a complex program of latency expression and the B-cell 
limited expression of LANA-2 may be an indication that KSHV latency expression is 
more complex than thought. In addition, a large number of infected B-cells in 
Castleman’s disease express a variety of proteins including proteins that are not 
classed as latent (Katano et al. 2000; Parravicini et al. 2000). It is not clear if this 
represents an expanded pattern of latent gene expression, or if these are cells 
undergoing lytic virus replication (Chang and Moore 2001). 
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1.2.2.3.1. Latency transcripts 
Latency-associated nuclear antigen-1  
LANA-1 is a large, highly immunogenic, protein expressed in all latently infected 
cells where it localises to the nucleus. It is a multifunctional protein with DNA 
replication, anti-apoptotic, cell cycle regulatory and gene regulatory functions, most 
of which are exerted by interactions with other proteins (Kaul et al. 2007). LANA-1 
is essential for the establishment and maintenance of the latent viral episome in the 
nucleus. It activates the semiconservative replication of the episome by binding to 
DNA sequences within the terminal repeats; thus showing functional resemblance to 
EBV EBNA-1 binding to the oriP sequence (Grundhoff and Ganem 2003; Hu et al. 
2002). Further, LANA-1 tethers the viral episome to host chromosomes during cell 
division to allow efficient segregation of the viral DNA to both daughter cells 
(Ballestas et al. 1999; Cotter and Robertson 1999). It is also involved in the 
regulation of several pathways affecting cell growth and survival; however, LANA-1 
itself does not seem to be sufficient for transformation (Watanabe et al. 2003). 
LANA-1 up- and down-regulates a range of host and viral genes, including the 
latency genes, through binding to the DNA in the terminal repeats and interacting 
with components of the transcriptional machinery (Garber et al. 2001; Renne et al. 
2001). It also inhibits lytic replication by decreasing the expression of the lytic 
transactivator rta and antagonising its function (Lan et al. 2004). 
Viral cyclin 
vcyclin is a homologue of the cellular protein cyclin D and acts in a similar fashion 
in regulating the cell cycle. It forms functional complexes with cellular  
cyclin-dependent kinase 6 (cdk6) which leads to phosphorylation of pRB; thus 
stimulating cell cycle progression (Chang et al. 1996). However, the viral cyclin has 
several differences from the cellular cyclin D. It has a wider range of substrates, such 
as histone H1 (Godden-Kent et al. 1997) and origin recognition complex 1  
(Laman et al. 2001), suggesting that vcyclin may regulate several cell-cycle phases 
as well as stimulate the replication of both host and viral genome. In addition, 
vcyclin is able to evade the inhibitors that regulate the activity of cellular cyclin-cdk 
complexes (Swanton et al. 1997). 
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Viral FLIP 
vFLIP is a homologue of the FLICE inhibitory protein (FLIP) and like its homologue 
has antiapoptotic activities; it up-regulates the antiapoptotic transcription factor 
NFκB by interacting with the inhibitory κB kinase complex (Liu et al. 2002). Since 
vFLIP also is a homologue of caspase 8 it may act as a functional homologue in 
activating the NFκB signalling pathway; thus enhancing cellular proliferation 
(Chugh et al. 2005). Activation of the NFκB signalling pathway has several effects, 
including inhibition of apoptosis by up-regulation of several antiapoptotic molecules 
(Guasparri et al. 2004). It also promotes latency by inhibiting the expression of rta 
and lytic replication (Ye et al. 2008; Zhao et al. 2007), is responsible for the spindle 
cell phenotype seen in KSHV infected endothelial cells (Matta et al. 2007) and  
up-regulates cytokines (Sun et al. 2006). vFLIP has also been shown to directly 
inhibit KSHV lytic gene expression by binding to lytic promoters (Matta et al. 2008). 
Kaposins 
The kaposin locus gives rise to at least three proteins by differential initiation of 
translation, as well as several miRNAs. Kaposin A is a transmembrane protein found 
to transform cultured cells and drives tumorigenesis in nude mice (Muralidhar et al. 
1998). Kaposin A-transformed cells show enhanced activation of several 
serine/threonine kinase pathways, some of which are known to regulate cell 
proliferation (Muralidhar et al. 2000). It also binds cytohesin-1 activating the 
ERK1/2 pathway, which is thought to be important for transformation (Kliche et al. 
2001). Kaposin B binds and activates mitogen-activated protein (MAP)  
kinase-associated protein kinase 2 (MK2), a target of the p38 MAP kinase signalling 
pathway and known inhibitor of decay of mRNAs with AU-rich elements (AREs). 
Kaposin B thereby increases the expression of cytokines by blocking the degradation 
of their mRNAs, which are usually unstable because they contain AREs (McCormick 
and Ganem 2005).  
Latency-associated nuclear antigen-2 
LANA-2, also called viral interferon regulatory factor 3 (vIRF-3), is a B-cell specific 
protein (Rivas et al. 2001) required for proliferation and survival of PEL cells  
(Wies et al. 2008). It has several functions including inhibition of apoptosis induced 
by p53 (Rivas et al. 2001) and PKR, an interferon (IFN)-regulated anti-viral product 
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(Esteban et al. 2003). It also inhibits NFκB activation (Seo et al. 2004), IRF-7 
activity (which leads to suppression of alpha interferon (IFN-α) production and  
IFN-mediated immunity) (Joo et al. 2007), as well as virus-mediated transcriptional 
activation of the IFN-A promoter (Lubyova and Pitha 2000). In contrast, LANA-2 
has also been shown to enhance the binding of IRF-3 and IRF-7 to IFN promoters; 
thus upregulating virus-mediated induction of IFN responses (Lubyova et al. 2004). 
LANA-2 has recently been found to disrupt the ND-10 sites in the nucleus and 
interfere with the tumour suppressor PML (Marcos-Villar et al. 2009).  
1.2.2.4. KSHV infection and associated diseases 
Primary KSHV infection is thought to be asymptomatic in most cases; however, 
fever and rash has been described in immunocompetent children  
(Andreoni et al. 2002). In a study of HIV-negative men mild symptoms such as 
fever, diarrhoea, fatigue, rash and enlarged lymph nodes was associated with primary 
KSHV infection; unlike primary EBV infection there were was no increase in  
T-lymphocyte numbers (Wang et al. 2001). Primary KSHV infection is brought 
under control by MHC class I-restricted cytotoxic T-lymphocyte responses (Osman 
et al. 1999; Wang et al. 2001). KSHV encodes two proteins (MIR-1 and MIR-2) that 
have been found to reduce cell surface MHC class I expression by increasing its 
endocytosis; thus enabling the virus to evade the immune response (Coscoy and 
Ganem 2000; Coscoy et al. 2001). Asymptomatic carriers harbour the virus mainly 
in CD19+ B-cells (Ambroziak et al. 1995). Most people remain asymptomatic unless 
they acquire an immunodeficiency and severe KSHV associated disease is a rare 
occurrence.  
1.2.2.4.1. Kaposi’s sarcoma 
KS lesions can occur in several tissues, but is most commonly located in the skin 
where it forms brownish-purple raised nodules. The disease can be divided into four 
epidemiological forms: classic, endemic, post-transplant or iatrogenic, and  
HIV- associated KS. HIV- associated KS is the most common neoplasm in patients 
with AIDS and in the early days KS in AIDS patients was at least 20 000 times more 
common than in the general population (Beral et al. 1990). However, the 
introduction of HAART (highly active anti-retroviral therapy) has resulted in a 
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reduction of KS in AIDS patients in the developed world (Schwartz et al. 2008). 
HIV-associated KS is extremely aggressive.  
KS is not a classical tumour, but is a complex lesion made up of spindle cells, 
infiltrating monocytes, T-lymphocytes, plasma cells and neovascular channels. The 
spindle cells are the main proliferating cells of the lesion and they are thought to be 
endothelial cells, possibly of lymphatic origin (Ganem 2007). KSHV is necessary for 
the development of KS, but is not sufficient for it. Various findings support this; 
including the correlation of seroprevalence and KS risk and that KSHV DNA is 
present in all KS tumours where nearly all spindle cells are latently infected  
(Boshoff and Weiss 2001; Ganem 2007). Lytic replication may have an important 
role in KS development since ganciclovir, a drug that blocks lytic replication, 
reduces the occurrence of new KS tumours in patients with advanced AIDS (Martin 
et al. 1999).  
1.2.2.4.2. Primary effusion lymphoma 
PEL is a rare disease that occurs mainly in HIV-infected individuals with advanced 
AIDS and presents as a proliferation of B-cells in the body cavities lacking 
detectable tumour mass. PEL is a classic malignancy with clonal expansion of  
B-cells and every tumours cell harbours KSHV genomes as circular episomes at very 
high copy numbers (Boshoff and Weiss 2001). The tumour cells are often co-infected 
with EBV; however, PEL is not seen without KSHV infection (Ganem 2007). PEL 
cells express the latent proteins and viral interleukin 6 (vIL-6) (Parravicini et al. 
2000) which might drive tumorigenesis. Both vFLIP and LANA-2 have been found 
to be essential for PEL cell survival in vitro (Guasparri et al. 2004; Wies et al. 2008).  
1.2.2.4.3. Multicentric Castleman’s disease 
Multicentric Castleman’s disease (MCD) is an aggressive, lymphoproliferative, 
systemic illness, resulting in sustained fever, weakness, enlarged lymph nodes and 
spleen (Ganem 2007). MCD occurs more frequently in AIDS patients and in these 
cases are always associated with KSHV, while in HIV-negative cases only 40-50% 
are associated with KSHV (Boshoff and Weiss 2001). MCD is a polyclonal lesion 
with KSHV present in plasmablasts that localise mainly to the mantle zones 
surrounding the germinal centres (Du et al. 2001; Dupin et al. 2000). These 
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plasmablasts are not present in KSHV-negative MCD. It is thought that KSHV 
infects naïve B-cells and drives their differentiation into plasmablasts, bypassing the 
germinal centre reaction (Du et al. 2001). The IL-6 receptor is expressed in the 
majority of KHSV-infected cells and vIL-6 is highly expressed in a proportion of 
cells, indicating that the IL-6 pathway may drive both the differentiation of KSHV 
infected cells and the development of lymphoproliferative lesions. The vIL-6 may 
also induce expression of human IL-6, and in line with this increased levels of human 
IL-6 have been described in patients with MCD and this is thought to be responsible 
for the systemic manifestation of the disease (Du et al. 2001). In contrast to  
HIV-associated KS, HIV-associated MCD does not usually resolve following 
HAART (Boshoff and Weiss 2001).  
1.3. Murine gammaherpesvirus-68 
1.3.1. Discovery and classification 
MHV-68 (also known as murid herpesvirus 4; MuHV-4) was originally isolated in 
1976 from bank voles together with two other viruses, MHV-60 and MHV-72, and 
two viruses isolated from wood mice, MHV-76 and MHV-78 (Blaskovic et al. 1980) 
These viruses are considered strains of MHV-68. The growth characteristics of the 
viruses in cell lines and virion structures as observed by electron microscopy led to 
their classification as herpesviruses (Blaskovic et al. 1980; Ciampor et al. 1981). 
They were further classified as part of the Alphaherpesvirinae based on their 
cytopatic effects, growth characteristics, and wide host range in different cell cultures 
(Svobodova et al. 1982a), as well as structural polypeptide similarities to HSV-1 
(Stancekova et al. 1987). However, in vivo studies with MHV-68 showed a 
pathogenesis inconsistent with alphaherpesviruses; the mice showed no neurological 
disease, but severe pneumonia with widespread haematogenous viral spread with the 
virus replicating predominantly in lung alveolar cells (Blaskovic et al. 1984; Rajcani 
et al. 1985). Short nucleotide sequence analysis of the MHV-68 genome revealed 
that it was actually closely related to the gammaherpesviruses EBV and HVS in 
terms of genome organisation, content, and structure (Efstathiou et al. 1990a; 
Efstathiou et al. 1990b), and that the genome organisation was more similar to that of 
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Rhadinoviruses, e.g. HVS and KSHV. Partial and full sequencing of the MHV-68 
genome further corroborated this (Mackett et al. 1997; Virgin et al. 1997).  
Although MHV-68 was initially isolated from bank voles subsequent 
epidemiological surveys of MHV-68 infection in free-living rodents found that the 
virus is endemic in wood mice, striped field mouse and yellow-necked mouse, and 
not bank voles, suggesting that the wood mouse and related mouse species are likely 
to be the natural hosts (Blasdell et al. 2003; Ehlers et al. 2007). At least three other 
mouse herpesviruses have been reported; MHV-Brest and wood mouse herpesvirus 
(WMHV) are thought to be strains of the same virus species (Chastel et al. 1994; 
Hughes et al. 2009).  
Since MHV-68 can infect mice it provides a small animal model for the study of 
virus-host interactions, virus pathogenesis and latency. MHV-68 can also be studied 
in vitro as it establishes productive and latent infections in several cell lines. In 
addition, the MHV-68 genome has been cloned into a bacterial artificial chromosome 
(BAC) which makes it relatively easy to generate virus mutants (Adler et al. 2000).  
1.3.2. MHV-68 virion 
The virion structure of MHV-68 as determined by electron microscopy and antigen 
analysis was early on found to be similar to other herpesviruses (Ciampor et al. 1981; 
Svobodova et al. 1982b). The sequencing of the genome revealed that MHV-68 does 
indeed encode homologues for several herpesvirus structural proteins  
(Virgin et al. 1997). Analysis of proteins associated with the MHV-68 virion 
identified a number of homologues of capsid, tegument, and envelope proteins, along 
with proteins not previously associated with virions, as well as cellular proteins such 
as annexin I, annexin II and a cytoplasmic β-actin homologue (Bortz et al. 2003). As 
described for other viruses (section 1.1.2) MHV-68 packages mRNAs, in addition to 
the vtRNAs (Cliffe et al. 2009b). The reason for the packaging of the non-coding 
RNAs is not known.  
1.3.3. MHV-68 genome 
The MHV-68 genome comprises a unique region of 118 kbp DNA with two internal 
repeats of 40 respectively 100 bp, flanked by terminal repeat regions made up of 
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variable numbers of 1.213 kbp repeat units (Efstathiou et al. 1990a; Virgin et al. 
1997). The genome encodes 73 protein-coding ORFs, most of which are homologues 
of HVS and KSHV genes and many also of EBV genes. The genome consists of 
conserved herpesvirus gene blocks separated by virus specific genes and can be 
aligned with other Rhadinoviruses such as KSHV and HVS (Figure 1.4)  
(Virgin et al. 1997). MHV-68, like the other gammaherpesviruses, encodes a number 
of cellular homologues, such as vcyclin, vGPCR, and vbcl-2 (Nash et al. 2001; 
Virgin et al. 1997). At the left end of the genome MHV-68 encodes four genes 
unique to the virus, eight vtRNAs and nine miRNAs (Bowden et al. 1997; Pfeffer et 
al. 2005; Virgin et al. 1997).  
1.3.4. MHV-68 life cycle 
1.3.4.1. Entry 
The mechanism by which MHV-68 enters the cells appears to be a complex process 
involving several molecules. Like other herpesviruses (1.1.4.1) the virion binds 
heparin sulphates via gH/gL or gp70 (Gillet et al. 2007a; Gillet et al. 2008) and entry 
also involves gB (Gillet and Stevenson 2007) and gp150 (Gillet et al. 2007a). While 
gH is essential for infectivity, gL is not (Gill et al. 2006; Gillet et al. 2007b). gp150 
appears to have an inhibitory role, blocking heparin sulphate-independent cell 
binding until the virion is already bound by gH/gL or gp70 (Gillet et al. 2009). The 
MHV-68 ORF75c tegument protein is involved in moving incoming capsids to the 
nucleus (Gaspar et al. 2008). It also disrupts the ND-10 sites, like LANA-2 of KSHV 
(Gaspar et al. 2008; Ling et al. 2008). 
1.3.4.2. Gene expression 
Following entry and DNA translocation to the nucleus the expression of viral genes, 
like that of all herpesviruses (section 1.1.4.2), takes place in a highly regulated 
cascade fashion (Ebrahimi et al. 2003; Martinez-Guzman et al. 2003). Viral gene 
expression starts as early as three hours post infection in vitro (Ahn et al. 2002) with 
lytic infection in cultured fibroblasts having a similar transcription program to 
infected lungs of mice (Martinez-Guzman et al. 2003). One of the immediate early 
genes, ORF 50, encodes the rta which is a well conserved viral replication and  
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Figure 1.4 Comparing the genome of MHV-68 with that of KSHV and HVS. Open 
boxes represent conserved gene blocks. The orientations of additional ORFs are shown 
as pointed boxes. Abbreviations: CCP, Complement control protein; TK, Thymidine 
kinase; rta, Replication and transcription activator; vGPCR, Viral G-protein coupled 
receptor; STP, Simian transformation-associated protein; DHFR, Dihydrofolate 
reductase; TS, Thymidylate synthase; vFLIP, Viral FLICE-like inhibitory protein; 
LANA, Latency associated nuclear antigen; LAMP2, Latent membrane protein 2. 
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transcription activator of gammaherpesviruses. The rta is essential for lytic 
replication, activating not only early genes but affecting all genes during both 
reactivation and de novo infection (Martinez-Guzman et al. 2003; Wu et al. 2001). 
Over-expression of rta was found to induce expression of specific lytic cycle genes, 
but repress the transcription of ORF 73 which is essential for establishment of 
latency (Hair et al. 2007). The mechanisms for MHV-68 rta transcription induction 
and repression are not known; however, the rta of KSHV has been found to activate a 
number of genes either through direct binding to promoter sequences or through 
other proteins. In addition, KSHV rta targets transcriptional suppressors for 
proteasomal degradation via an E3 ubiquitin ligase activity (Gould et al. 2009). 
1.3.4.3. Viral DNA replication 
MHV-68 has homologues of six of the seven herpes proteins required for viral DNA 
synthesis (see section 1.1.4.3)(Virgin et al. 1997). The seventh protein, a protein with 
origin binding function which differs between herpesviruses (UL9 of HSV, Zta of 
EBV and K8 of KSHV), has not been found for MHV-68 (Gong et al. 2009).  
MHV-68, like KSHV, has two origins of lytic replication (oriLyt) located at either 
end of the genome and a packaging signal in the terminal repeats (Adler et al. 2007; 
Deng et al. 2004). The cellular transcription factor NF-Y has recently been found to 
bind to the oriLyt sequences and is important for MHV-68 lytic replication  
(Gong et al. 2009) 
The generation of a MHV-68 BAC plasmid has simplified the construction of mutant 
viruses. This enabled two studies using signature-tagged mutagenesis to identify 
candidate viral genes involved in virus replication. In these studies 16 and 41 
essential genes were identified, respectively; many of which are conserved between 
herpesviruses, including gB, gH, gM and rta (Moorman et al. 2004; Song et al. 
2005). Further studies on individual genes, using the BAC system, have found that 
some of the genes (ORF 18, 24, 30 and 34) required for infectious virus production 
are essential for late gene expression, but dispensable for viral DNA replication 
(Arumugaswami et al. 2006; Wong et al. 2007; Wu et al. 2009). While some, like 
rta, are essential for both gene expression and DNA replication (Pavlova et al. 2003) 
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1.3.4.4. Assembly and egress 
Following capsid assembly the virion is enveloped and released as described in 
section 1.1.4.4. ORF 52 and ORF33 of MHV-68 encode virion-associated tegument 
proteins important for envelopment and egress into the cytoplasm (Bortz et al. 2007; 
Guo et al. 2009). The glycoprotein gp150 is important for virus release into the 
extra-cellular space, but not for cell-to-cell spread which is thought to be the major 
spread of virus during in vivo infection, avoiding the host immune response  
(de Lima et al. 2004). ORF58 and gp48 are both important for cell-to-cell spread, 
with ORF58 transporting gp48 to the cell surface where it induces outgrowths of 
actin-based membrane projections to create intercellular networks for virion spread 
(Gill et al. 2008; May et al. 2005b; May et al. 2005a). 
1.3.5. MHV-68 primary infection  
MHV-68 infection in vivo is studied by intranasal or intraperitoneal infection of 
laboratory mice. Intranasal infection seems most likely to mimic natural infection, 
since the main site of viral replication in wood mice is the lung and by comparison to 
other gammaherpesviruses (Blasdell et al. 2003). Following intranasal infection of 
anaesthetised mice primary MHV-68 replication takes place in the respiratory tract, 
mainly in alveolar epithelial cells but also mononuclear cells and in the nose, with 
replication spreading to distal epithelial sites such as the adrenal gland (Milho et al. 
2009; Sunil-Chandra et al. 1992b). Primary infection induces an inflammatory 
infiltrate in the lung, made up mainly of macrophages, monocytes, CD4+ and CD8+ 
T-cells, leading to bronchiolitis and interstitial pneumonia (Sarawar et al. 2002; 
Sunil-Chandra et al. 1992b). The lytic infection is controlled by day 10 post infection 
and the inflammation is resolved by the second week, with both CD4+ and CD8+  
T-cells contributing to the control of virus replication (Christensen et al. 1999; 
Stevenson et al. 1999). The CD4+ T-cell antiviral response is dependent on IFN-γ but 
not CD8+ T-cells or B-cells (Christensen et al. 1999; Sparks-Thissen et al. 2004; 
Sparks-Thissen et al. 2005).  
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1.3.6. MHV-68 latency  
Following clearance of lytic virus from the lung low levels of persistent virus can 
still be detected in epithelial cells and during long-term latency virus persists in  
B-cells (Flano et al. 2003; Stewart et al. 1998). The lung has been found to be a 
major site of persistence both in laboratory mice and wood mice (Blasdell et al. 
2003; Stewart et al. 1998). From the lung the virus spreads to the mediastinal lymph 
node (MLN) where dendritic cells, macrophages and B-cells are infected (Nash et al. 
2001). The B-cells undergo a CD4+ T-cell dependent proliferation leading to 
lymphadenopathy and an increase in the number of infected B-cells which spread to 
the spleen and other lymphoid organs where the virus establishes latency (Stewart et 
al. 1998; Usherwood et al. 1996b). During latency in the spleen MHV-68 can be 
detected within germinal centre B-cells, macrophages and dendritic cells (Flano et al. 
2000; Sunil-Chandra et al. 1992a; Weck et al. 1999). Like EBV MHV-68 utilises the 
B-cell differentiation pathway to gain entry into the B-cell memory pool, ensuring 
life-long persistence (Kim et al. 2003). Splenomegaly occurs by day 10 with an 
increase in both size and numbers of germinal centres and a 2-3 fold increase in 
spleen cells, such as B-cells, CD4+ and CD8+ T-cells (Sunil-Chandra et al. 1992b; 
Usherwood et al. 1996a). Infected B-cells and CD4+ T-cells are necessary for the 
development of splenomegaly (Ehtisham et al. 1993; Usherwood et al. 1996c; 
Usherwood et al. 1996b). Splenomegaly is however not a requirement for 
establishment of latency in the spleen (Usherwood et al. 1996b). The number of 
latently infected cells peak at around day 10-14 and decline to a low level with long-
term latency maintained in germinal centre and memory B-cells, as well as 
macrophages and dendritic cells (Flano et al. 2003; Sunil-Chandra et al. 1992b; 
Usherwood et al. 1996c; Willer and Speck 2003).  
Following splenomegaly there is a massive expansion of CD8+ T-cells in the 
peripheral blood, dominated by Vβ4+ CD8+ T-cells, causing an IM-like syndrome 
(Tripp et al. 1997). This selective expansion seems to be MHC-independent, but like 
splenomegaly dependent on CD4+ T-cells and B-cells (Brooks et al. 1999; Coppola 
et al. 1999; Flano et al. 1999). The oligoclonal expansion of Vβ4+ CD8+ T-cells is 
driven by a ligand encoded by the M1 gene that is expressed by latently infected 
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germinal centre B-cells (Coppola et al. 1999; Evans et al. 2008; Hardy et al. 2000). 
Even though these T-cells have the ability to exert effector functions they are not 
essential for the control of latent infection; however, they may function as a back-up 
defence (Braaten et al. 2006; Flano et al. 2004).  
CD4+ T-cells are important for the control of latent infection. Despite a functional 
CD8+ T-cell response, long term MHV-68 infection of mice lacking CD4+ T-cells 
leads to reactivation of virus in the respiratory tract and a chronic wasting disease 
(Belz et al. 2003; Cardin et al. 1996; Stevenson et al. 1998). The CD4+ T-cell control 
of latent infection is not only mediated by IFN-γ but also by direct cytotoxicity 
(Sparks-Thissen et al. 2005; Stuller and Flano 2009). The IFN-γ control however 
seems to be cell type specific, suppressing reactivation in macrophages but not  
B-cells (Steed et al. 2007). CD4+ T-cells are also needed to drive B-cell proliferation 
and maturation leading to a polyclonal non-specific antibody response. This is 
followed by a slow-developing virus-specific antibody response which plays a role in 
the control of latent infection (Kim et al. 2002; Sangster et al. 2000; Stevenson and 
Doherty 1998). The CD4+ T-cells remain activated during the latent infection 
(Christensen and Doherty 1999) with cells specific for viral gp150 and ORF11 
peptides making up 10-20% of the virus specific population (Flano et al. 2001).  
Despite being insufficient in controlling latency, CD8+ T-cells regulate the latent 
load by a single epitope within the M2 protein (Husain et al. 1999; Marques et al. 
2008). 
1.3.6.1. Latency in vitro 
In vitro MHV-68 establishes latency in mouse myeloma B-cell lines, such as NS0 
(Sunil-Chandra et al. 1993). During latent infection of NS0 cells approximately 5% 
undergo reactivation to lytic infection (Nash et al. 2001). Several B-cell lines derived 
from mice with MHV-68 associated lymphomas e.g. S11 have been established 
(Usherwood et al. 1996a). Infection of primary B-cells leads to phenotypic changes 
such as increased proliferation, however the cells are not transformed and the 
genome does not circularise (Dutia et al. 1999).  
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1.3.6.2. Latency transcripts 
In common with other herpesviruses the switch from lytic to latent MHV-68 
infection is accompanied by a shutdown of gene expression, with only a subset of 
genes expressed. Genes expressed during the establishment of latency include  
M1-M4, K3, ORF 72 (vcyclin), ORF 73, ORF 74 (vGPCR), M11 (vbcl-2), ORF 65, 
and the vtRNAs and miRNAs (Bowden et al. 1997; Diebel et al. 2010; Marques et 
al. 2003). The gene expression is cell type dependent, with B-cells of different 
differentiation stages, macrophages and dendritic cells expressing different genes, 
indicating the existence of latency programs (Marques et al. 2003). The gene 
expression during long-term latency has not been well defined.  
The latency associated genes of MHV-68, like that of other gammaherpesviruses, 
play a role in establishment of latency, maintenance of the episome and promoting 
reactivation from latency. ORF 73, a positional homologue of KSHV LANA-1 with 
24.2% sequence homology, is important for the establishment of latency (Fowler et 
al. 2003; Moorman et al. 2003b; Virgin et al. 1997). It is thought to have functions 
similar to the LANA-1 (see section 1.2.2.3.1) in tethering the viral episome to the 
host chromosome during cell division and inhibiting the activity of rta. ORF73 and 
rta thereby regulate each others expression, with the balance between ORF73 and rta 
determining between latency and reactivation. Other latency associated proteins also 
play a part in the establishment of latency in the spleen. These include M11 (vbcl-2) 
(de Lima et al. 2005), M2 (Jacoby et al. 2002; Macrae et al. 2003; Simas et al. 
2004), M3 (Bridgeman et al. 2001), M4 (Evans et al. 2006; Geere et al. 2006) and 
K3 (Stevenson et al. 2002). M2, ORF 72 (vcyclin) and ORF 74 (vGPCR)  
(Moorman et al. 2003a) promote reactivation from latency (Herskowitz et al. 2005; 
Jacoby et al. 2002; van Dyk et al. 2000). 
Cellular proteins are also involved in the establishment and maintenance of latency: 
NFκB inhibits viral replication and IFN-α/β regulates the viral gene expression, 
thereby directing the switch between lytic and latent infection and inhibiting 
reactivation from latency (Barton et al. 2005; Brown et al. 2003; Krug et al. 2009).  
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1.3.7. MHV-68 evasion of the host’s immune system 
MHV-68, like other herpesviruses, has evolved strategies to avoid the host immune 
response, especially during latency amplification. The K3 protein (a homologue of 
KSHV MIR-1) down-regulates MHC class I expression by degrading the MHC class 
I heavy chains and TAP, thereby avoiding CD8+ T-cell recognition during latency 
amplification (Boname and Stevenson 2001; Boname et al. 2004; Lybarger et al. 
2003; Stevenson et al. 2002). M3 is a chemokine binding protein that blocks 
chemokine signalling and thus leukocyte recruitment, including CD8+ T-cells, 
enabling the amplification of latent virus in lymphoid tissue (Bridgeman et al. 2001; 
Martin et al. 2006; Parry et al. 2000; van Berkel et al. 2000). ORF36 encodes a 
multifunctional kinase that is conserved among herpesviruses. This protein binds to 
the activated form of IRF-3 and thereby inhibits the virus-induced type-I IFN 
response, promoting persistent infection (Hwang et al. 2009). The episome 
maintenance protein encoded by ORF73 has a cis-acting CD8+ T-cell evasion 
mechanism, like EBNA-1, so that it can avoid recognition by the immune system 
(see section 1.2.1.1.1) (Yin et al. 2003). Disruption of this evasion mechanisms leads 
to a reduction in latency (Bennett et al. 2005).  
1.3.8. MHV-68 pathogenesis 
MHV-68 associated diseases vary in severity from splenomegaly to 
lymphoproliferative disorders. The outcome of infection depends on the type and 
immunological status of the infected mouse; with severe disease usually not 
occurring in immunocompetent mice. Infection of inbred BALB/c mice leads to both 
lymphoid and non-lymphoid lymphomas in 10% of infected mice, with the number 
of virus DNA positive lymphocytes varying from low to very high numbers. The 
incidence of lymphoma was increased following treatment with the 
immunosuppressant drug cyclosporine A (Sunil-Chandra et al. 1994). Infection of 
BALB/c mice with MHV-72 leads to a similar incidence of lymphomas (Mistrikova 
et al. 1996). MHV-68 infection of BALB β2-microglobulin deficient mice is 
associated with a higher occurrence of lymphoproliferative disease than BALB/c 
mice, with two types of lesions observed: B-cell lymphoma and atypical lymphoid 
hyperplasia (ALH). The AHL lesions, resembling EBV-associated PTLD, commonly 
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contained MHV-68 infected cells, while lymphomas contained few infected cells 
(Tarakanova et al. 2005). The MHV-68 positive B-cell line S11 induces tumours 
when introduced into nude mice, with CD4+ T-lymphocytes found to be important 
for tumour regression (Robertson et al. 2001; Usherwood et al. 1996a). 
There are several candidate viral genes for transformation of cells, including ORF72 
(vcyclin), ORF-74 (vGPCR) and M11 (vbcl-2). vcyclin is an oncogene that binds and 
activates cellular cdks, promoting cell cycle progression and inhibiting T-lymphocyte 
differentiation (Upton et al. 2005; van Dyk et al. 1999). vcyclin is important for in 
vivo replication and reactivation from latency; with its role in reactivation at least in 
part cdk-independent (Upton and Speck 2006; van Dyk et al. 2000). The vGPCR is 
expressed during both lytic infection and latency and has the ability to transform 
cells in vitro (Wakeling et al. 2001). The viral bcl-2 homologue is expressed during 
lytic and latent infection and inhibits apoptosis and autophagy; thus promoting cell 
survival and tumour formation (Ku et al. 2008; Roy et al. 2000; Wang et al. 1999). 
vbcl-2 and vcyclin have been shown to be involved in the development of ALH in 
MHV-68 infected BALB β2-microglobulin deficient mice, while vGPCR is not 
(Tarakanova et al. 2008). 
MHV-68 is also involved in other disorders in immunocompromised mice. Infection 
of young or immunocompromised mice lacking IFN-γ response or B-cells is 
associated with arthritis of large elastic arteries, eventually leading to death  
(Weck et al. 1997). Infection of IFN-γ receptor deficient mice is also associated with 
fibrosis and atrophy of lymphoid tissue, liver, and lungs, with at least splenic fibrosis 
being dependent on a Th2 response (Dutia et al. 1997; Ebrahimi et al. 2001; 
Gangadharan et al. 2008; Mora et al. 2005). Pulmonary inflammation was found to 
lead to more severe disease over time, with 80% developing lymphoid hyperplasia or 
pulmonary lymphoma after 12 months (Lee et al. 2009b). 
1.3.9. MHV-76 and other related viruses 
MHV-76 and MHV-72 were discovered at the same time as MHV-68 and are 
considered strains of MHV-68. MHV-76 is identical to MHV-68 except for a 9538 
bp deletion in the left end of the genome, encompassing M1-M4, the eight vtRNAs, 
and nine miRNAs (Macrae et al. 2001). MHV-76 thereby appears to be a deletant 
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virus occurring during either in vivo or in vitro passaging. This was further supported 
by the generation of a spontaneous deletion mutant with a nearly identical deletion 
affecting the same genes through in vitro passaging (Clambey et al. 2002). MHV-76 
replicates with similar kinetics to MHV-68 in vitro. However, following intranasal 
infection of mice MHV-76 shows an attenuated phenotype (Macrae et al. 2001). 
During acute infection in the lungs, MHV-76 induces a greater inflammatory 
response and is cleared more rapidly. In addition, the virus does not induce 
splenomegaly to the same degree and establishes latency in the spleen at a much 
lower level. Following establishment of latency MHV-76 is able to persist in the 
spleen, but not in the lungs. MHV-72 lacks the first 7 kbp of the genome, 
encompassing M1-M3, vtRNAs and miRNAs (Oda et al. 2005).  
MHV-Brest and WMHV are closely related viruses with 99.2% sequence identity 
considered strains of viruses related to MHV-68 (Chastel et al. 1994; Hughes et al. 
2009). WMHV has 85% sequence identity with MHV-68, with the left end region 
highly conserved, particularly M1 and M4 and the vtRNAs, while five of the 
miRNAs are less conserved (Hughes et al. 2009). The left end of MHV-Brest is also 
highly conserved, with least sequence similarities in the M2 gene  
(Chastel et al. 1994). 
1.3.10. Left-hand end of MHV-68 
The left end of the genome contains the genes that are unique to MHV-68; M1-M4, 
the vtRNAs and miRNAs (Figure 1.5A). The functions of these genes are not fully 
understood, but what is known will be discussed below.  
1.3.10.1. M1 
The M1 ORF has 25% sequence homology with M3 (van Berkel et al. 1999) and is 
expressed during lytic infection both in vitro and in vivo and during latent infection 
in the spleen (Ebrahimi et al. 2003; Marques et al. 2003; Martinez-Guzman et al. 
2003; Simas et al. 1999). M1 is a secreted protein responsible for the expansion of 
Vβ4+ CD8+ T-cells during MHV-68 infection (Evans et al. 2008). It suppresses viral 
reactivation through the action of Vβ4+ CD8+ T-cells, apparently by IFN-γ  








Figure 1.5 (A) The unique genes in the left side of the genome, showing the four unique 
protein coding genes M1-M4 and the vtRNA and miRNA genes. (B) The miRNAs are 
transcribed as part of the vtRNA transcripts (taken from Pfeffer et al. 2005).  
(C) Predicted cloverleaf structure of vtRNA5 (taken from Bowden et al. 1997). 
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production (Clambey et al. 2000; Evans et al. 2008). M1 driven expansion of Vβ4+ 
CD8+ T-cells causes inflammation and multi-organ fibrosis in IFN-γ receptor 
deficient mice (Clambey et al. 2000; Evans et al. 2008). In contrast, M1 was found to 
repress the severity of the lymphoproliferative disease seen in MHV-68 infected 
BALB β2-microglobulin deficient mice (Tarakanova et al. 2008). The M1 driven 
expansion of Vβ4+ CD8+ T-cells also mediates resistance to transplantation tolerance 
during latent infection (Stapler et al. 2008). 
1.3.10.2. M2 
M2 is a membrane-associated protein expressed during lytic infection in the lungs 
and transiently during latent infection in the spleen (Macrae et al. 2003; Marques et 
al. 2003; Usherwood et al. 2000). This protein has been found to be critical for the 
efficient establishment of latency in the spleen and reactivation from latency 
(Herskowitz et al. 2005; Jacoby et al. 2002; Macrae et al. 2003; Simas et al. 2004). 
M2 is not involved in the splenomegaly or expansion of Vβ4+ CD8+ T-cells seen 
during the establishment of latency (Macrae et al. 2003), but is required for 
colonisation of splenic follicles and the differentiation of these cells into memory  
B-cells and plasma cells (Herskowitz et al. 2005; Liang et al. 2009; Simas et al. 
2004). Lack of M2 has been associated with an increase of latently infected germinal 
centre B-cells during long-term latency indicating an inability of these cells to 
differentiate into memory B-cells (Herskowitz et al. 2005; Simas et al. 2004). M2 
promotes B-cell differentiation, proliferation and survival through interactions with 
the guanine nucleotide exchange factor vav, affecting its activity and thereby 
lymphocyte signalling (Madureira et al. 2005; Rodrigues et al. 2006). In primary  
B-cells M2 was found to increase B-cell production of and sensitivity to IL-10 by 
modulating B-cell signalling, thereby driving B-cell proliferation and differentiation 
(Siegel et al. 2008). M2 driven proliferation of B-cells into plasma cells is associated 
with an increase in reactivation (Liang et al. 2009). M2 also protects latently infected 
cells by inhibiting IFN- and apoptosis-mediated innate immunity (Liang et al. 2004; 
Liang et al. 2006). In addition, M2 has a CD8+ T-cell epitope that affects the viral 
latent load during long-term latency (Husain et al. 1999; Marques et al. 2008). 
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1.3.10.3. M3 
M3 encodes a secreted high-affinity broad spectrum chemokine binding protein with 
no sequence similarity to known chemokine receptors (Parry et al. 2000; van Berkel 
et al. 1999). It is expressed abundantly during lytic infection and the establishment of 
latency, but does not seem to be expressed during long-term latency in the spleen 
(Marques et al. 2003; Martinez-Guzman et al. 2003; Simas et al. 1999). M3 is able to 
bind chemokines from all four subfamilies and by blocking their interaction with 
both GPCRs and GAGs inhibits chemokine signalling (Alexander et al. 2002; Parry 
et al. 2000; van Berkel et al. 2000; Webb et al. 2004). In mice M3 was found to be 
critical for the establishment of latency by inhibiting CD8+ T-cell recruitment 
(Bridgeman et al. 2001). This effect on latency was however not seen in a different 
study, instead M3 was found to be involved in the induction of the lethal meningitis 
caused by MHV-68 by regulating the inflammatory responses (van Berkel et al. 
2002). The ability of M3 to block leukocyte recruitment, including CD8+ T-cells, 
through cytokine binding in vivo has been verified in two separate studies using 
transgenic mice (Jensen et al. 2003; Martin et al. 2006). 
1.3.10.4. M4 
M4 encodes a secreted glycoprotein expressed during lytic infection in the lung and 
establishment of latency in the spleen, but not during long-term latency (Evans et al. 
2006; Marques et al. 2003; Townsley et al. 2004). Studies using recombinant viruses 
either by inserting M4 into MHV-76 or disruption of the M4 gene in MHV-68 have 
found that M4 is important for the establishment of latency; however, not for the 
maintenance of long-term latency (Evans et al. 2006; Geere et al. 2006; Townsley et 
al. 2004). Lack of M4 leads to an increased clearance of virus, suggesting that M4 
modulates the immune response (Geere et al. 2006); consistent with this M4 has 
been shown to bind the chemokine CXCL4 and reduce its levels (pers commun  
Y. Ligertwood and B.M. Dutia). M4 did not have an effect on splenomegaly, again 
showing that the increase in latent load is not dependent on lymphocytosis (Geere et 
al. 2006; Townsley et al. 2004).  
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1.3.10.5. vtRNAs and miRNAs 
MHV-68 encodes eight vtRNAs and nine miRNAs which are transcribed by RNA 
polymerase III as dicistronic transcripts, with one or two 20-25 bp pre-miRNA 
hairpins following the tRNA (Figure 1.5B) (Bowden et al. 1997; Pfeffer et al. 2005). 
The vtRNA sequences contain internal RNA polymerase III type-2 promoter 
elements with three overlapping A-box promoter elements and one B-box promoter 
element (Diebel et al. 2010). 
The vtRNAs contain up to 75% sequence homology with some cellular tRNAs and 
are predicted to form cloverleaf-like secondary structures in which the majority of 
invariant and semi-invariant bases typical of tRNAs are conserved (Figure 1.5C; see 
section 1.4.2.1) (Bowden et al. 1997). However, the prediction of amino acid 
specificity is difficult because the vtRNAs have atypical anti-codon arms, differing 
in size and sequence from known cellular tRNAs. In addition, the vtRNAs do not 
have more similarity to tRNAs sharing the same anticodon than other tRNAs. 
vtRNA7 contains an intron, but lacks the purine residue needed for splicing, 
indicating that at least this vtRNA is unlikely to function in translation. The 
determinant bases (nt73), which are known to be important for recognition by 
cellular aminoacyl-tRNA synthases, are not conserved; consistent with this at least 
four of the vtRNAs are not aminoacylated (Bowden et al. 1997). At least two of the 
vtRNAs are however recognised as tRNAs by the cellular machinery and processed 
into mature tRNAs with the post-transcriptional addition of the 3’ CCA sequence. 
The vtRNAs are expressed at high levels during both lytic infection in the lung and 
latent infection in the spleen. They can be detected by in situ hybridisation in spleens 
in the absence of viral DNA, which has lead to the vtRNAs being used to detect 
latently infected cells (Bowden et al. 1997). During lytic infection in vitro the 
vtRNAs are located in both the nucleus and cytoplasm of the cell, at later times 
predominantly in the cytoplasm (Cliffe et al. 2009b). The functions of these vtRNAs 
are not known; however, they are not thought to act as part of the normal translation 
machinery. They are selectively packaged in the virion, indicating their need either 
as structural components of the virion or immediately upon entry into the cell  
(Cliffe et al. 2009b).  
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MHV-68 has been predicted to encode at least 14 miRNAs, with nine identified 
through cloning (Pfeffer et al. 2005). These miRNAs can be detected in both lytically 
and latently infected tissues ex vivo with varying levels of expression  
(Diebel et al. 2010). The miRNAs are able to down-regulate expression of genes 
containing their target sequence in vitro, with three miRNAs able to reduce luciferase 
expression by at least 50% (Diebel et al. 2010). miRNA 8 appears to be post-
transcriptionally modified with the addition of uracils (Diebel et al. 2010). How the 
miRNAs are processed from the vtRNA-pre-miRNA transcript into mature miRNAs 
and what targets and thereby functions they might have is currently not known. 
1.4. Non-coding RNAs 
1.4.1. Viral non-coding RNA molecules 
Several viruses express diverse non-coding RNAs that differ in structure, expression 
and function. Some of these are reviewed below. 
1.4.1.1. Alphaherpesvirus non-coding RNA molecules 
1.4.1.1.1. HSV LATs 
The only abundant viral transcripts detected during latent infection with HSV-1 are 
the LATs that were initially detected in latently infected murine (Spivack and Fraser 
1987; Stevens et al. 1987) and then also rabbit (Rock et al. 1987) and human  
(Krause et al. 1988) trigeminal ganglia. The primary LAT transcript is a 8.3-8.5kb 
capped, polyadenylated, non-coding RNA that is spliced into a stable, non-
polyadenylated 2.0 kb intron, which can be further spliced into a 1.5 kb intron in 
some neurons (Farrell et al. 1991; Spivack et al. 1991; Wagner et al. 1988a; Wagner 
et al. 1988b). The 2.0 kb intron is the most abundant LAT species and is located 
mainly in the nucleus during latent infection (Stevens et al. 1987; Wagner et al. 
1988b). The introns are unusually stable because of a lariat structure, while the 
predicted 6.3 kb exon is highly unstable (Kang et al. 2006; Thomas et al. 2002). The 
primary LAT transcript is expressed from a neuron-specific promoter or enhancer 
(Berthomme et al. 2000; Zwaagstra et al. 1990). The region encoding the LATs, 
located in the inverted repeats, is complex with several ORFs and transcripts thought 
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to be encoded. The last 750 bp of the 2.0 kb LAT intron lies anti-sense to the lytic 
transactivator ICP0. Further, the primary LAT transcript lies anti-sense to ICP4 and 
γ134.5 and is co-linear with ORF P, L/STs, αX and βX (reviewed in Roizman et al. 
2007). Several other transcripts have been described that lie within the promoter 
regulatory region or first 1.5 kb of the LAT coding sequence; some reported to 
express proteins (UOL, AL and AL3) and some RNAs (AL2, sRNA1 and sRNA2) 
(Jaber et al. 2009; Naito et al. 2005; Perng et al. 2002; Shen et al. 2009). The LAT 
region has also been shown to encode several miRNAs, six in the unstable large exon 
and two upstream of LAT (Cui et al. 2006; Umbach et al. 2008; Umbach et al. 
2009). 
Because of the complexity of the LAT region determining the functions of the LATs 
has been difficult, with contradictory results obtained with different parts of the LAT 
region deleted or in different animal models. Even though the LATs do not seem to 
be critical for latency several studies have implicated LATs in facilitating efficient 
reactivation, both in mouse and rabbit animal models (Garber et al. 1997; Hill et al. 
1990; Kang et al. 2003; Leib et al. 1989; Perng et al. 1994; Steiner et al. 1989). 
Several of these studies did not find a role for the LATs in establishing latency; 
however, more sensitive PCR techniques have found a defect in the establishment of 
latency during infection with deletion mutants, with the decrease in the number of 
latently infected neurons causing the lack of reactivation (Sawtell and Thompson 
1992; Thompson and Sawtell 1997, 2001). The deficiency in establishing latency 
was caused by an increase in neuronal cell death (Thompson and Sawtell 2001). The 
region implicated in reactivation, and thus possibly establishment of latency, has 
been mapped to a 348 bp region of the 5’of LAT (Bloom et al. 1996).  
The mechanism by which the LATs facilitate the establishment of latency and 
reactivation is not clear. The LATs have been shown to reduce the production of lytic 
gene transcripts during both lytic infection and latent infection of mice (Chen et al. 
1997; Garber et al. 1997) and in cultured murine neuronal cells (Mador et al. 1998); 
however, they seem to have the opposite effect during infection of rabbits  
(Giordani et al. 2008). One of the mechanisms by which the LATs inhibit lytic gene 
expression is by inducing epigenetic changes, with LAT transcription promoting 
heterochromatin on lytic promoters (Cliffe et al. 2009a; Wang et al. 2005b). Mutants 
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lacking LATs have been found to cause more neuronal death, higher mortality in 
mice and increased apoptosis (Ahmed et al. 2002; Branco and Fraser 2005; Perng et 
al. 2000; Thompson and Sawtell 2001; Wang et al. 2005b). It is therefore speculated 
that the LATs protect infected neurons from cell death by inhibiting lytic gene 
transcription and protecting against apoptosis; thus increasing the number of latently 
infected cells and preventing their death prior to reactivation.  
The 2 kb LAT intron may also have a role in translation. During lytic infection the  
2 kb LAT intron locates to the cytoplasm as well as the nucleus, apparently 
transported there as part of the 60S ribosomal subunit. Its interaction with ribosomal 
proteins associated with the 60S ribosomal subunit suggests that it may have a 
structural role of the ribosomal complex and thereby affect the translation machinery 
(Ahmed and Fraser 2001; Atanasiu and Fraser 2007). 
Recently two small RNAs identified within the 5’ end of the 2.0 kb LAT intron were 
found to inhibit apoptosis, reduce infectious virus production, and inhibit expression 
of the transcription factor ICP4 in in vitro studies (Shen et al. 2009).  
Of the eight miRNAs expressed from the LAT region, two have been found to  
down-regulate ICP0 and ICP4 (Umbach et al. 2008).  
1.4.1.2. Gammaherpesvirus non-coding RNA molecules 
1.4.1.2.1. EBV EBERs 
The two EBERs, EBER-1 and EBER-2, are the most abundant transcripts expressed 
during latent EBV infection (Lerner et al. 1981). Like the vtRNAs expressed by 
MHV-68, the EBERs are small, non-polyadenylated, uncapped, non-coding RNAs 
transcribed by RNA polymerase III into RNAs of 167 and 172nt, respectively 
(Arrand and Rymo 1982; Lerner et al. 1981; Rosa et al. 1981). However, the 
presence of RNA polymerase II promoter elements makes it possible that they are 
also transcribed by RNA polymerase II (Howe and Shu 1989). The EBERs have 
highly conserved sequences, but only have 54% sequence homology between each 
other (Arrand et al. 1989). They both form very similar stable secondary structures 
due to extensive base-pairing, forming a number of short stem-loops (Figure 1.6A) 
(Glickman et al. 1988). These predicted secondary structures show similarity to both  





Figure 1.6 Predicted secondary structures of viral non-coding RNA molecules.  
(A) EBER-2 of EBV (taken from Rosa et al. 1981). (B) HSUR-1 of HVS (taken from Lee 




Chapter One  Introduction 
 49
herpesvirus papio small RNAs and adenovirus VAI and VAII molecules (Howe and 
Shu 1988; Rosa et al. 1981). The biological functions of the EBERs seem to depend 
on their secondary structures since disruption of the secondary structure by replacing 
GTP with ITP reduces EBER-1 binding to PKR (Clarke et al. 1991). Both EBERs 
can be detected during all forms of latency, with EBER-1 10 times more abundant 
than EBER-2 due to differences in half-life (Clarke et al. 1992). The EBERs are 
expressed during many EBV-associated diseases; however, are absent in disorders 
such as oral hairy leukoplakia that consists of replicating cells (Gilligan et al. 1990).  
The EBERs seem to localise to both the nucleus and the cytoplasm as they have been 
found to interact with cellular proteins in both locations. They form complexes with 
lupus erythematosis-associated antigen (La) (Lerner et al. 1981), ribosomal protein 
L22, RIG-I and PKR. La is a highly abundant nuclear phosphoprotein that binds the 
3’ end of newly synthesised RNA polymerase III transcripts, protecting them from 
exonuclease digestion (Wolin and Cedervall 2002). The EBERs also bind to the 
latent form of PKR and inhibit its phosphorylation by preventing its dimerisation. 
This inhibits the virus induced phosphorylation and inactivation of the protein 
synthesis factor eIF-2α and interferes with the inhibition of translation (Clarke et al. 
1991; McKenna et al. 2007; Sharp et al. 1993). The EBERs have also been found to 
prevent the inhibition of protein synthesis in an PKR-independent manner  
(Laing et al. 2002). They are also associated with polyribosomes in the cytoplasm, 
binding to L22, an abundant ribosomal protein (Toczyski and Steitz 1991). The 
function of L22 is not clear; however, it has been implicated in the chromosomal 
3;21 translocation seen in some cases of acute and chronic myeloid leukaemias 
(Nucifora et al. 1993). The EBERs have multiple binding sites for L22 and it is 
possible that the EBERs may have an affect on translation by interacting with the 
ribosome (Fok et al. 2006). However, binding of L22 to the EBERs out-competes 
other proteins, e.g. PKR, and thus interferes with the EBERs’ PKR-dependent and 
 -independent regulation of protein synthesis (Elia et al. 2004). EBER binding to  
RIG-I leads to its activation and induction of IL-10, as well as type-I IFNs and 
thereby apoptosis, through phosphorylation of NFκB and IRF-3 (Samanta et al. 
2006; Samanta et al. 2008). To avoid apoptosis the EBERs inhibit IFN-α-mediated 
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as well as Fas-mediated apoptosis by interaction with PKR (Nanbo et al. 2002; 
Nanbo et al. 2005). 
Several studies have shown that the EBERs have growth-promoting properties. The 
EBERs are responsible for the malignant phenotype seen in BL cells and contribute 
to tumorigenicity in SCID mice (Komano et al. 1999) (Ruf et al. 2000). EBER-2 is 
also important for efficient EBV-induced B-lymphocyte growth transformation, 
promoting growth by inducing IL-6 production (Wu et al. 2007). The EBERs also 
induce other cytokines in different cell types, e.g. IL-10, IGF-I, IL-9, which all act as 
autocrine growth factors (Iwakiri et al. 2005; Samanta et al. 2008; Yang et al. 2004). 
A recent study showed that the EBERs released from EBV-infected cells activate 
toll-like receptor 3 (TLR3) signalling, thereby inducing type-I IFNs and 
proinflammatory cytokines which contribute to the immunopathological diseases 
caused by EBV-infection (Iwakiri et al. 2009). 
1.4.1.2.2. HVS U RNAs 
HVS causes T-cell lymphomas in new world primates. The most abundant viral gene 
products in latently infected transformed T-cells are seven small nuclear U RNAs, 
HSURs (Figure 1.6B) (Albrecht and Fleckenstein 1992; Lee et al. 1988; Murthy et 
al. 1986; Wassarman et al. 1989). These HSURs are 75 to 143nt long and are 
encoded by a cluster of genes at the left end of the genome, which is essential for 
oncogenicity and immortalisation, but is not required for replication (Desrosiers et al. 
1986). The HSURs are not required for viral transformation in vitro (Ensser et al. 
1999; Murthy et al. 1989). The HSURs have no sequence similarity to cellular  
U RNAs, but share several other features: they are transcribed by RNA polymerase II 
and have the same typical promoters, enhancers and 3’-end signals, acquire  
5’ trimethylguanosine caps and have the Sm protein binding site sequences  
(Lee et al. 1988). Like cellular U RNAs that form small nuclear ribonucleoproteins 
(snRNPs) involved in RNA maturation such as splicing and polyadenylation, HSURs 
associate with snRNPs, of the class Sm, using the cellular protein survival of motor 
neurons (SMN) (Golembe et al. 2005). The HSURs have a high affinity for SMN 
and can out-compete host U RNAs for snRNP assembly; the significance of this is 
not clear.  
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The 5’-ends of HSURs 1, 2 and 5 have conserved AUUUA sequences of different 
copy numbers. Similar AUUUA motifs, known as AREs, are present in the 3’ 
untranslated region (UTR) of short-lived mRNAs such as protooncogenes, cytokines, 
and lymphokines and target these mRNAs for degradation. Given that the HSURs 
bind proteins known to bind AREs and regulate mRNA stability, such as HuR which 
protects ARE-containing mRNAs, they are thought to compete with these cellular 
proteins and alter the expression of cytokines and protooncogenes (Fan and Steitz 
1998; Myer et al. 1992; Myer et al. 1997). However, HSUR1 and HSUR2 were not 
found to affect the levels of ARE-containing mRNAs in vitro, but they were found to 
up-regulate a small number of genes associated with T-cell activation in transformed 
cells (Cook et al. 2004; Cook et al. 2005). The HSUR1 ARE was also found to 
induce degradation of small nuclear RNAs, including itself, HSUR2 and cellular U1 
(Fan et al. 1997). 
1.4.1.2.3. KSHV PAN RNAs 
The PAN RNA is an early lytic 1.2 kb polyadenylated non-coding RNA of unknown 
function that accumulates to high levels in the nucleus (Sun et al. 1996; Zhong et al. 
1996; Zhong and Ganem 1997). It has features of both U RNAs and mRNAs in that 
it is transcribed by RNA polymerase II, lacks a 5’ trimethylguanosine cap, is not 
associated with polyribosomes and has several parts with sequence homology to  
U1 RNA, 5’ sequence elements typical of regulatory regions of U RNAs and 33% 
uracils content typical of U RNAs (Sun et al. 1996). In addition, it associates with 
Sm forming ribonucleoprotein complexes in the nucleus (Sun et al. 1996; Zhong and 
Ganem 1997). The high level of PAN expression is attributed to two factors. First, 
PAN expression is up-regulated by the transactivators rta and Mta, with rta binding 
to a very strong rta-response element (RRE) located in the promoter (Chang et al. 
2002; Kirshner et al. 2000; Palmeri et al. 2007; Song et al. 2001; Song et al. 2002). 
In addition, PAN contains a cis-acting element PAN-ENE (PAN RNA expression 
and nuclear retention element) that protects polyadenylated intronless transcripts 
from rapid decay by interactions with the poly-A tail and retains these transcripts in 
the nucleus (Conrad and Steitz 2005; Conrad et al. 2006; Conrad et al. 2007).  
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1.4.1.3. Adenovirus non-coding RNAs 
1.4.1.3.1. VAI and VAII 
All adenoviruses examined encode one or two non-coding RNAs known as VAI and 
VAII that vary in sequence and length, 149-174nt, between different viruses (Ma and 
Mathews 1996; Ohe and Weissman 1971; Reich et al. 1966; Soderlund et al. 1976). 
The VA RNAs are transcribed by RNA polymerase III early during the infection. 
VAI is synthesised in increasing amounts during the later stages to become the most 
abundant RNA in the cytoplasm, while VAII is slightly less abundant (Soderlund et 
al. 1976). The VAs form highly structured and stable secondary structures consisting 
of three major domains: terminal stem, central domain and apical stem; with specific 
functions attributed to each domain (Figure 1.6C) (Coventry and Conn 2008; Ma and 
Mathews 1993).  
VAI was found to be critical for efficient translation when a deletion mutant lacking 
VAI showed impaired growth (Thimmappaya et al. 1982). It was further found that 
VAI blocks the antiviral activation of PKR (Kitajewski et al. 1986; O'Malley et al. 
1986) using the same mechanism as the EBERs (see section 1.4.1.2.1)  
(McKenna et al. 2007). In fact it was the similarities of gene organisation, size and 
predicted secondary structure between the VAs and EBERs that lead to the idea that 
the EBERs, like the VAs, may influence translation. The EBERs were subsequently 
shown to substitute for the VAs and rescue translation during infection with deletion 
mutants lacking the VAs (Bhat and Thimmappaya 1983, 1985). The apical stem of 
VAI is important for binding to PKR, while the central domain is critical for 
inhibition of PKR (Clarke et al. 1994; Coventry and Conn 2008; Ghadge et al. 1991; 
Ghadge et al. 1994). The terminal stem is however dispensable for PKR inhibition 
(Wahid et al. 2008). In addition to regulating translation VAI may also regulate RNA 
editing since it binds the RNA-specific adenosine deaminase, ADAR, and inhibits its 
interferon-inducible RNA-editing activity (Lei et al. 1998). VAII has limited ability 
to block PKR but is able to bind other proteins with double stranded-binding motifs, 
such as RNA helicase A and nuclear factor 90 (NF90), both involved in 
transcriptional regulation (Liao et al. 1998; Ma and Mathews 1993; Reichman et al. 
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2002). Like the EBERs both VAI and VAII form ribonucleoprotein complexes with 
La (Rosa et al. 1981). The significance of these interactions is not known.  
The VAs also inhibit RNA interference (RNAi). As discussed in section 1.4.2, RNAi 
is a posttranscriptional gene silencing mechanism where 21-23nt RNAs generated 
from cytoplasmic processing of endogenous distinct hairpin structures (miRNAs), 
either degrade or inhibit translation of mRNA targets. The VAs out-compete binding 
to the Exportin-5 nuclear export factor and Dicer, preventing the export of  
pre-miRNAs from the nucleus and their processing into functional miRNAs that can 
be incorporated into the RNA-induced silencing (RISC) complex (Andersson et al. 
2005; Lu and Cullen 2004). In addition, the terminal stem is cleaved by Dicer 
generating miRNAs named svaRNAs or mivaRNAs (Andersson et al. 2005; Aparicio 
et al. 2006; Sano et al. 2006). 80% of RISC complexes are associated with 
mivaRNAs and VAII mivaRNAs account for 60% of small RNAs in RISC 
complexes, indicating that cellular miRNAs are out-competed (Xu et al. 2007). The 
mivaRNAs are thought to be functional because: they are able to inhibit the 
expression of genes with complementary sequences, were detected on 
polyribosomes, and inhibition of VAI mivaRNAs affects virus production  
(Aparicio et al. 2006; Sano et al. 2006; Xu et al. 2007). Recently 30 cellular genes 
involved in cell growth, transcription, RNA metabolism and DNA repair were found 
to be down-regulated in adenovirus infected or transfected cells expressing 
mivaRNAs. Of these TIA-1, a splicing and translational regulator, is a direct target of 
mivaRNAI-138 and is down-regulated both at mRNA and protein level  
(Aparicio et al. 2009).  
1.4.2. tRNAs 
1.4.2.1. tRNA structure 
The tRNAs are small RNA molecules, usually 74 to 95nt, that play a central role in 
translation by providing the link between mRNA and protein. As one of the first 
nucleic acids to be sequenced the tRNAs were found to form a predicted canonical 
cloverleaf secondary structure (Figure 1.7A) with three arms and loop regions, a 
variable loop and acceptor arm (Holley et al. 1965). The acceptor arm made up of  




Figure 1.7 Secondary (A) and tertiary (B) structure of a typical tRNA molecule, 
showing the acceptor stem (purple) with the CCA tail (orange) and discriminator 
nucleotide (pink), D arm and loop (red), T arm and loop (green), variable loop (yellow) 
and anticodon arm and loop (blue) with the anticodon (black). Tertiary structure (B) 
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seven base pairs has a 3’ CCA invariant sequence added transcriptionally to which 
the amino acid is attached. The D arm has three or four base pairs, while the T and 
anticodon arms have five base pairs (Dirheimer et al. 1995). The loops vary more in 
length with the anti-codon and T loops comprising seven nucleotides, while the D 
and V loops vary in length. The tRNAs have several invariant (the same nucleotide) 
and semi-invariant (always purine or always pyrimidine) nucleotides, that often are 
important for the tertiary structure of the tRNA (Dirheimer et al. 1995). Using X-ray 
crystallography the tRNAs were found to form a stable L-shaped tertiary structure 
through base pairing of nucleotides in the D and T loops (Figure 1.7B) (Robertus et 
al. 1974; Suddath et al. 1974). The acceptor arm thereby folds onto the T arm 
creating the acceptor stem and the D arm onto the anticodon arm creating the 
anticodon stem (Dirheimer et al. 1995). 
1.4.2.2. tRNA expression 
Unlike mRNAs, tRNAs are transcribed by RNA polymerase III. The eukaryotic 
tRNA genes have internal promoters made up of highly conserved box-A and box-B 
promoter elements which form the binding site for the multisubunit transcription 
factor TFIIIC (Sprauge 1995). TFIIIC recruits TFIIIB to a ~50bp conserved 
sequence pattern upstream of the transcription start site (Giuliodori et al. 2003). 
TFIIIB forms a stable complex with the DNA and recruit RNA polymerase III 
promoting multiple rounds of transcription initiation. Transcription is terminated at a 
short run of T residues and is dependent on upstream promoter elements in the 
TFIIIB binding site (Sprauge 1995). The TATA-box binding protein (TPB) is a 
component of TFIIIB that binds to a TATA-like sequence and is necessary for 
transcription (Dieci et al. 2007). This region has also been implicated in regulation of 
transcription and tissue specific expression of tRNAs (Sprauge 1995). A number of 
viruses up-regulate RNA polymerase III transcription. The adenovirus E1a protein 
increases the amount of TFIIIC; thus increasing the transcription of RNA polymerase 
III genes such as tRNAs and VAs (Berger and Folk 1985; Yoshinaga et al. 1986). 
EBV induces TFIIIC and BDP1, one of the subunits of TFIIIB, stimulating 
transcription of the EBERs as well as other RNA polymerase III transcripts such as 
tRNAs (Felton-Edkins et al. 2006). In addition, transcription of tRNAs is  
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up-regulated in cancers by oncoproteins such as c-Myc, while controlled by tumour 
suppressors (White 2008). Up-regulated tRNA expression, in particular the initiation 
tRNA (tRNAiMet) has been implicated in cellular transformation  
(Marshall et al. 2008) 
Following transcription the tRNAs go through further processing, e.g. removal of 
extra 3’and 5’ sequences, modification of residues, excision of any introns, and the 
addition the CCA sequence, which requires several enzymes. 
1.4.2.3. tRNA functions 
1.4.2.3.1. Translation 
The tRNAs function during translation is well known and will not be described in 
detail here. During translation the tRNAs interact with several proteins and RNAs, 
some are specific for that type of RNA and some interact with all tRNAs; thus 
requiring highly conserved regions. The attachment of the correct amino acid to the 
tRNA requires interaction between the correct aminoacyl-tRNA synthetase and the 
anticodon loop (which specifies the amino acid), acceptor arm with the discriminator 
nucleotide at position 73, as well as individual nucleotides in the D and T arms 
(Meinnel 1995). Through associations with the ribosome and different factors the 
tRNAs recognise the codon sequence in the mRNA through complementary  
base-pairing with the anticodon and line up the amino acids, forming the 
polypeptide. 
1.4.2.3.2. Amino acid starvation 
It is important for the survival of the cell to have sufficient amounts of 
aminoacylated tRNAs available. Uncharged tRNAs as a result of amino acid 
starvation have been found to play important roles in the regulation of protein 
synthesis in both eukaryotic and prokaryotic cells. In bacteria the binding of an 
uncharged tRNA to the ribosome stalls translation and triggers a stringent response 
with production of specific signalling nucleotides, (p)ppGpp, which act as global 
transcription regulators lowering the cell’s metabolism, while over-expressing genes 
involved in amino acid synthesis (Jain et al. 2006). In gram-positive bacteria 
aminoacyl-tRNA synthetase genes and genes involved in amino acid synthesis have 
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riboswitch leader elements (T boxes) to which specific tRNAs bind that allow for 
monitoring of amino acid conditions. Binding of an aminoacylated tRNA to the  
T box leads to the formation of a terminator helix and termination of transcription. 
However, the binding of an uncharged tRNA leads to the stabilisation of an anti-
terminator and transcription can proceed (Green et al. 2010). Uncharged tRNAs have 
also been implicated in regulation of replication of ColE1-like replicons in E.coli, by 
binding to or mediating tRNA-dependent cleaving of RNA I, a negative regulator of 
replication (Wang et al. 2006; Wegrzyn and Wegrzyn 2008).  
In eukaryotic cells the response to amino acid starvation is different. The build up of 
uncharged tRNAs activates the protein kinase GCN2 which phosphorylates and 
inactivates eIF-2, leading to a reduction in global protein synthesis (Wek et al. 1995). 
In yeast phosphorylation of eIF-2 also induces translation of GCN4 mRNA, a 
transcriptional activator of a large number of amino acid biosynthesis genes and 
genes encoding aminoacyl-tRNA synthetases (Hinnebusch 2005). In mammalians the 
translation of the activating transcription factor 4 (ATF4) is induced, leading to 
activation of several genes and pathways, as well as ATF3 and ATF5, ultimately 
leading to regulation of gene expression at different levels, such as chromatin 
structure, mRNA splicing, export and translation (Harding et al. 2000; Jiang et al. 
2004; Kilberg et al. 2005; Zhou et al. 2008). 
1.4.2.4. tRNA genes and chromatin 
tRNA genes have been shown to regulate gene expression by affecting the chromatin 
organisation (McFarlane and Whitehall 2009). tRNA genes can act as chromatin 
barriers that limit the spread of heterochromatin (silencing) into a euchromatin 
(transcriptional active) region in budding and fission yeast (Biswas et al. 2009; 
Donze et al. 1999; Donze and Kamakaka 2001; Scott et al. 2006; Scott et al. 2007; 
Simms et al. 2004). The functions of these tRNAs are dependent on the ability of the 
gene to be transcribed. However, in both fission and budding yeast ectopic B-box 
elements not linked to functional polymerase III genes have been found to act as 
chromatin barriers (reviewed in McFarlane and Whitehall 2009). In mammals short 
interspersed elements (SINES), believed to derive from tRNAs and containing B-box 
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elements, are thought to protect promoters from spread of heterochromatin; this was 
found for an Alu SINE element in transgenic mice (Willoughby et al. 2000).  
tRNA genes have also been shown to block enhancers or silencers from affecting 
promoters of nearby genes in yeast (Bolton and Boeke 2003; Hull et al. 1994). In one 
study this was found to be dependent on the localisation of tRNA genes in or near the 
nucleolus (Wang et al. 2005a). Some of the ectopic B-box elements have also been 
found to have repressive effects on nearby genes (McFarlane and Whitehall 2009). 
1.4.2.5. tRNA functions during viral infections 
In retroviruses the ssRNA genome is converted into dsDNA by the reverse 
transcriptase (RT) for integration into the host genome. This DNA synthesis, as well 
as that of retrotransposons and plant pararetroviruses, is primed by specific tRNAs. 
In retroviruses and plant pararetroviruses the primer binding site is complementary to 
18 respective 8-12 nucleotides in the 3’ end of the primer tRNA, while 
retrotransposons can bind both the 3’ end and internal regions (Marquet et al. 1995). 
However, there are also other interactions between the primer and RNA molecule 
which are not understood. The tRNA used for priming differs, e.g. Rous sarcoma 
virus (RSV) uses tRNATrp, and HIV-1 tRNALys3 (Harada et al. 1975; Wakefield et al. 
1995). The primer tRNA is selectively packaged in the virion (Jiang et al. 1993; 
Sawyer and Dahlberg 1973), and in the case of HIV-1 the cognate aminoacyl-tRNA 
synthetase is as well (Cen et al. 2001). 
Bacteriophages carry tRNA genes that are thought to compensate for the codon 
differences in the phage and host genomes (Bailly-Bechet et al. 2007; Desai et al. 
1986; Weiss et al. 1968).  
1.4.2.6. tRNA-like molecules 
Many tRNA-like molecules with structural or functional resemblance to tRNA 
molecules have been identified that have various functions, such as initiation and 
regulation of replication, intron splicing, regulation of gene expression, and tagging 
of abnormal proteins for proteolysis (Giege et al. 1998). Some of these will be 
discussed here.  
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1.4.2.6.1. Plant virus tRNA-like molecules 
Plant viruses of a number of virus genera have tRNA-like structures (TLSs) at their 
3’ termini. Three aminoacyl identities have been identified: valine, histidine and 
tyrosine; however, not all of the TLSs are dependent on aminoacylation for function 
and the ability of aminoacylation varies between TLSs (reviewed in Dreher 2009; 
Florentz and Giege 1995). The TLS-containing viruses are exemplified by: Turnip 
yellow mosaic virus (TYMV; valin), Tobacco mosaic virus (TMV; histidine) and 
Brome mosaic virus (BMV; tyrosine). The TLS of TYMV is the one that most 
closely resembles cellular tRNAs: it has an anticodon-D stem and a pseudoknot 
structured acceptor-T stem that allows for the typical L-shape (Rietveld et al. 1983). 
In addition to being recognised by cellular aminoacyl-tRNA synthetases, the TLSs 
are adenylated by CCA nucleotidyltransferases and form ternary complexes with 
eEF1A elongation factor. TYMV is also cleaved by Ribonuclease P (RNase P) and is 
further processed by tRNA modifying enzymes (Dreher 2009; Guerrier-Takada et al. 
1988).  
Various functions have been attributed to the TLSs. The promoters for minus strand 
replication by the replicase are located within the TLSs opposite the 3’ C of TYMV, 
BMV, and TMV. However, initiation of replication is not dependent on the TLS 
structure, though it might help to present the promoter elements in the correct 
conformation (Dreher 2009). The TLS of TYMV has high affinity for eEF1A and 
through this interaction it acts as a translational enhancer, a function that is 
dependent on aminoacylation (Dreher et al. 1999; Matsuda and Dreher 2004). 
However, binding of eEF1A to the TLS represses minus strand synthesis, and it is 
therefore speculated that the TLS down-regulates minus-strand synthesis and 
enhance translation until replicase levels increase and can out-compete eEF1A for 
binding to the TLS (Matsuda et al. 2004). The TLS of BMV, like that of TYMV, is 
also a regulator of translation. In addition it functions as a telomere with the host 
CCA nucleotidyltransferase maintaining intact termini and is also required for virion 
assembly (Barends et al. 2004; Choi et al. 2002; Rao et al. 1989).  
1.4.2.6.2. Transfer messenger RNA 
The transfer messenger RNA (tmRNA) is a bacterial molecule with features of both 
tRNAs and mRNAs. Aminoacylated tmRNAs recognise stalled ribosomes, move the 
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started polypeptide to its amino acid and replace the faulty mRNA with an ORF 
within the tmRNA to tag the protein for proteolysis (reviewed in Dulebohn et al. 
2007).  
1.4.2.6.3. The threonyl-tRNA synthetase gene of E.coli 
The threonyl-tRNA synthetase (ThrRs) gene of E.coli regulates its own translation. 
When there is a high level of ThrRs it binds to tRNA-like structures in the operator 
that mimic the anticodon arm of E.coli tRNAThr, thereby blocking translation 
(Romby et al. 1996).  
1.4.3. miRNAs 
The first small RNA was discovered in 1993 during studies of genes controlling the 
timing of developmental stages of Caenorhabditis elegans (C. elegans) larva. The  
lin-4 gene, known to control timing, was found to not encode a protein but two small 
RNAs of 22 and 61nt (Lee et al. 1993). It was further found that the small lin-4 
RNAs had sequences complementary to 3’ sequences of lin-14 and that this 
interaction reduced the amount of lin-14 protein without affecting the mRNA levels 
(Wightman et al. 1993). Since then these small RNAs, now called miRNAs, have 
been found in worms, flies, and mammals, and affect many cellular pathways 
including control of development, cellular differentiation, proliferation and 
apoptosis. Dysregulation of miRNAs have been found in human disorders, including 
cancers (Iorio and Croce 2009). More than 700 miRNAs have been identified in 
human cells to date (MiRBase) and since one miRNA might have hundreds of 
targets, thousands of genes may be regulated by miRNAs (Selbach et al. 2008). 
Many miRNAs are conserved between species; around 50% of C. elegans miRNAs 
have homologues in humans, indicating the importance of these miRNAs (Ibanez-
Ventoso et al. 2008).  
1.4.3.1. miRNA biogenesis 
miRNAs are transcribed by RNA polymerase II or III in the form of long primary 
miRNAs (pri-miRNAs) that can form stable hairpin structures (Borchert et al. 2006; 
Cai et al. 2004; Lee et al. 2004). It was originally thought that miRNAs were 
transcribed only by RNA polymerase II, and the MHV-68 miRNAs were the first 
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found to be transcribed by RNA polymerase III. Recent research show that tRNA or 
tRNA-like coding units such as Alu elements can drive expression of miRNAs in 
mammalian genomes and it is estimated that more than 20% of human miRNAs 
could be transcribed by polymerase III (Borchert et al. 2006). The pri-miRNA 
transcripts often contain several miRNA sequences clustered together, can be capped 
and adenylated, and encoded from non-coding sequences or from introns, exons or 
UTRs of protein-coding sequences (Cai et al. 2004; Lee et al. 2002; Lee et al. 2004; 
Saini et al. 2007). miRNA expression is under the control of transcription factors and 
depends on the methylation status of the gene (Weber et al. 2007). Mammalian 
miRNAs often have multiple isoforms that may have some overlapping functions, 
but may also have distinct functions depending on target binding and different 
expression patterns (Tanzer and Stadler 2004; Ventura et al. 2008). 
Following transcription the hairpin structure with unpaired flanking regions is 
recognised and cleaved by the microprocessor complex, made up of at least two 
subunits (Figure 1.8) (Gregory et al. 2004). DGCR8 binds to the pri-miRNA and 
determines the cleavage site for Drosha, a RNase III enzyme, that makes a double 
stranded cleavage near the base of the hairpin generating a pre-miRNA hairpin with a 
3’ 2nt overhang and a 5’ terminal phosphate (Han et al. 2004; Han et al. 2006; 
Landthaler et al. 2004; Lee et al. 2003; Zeng and Cullen 2005; Zeng et al. 2005). 
Drosha cleavage occurs co-transcriptionally and, in the case of miRNAs present 
within introns, prior to splicing (Morlando et al. 2008). Following processing by the 
microprocessor the pre-miRNA is exported out of the nucleus through the nuclear 
pore complex by a protein complex containing the nucleoplasmic transport factor 
Exportin-5 and RanGTP (Lund et al. 2004; Yi et al. 2003). Exportin-5 binding is not 
dependent on sequence, but the length of the stem and 3’ overhang (Lund and 
Dahlberg 2006; Zeng and Cullen 2004). This interaction also protects the nuclear 
pre-miRNA from degradation (Zeng and Cullen 2004).  
In the cytoplasm the pre-miRNA is processed by the RISC loading complex (RLC), a 
multi-protein complex made up of Dicer, TRBP, PACT and Argonaute-2 (Ago2) 
(Chendrimada et al. 2005; Gregory et al. 2005; Lee et al. 2006; Maniataki and 
Mourelatos 2005). Dicer, a RNase III enzyme, cleaves the pre-miRNA into small 
RNA duplexes of ~22bp, removing the hairpin loop and generating 3’ 2nt overhangs  







Figure 1.8 An overview of miRNA processing, showing the different processing steps. 
For more information see the text. Taken from Winter et al. 2009. 
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and 5’ terminal phosphates (Bernstein et al. 2001; Elbashir et al. 2001; Hutvagner et 
al. 2001). Following cleavage one arm of the miRNA duplex, usually the one with 
less stable base pairs at its 5’ end, is loaded onto Ago2, making up the core subunit 
of the RISC complex which is made up of over 50 proteins (Gregory et al. 2005; 
Hock et al. 2007; Khvorova et al. 2003; Liu et al. 2004; Maniataki and Mourelatos 
2005). The RISC complex then uses the mature miRNA bound to Ago to silence 
fully or partially complementary target genes.  
The above description of miRNA biogenesis is the general one; specific steps for 
individual miRNAs have been reported. In addition, each of the steps of the miRNA 
processing is under regulatory influence. Lin-28 has been found to inhibit both 
Drosha and Dicer cleavage of let-7, while let-7 targets Dicer mRNA creating a 
feedback loop (reviewed in Winter et al. 2009). Subunits of the microprocessor have 
been found to act as specificity factors and to regulate each others expression. In 
addition, factors binding individual pri-miRNAs enhance their cleavage by Drosha 
(Winter et al. 2009). By blocking or enhancing Drosha or Dicer cleavage tissue and 
cell type specific expression of miRNAs can be achieved (Obernosterer et al. 2006). 
The miRNAs are also subject to editing with ADAR changing adenines to inosines, 
which may affect processing or target specificity of the miRNA (Kim et al. 2009; 
Winter et al. 2009). The ends of the miRNA can also be subject to 1-2nt deletions or 
additions, most often uracil and adenine (Kim et al. 2009). 
1.4.3.2. miRNA functions 
In mammals the RISC complexes usually bind to partially complementary binding 
sites leading to translational arrest or RNA destabilisation; although Ago2 catalysed 
cleavage of fully complementary targets have been reported (Davis et al. 2005; 
Yekta et al. 2004). In addition, other types of regulation including heterochromatin 
formation have been reported (Bao et al. 2004; Kim et al. 2008).  
Binding of the miRNA to the target usually involves the 5’ seed region  
(nucleotides 2-8) of the miRNA, with partial pairing of the 3’end supplementing or 
sometimes compensating for a single nucleotide mismatch in the seed region  
(Bartel 2009). The binding site is most often in the 3’ UTR of the mRNA, although 
binding to ORFs and 5’ UTRs have also been reported, including miRNAs that bind 
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with their 3’ end to the 5’ UTR and 5’ end to the 3’UTR of a mRNA (Bartel 2009; 
Lee et al. 2009a). Some mRNAs have multiple binding sites for the same or different 
miRNAs that work independently or cooperate to control protein synthesis  
(Bartel 2009).  
The mechanism of translation repression is debated; however, inhibition of 
translation initiation and post-initiation steps as well as co-translational protein 
degradation have been reported (reviewed in Chekulaeva and Filipowicz 2009; 
Eulalio et al. 2008; Filipowicz et al. 2008). In addition, protein translation is 
inhibited by deadenylation of mRNAs leading to destabilisation and sometimes 
degradation or sequestering of mRNAs within P bodies (reviewed in Eulalio et al. 
2008; Filipowicz et al. 2008; Nilsen 2007). During certain circumstances miRNAs 
are able to up-regulate the expression of genes (reviewed in Chekulaeva and 
Filipowicz 2009). In one example the liver specific mir-122 up-regulates Hepatitis C 
virus (HCV) replication when binding to the 5’UTR of the HCV RNA; however, 
insertion of the binding site into the 3’UTR leads to repression of replication  
(Henke et al. 2008; Jopling et al. 2005; Jopling et al. 2008). 
miRNAs can act to switch off protein synthesis, but most often they fine-tune the 
protein expression to keep proteins at optimal levels; this means that although some 
proteins can be down-regulated by 50-80%, individual miRNAs often only reduce 
protein expression by less than 50% and often not by more than a third (Bartel 2009). 
1.4.3.3. Viruses and miRNAs 
The first virally encoded miRNAs were identified in 2004 in EBV (Pfeffer et al. 
2004). Since then every herpesvirus examined have been found to express several 
miRNAs, with several other DNA viruses found to encode one miRNA (Table 1.3) 
The most likely reason that all of these viruses are nuclear DNA viruses is that 
Drosha cleavage takes place in the nucleus and would destroy a RNA genome 
encoding RNAs. A miRNA that avoids the Drosha cleavage step has been proposed 
for HIV-1 (Ouellet et al. 2008); however, this miRNA has not been found in other 
studies (Pfeffer et al. 2005). For viruses with short life cycles the use of miRNAs 
would be limited as the miRNAs may not have time to affect the protein pool; 
consistent with this DNA viruses that are capable of establishing latency or persistent  
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Virus family Subfamily Name 
Number of 
pre-miRNAs References 
Herpesvirus alpha HSV-1 8 Cui et al. 2006; Umbach et al. 2008; 
Umbach et al. 2009 
  HSV-2 6 Tang et al. 2008; Tang et al. 2009; 
Umbach et al. 2010 
  MDV 1 14 Burnside et al. 2006; Yao et al. 2008 
 
  MDV 2 17 Waidner et al. 2009; Yao et al. 2007 
 
  HVT 17 Waidner et al. 2009; Yao et al. 2009 
 
  BV 3 Besecker et al. 2009 
 
  BoHV-1 10 Glazov et al. 2010 
 
  ILTV 7 Rachamadugu et al. 2009; Waidner et 
al. 2009 
 beta HCMV 11 Grey et al. 2005; Pfeffer et al. 2005 
 
  MCMV 18 Buck et al. 2007; Dolken et al. 2007 
 
 gamma EBV 25 Cai et al. 2006; Grundhoff et al. 2006; 
Pfeffer et al. 2004; Zhu et al. 2009 
  rLCV 16 Cai et al. 2006 
 
  KSHV 12 Cai et al. 2005; Grundhoff et al. 2006; 
Pfeffer et al. 2005; Samols et al. 2005 
  RRV 7 Schafer et al. 2007 
 
  MHV-68 9 Pfeffer et al. 2005 
 
Polyomavirus  SV40 1 Sullivan et al. 2005 
 
  SA12 1 Cantalupo et al. 2005 
 
  MCV 1 Seo et al. 2009 
 
  BKV 1 Seo et al. 2008 
 
  JCV 1 Seo et al. 2008 
 
  mPy 1 Sullivan et al. 2009 
 
Adenovirus  hAV 1 Aparicio et al. 2006; Sano et al. 2006 
 
Ascovirus  HvAV 1 Hussain et al. 2008 
 
 
Table 1.3 List of identified viral miRNAs. Abbreviations: HSV, Herpes simplex; MDV, Marek’s 
disease virus; HVT, Herpesvirus of Turkeys; BV, Herpes B virus; BoHV-1, Bovine herpesvirus-
1; ILTV, Infectious laryngotracheitis  virus; HCMV, Human cytomegalovirus; MCMV, Mouse 
cytomegalovirus; EBV, Epstein-Barr virus; rLCV, Rhesus Lymphocryptovirus; KSHV, 
Kaposi’s sarcoma-associated herpesvirus; RRV, Rhesus monkey Rhadinovirus; MHV-68, 
Murine gammaherpesvirus 68; SV40, Simian virus 40; SA12, Simian agent 12; MCV, Merkel 
cell polyomavirus; BKV, BK polyomavirus; JCV, JC polyomavirus; mPy, Murine 
polyomavirus; hAV, Human adenovirus; HvAV, Heliothis virescens ascovirus. 
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infection have been found to encode most of the miRNAs. The viral miRNAs are 
expressed during lytic, latent or both stages of infection, in clusters that can be 
expressed differently, or scattered. The miRNAs are advantageous to the viruses as 
they allow regulation of specific genes, one miRNA is capable of regulating several 
genes, they do not take up much space in the genome, and they are  
non-immunogenic.  
Viral miRNAs can target viral or cellular mRNAs or both (Table 1.4). Most viral 
mRNA targets identified encode proteins that would be targets of the host immune 
response (e.g. SV40 miR-S1 that cleaves the T antigen mRNAs), or viral gene 
regulators (e.g. HSV-1 miR-H2-3p targeting ICP0 and miR-H6 ICP4, both important 
for initiating productive infection) (Sullivan et al. 2005; Umbach et al. 2008). Most 
cellular mRNA targets are either regulators of apoptosis (e.g. EBV miR-BART5 
targeting PUMA) or immunomodulators (e.g. HCMV miR-UL112-1 targeting 
MICB) (Choy et al. 2008; Stern-Ginossar et al. 2007). However, the effect of these 
viral miRNAs in vivo still needs to be investigated. Viral targets can lie antisense to 
the miRNA leading to cleavage of the mRNA (e.g. EBV miR-BART2 and the viral 
DNA polymerase), or just down-regulation of the protein (HSV-1 miR-H2-3p and 
ICP0) or show partial complementary to an mRNA in other parts of the genome 
(Barth et al. 2008; Umbach et al. 2008). Fully complementary cellular targets have 
not been found. Some viral miRNAs mimic cellular miRNAs. KSHV miR-K12-11 
and MDV-1 miR-M4 have identical seed regions to the oncogenic cellular miR-155, 
while EBV instead induces miR-155 expression (Gottwein et al. 2007; Lu et al. 
2008; Skalsky et al. 2007; Yin et al. 2008; Zhao et al. 2009). MHV-68 miR-M1-4 
shares a seed region with murine miR-151 of unknown function, and EBV  
miR-BART5, rhesus lymphocryptovirus (rLCV) miR-rL1-8 and MHV-68  
miR-M1-7-5p with cellular miR-18 and miR18b, which are encoded within the 
oncogenic miR-17-92 cluster (Gottwein and Cullen 2008). 
In addition, virus infection has been shown to induce or inhibit cellular miRNAs in 
general or specific miRNAs, presumably to create a more optimal environment. It 
has been suggested that cellular miRNAs directly target viral transcripts. This seems 
unlikely since many cellular miRNAs are conserved between species, while viruses 
are not, and viruses that were not targeted by miRNAs would have been selected;  




Virus miRNA mRNA target Function of protein Reference 
EBV miR-BART2 BALF5 DNA polymerase Barth et al. 2008 
 
  miR-BART1-5p 
/16/17-5p 
LMP1 Signalling molecule Lo et al. 2007 
 
  MiR-BART22 LMP2A Immunogenic antigen Lung et al. 2009 
 
HvAV miR-1 ORF1 DNA polymerase Hussain et al. 2008 
 
SV40 miR-S1 T antigens Transcription factors, 
recognised by T-cells 
Sullivan et al. 2005 
 
HSV-1 miR-H2-3p ICP0 Initiate productive 
infection 
Umbach et al. 2008 
 
  miR-H6 ICP4 Initiate productive 
infection 
Umbach et al. 2008 
 
HSV-2 miR-H2-3p ICP0 Initiate productive 
infection 
Tang et al. 2009 
 
  miR-H3/H4 ICP34.5 Neurovirulence factor Tang et al. 2008; Tang et 
al. 2009 
HCMV miR-UL112 IE1 Transcription activator Grey et al. 2007; Murphy 
et al. 2008 
  miR-UL112 UL114 Uracil DNA glycosylase Stern-Ginossar et al. 
2009 
KSHV miR-K12-9* rta Replication and 
transcription activator Bellare and Ganem 2009 
 
Cellular targets 





Transcriptional suppressor Gottwein et al. 2007; 
Skalsky et al. 2007 




Samols et al. 2007 
  miR-K5/9/10 BCLAF1 apoptotic factor Ziegelbauer et al. 2009 
 
  miR-K1 IκBα Inhibitor of NFκB 
complexes 
Lei et al. 2010 
 
  miR-K12-7  MICB NK cell-surface receptor 
ligand 
Nachmani et al. 2009 
HCMV miR-UL112 MICB NK cell-surface receptor 
ligand 
Stern-Ginossar et al. 
2007 
EBV miR-BART5 PUMA Proapoptotic factor Choy et al. 2008 
 
  miR-BHRF1-3 CXCL11 Chemokine, T-cell 
chemoattractant 
Xia et al. 2008 
 
  miR-BART2-5p MICB NK cell-surface receptor 
ligand 





Transcriptional suppressor Zhao et al. 2009 
 
 
Table 1.4 Viral and cellular mRNA targets of viral miRNAs. KSHV miR-K12-11 and 
MDV-1 miR-M4 both have seeds identical to the cellular miR-155 and target at least 
some of the same mRNAs. 
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unless the virus could take advantage of the cellular miRNAs (Mahajan et al. 2009). 
This is the case for HCV whose replication is induced by 5’UTR binding of the liver 
specific miR-122 (Henke et al. 2008; Jopling et al. 2005). It is also possible that 
viruses could use cellular miRNAs to limit viral replication and facilitate the 
establishment of latency. Viruses can up-regulate cellular miRNAs that are beneficial 
to the virus or down-regulate anti-viral miRNAs. EBV infection leads to a reduction 
in cellular miRNAs and following initiation of the lytic cycle the immunomodulator 
miR-146a is induced by LMP1 (Godshalk et al. 2008; Motsch et al. 2007). MDV-1 
induces the expression of miR-221 and miR-222, which are involved in 
tumorigenesis (Lambeth et al. 2009). MCMV on the other hand down-regulates the 
anti-viral miR-27a and miR-27b (Buck et al. 2010). It is possible that the cellular 
miRNAs can be used as a part of the immune response against viruses by acting on 
cellular targets affecting the virus, without targeting the virus it self. 
The herpesvirus miRNAs are generally not well conserved; the exception being EBV 
and rLCV which have eight miRNAs that are highly similar and encoded at a similar 
location in the genomes (Cai et al. 2006). Even though there is poor sequence 
conservation the miRNA locations in the genomes are conserved in closely related 
viruses such as HSV-1 and HSV-2, MDV-1 and MDV-2, KSHV and RRV, and 
HCMV and MCMV. The lack of sequence similarity does not mean that the miRNAs 
do not have similar effects; they could have evolved to target different regions of the 
same mRNA or different mRNAs in the same cellular pathway. An example is the 
NK cell-surface receptor ligand MICB which is a target for HCMV miR-UL122-1, 
EBV miR-BART2-5p and KSHV miR-K12-7 as well as cellular miRNAs, leading to 
reduced NK cell killing of infected cells (Nachmani et al. 2009; Stern-Ginossar et al. 
2007; Stern-Ginossar et al. 2008). These viral miRNAs do not have any sequence 
homology and all target the 3’UTR at sites that do not overlap.  
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1.5. Project outline 
The role of the vtRNAs and miRNAs of MHV-68 during infection has not been 
extensively characterised and their biological functions are unknown. The functions 
of these non-coding RNAs were examined in a previous experiment using two 
viruses made through insertion of five of the vtRNAs and six of the miRNAs into 
MHV-76, which lacks the non-coding RNAs. These viruses behaved like MHV-76 
during lytic infection in vitro and during in vivo infection; like MHV-76 they were 
cleared more rapidly and established low levels of latency in the spleen compared to  
MHV-68 (Cliffe 2005).  
The aim of this study was to investigate the role of the non-coding RNAs during 
latent infection in vitro, utilising the insertion viruses. The initial objective was to 
determine if the mouse B-cell line NS0 was appropriate as an in vitro model to study 
the non-coding RNAs during latency and to study the expression of the vtRNAs and 
miRNAs. A second objective was to study the effects of the non-coding RNAs on the 
replication and reactivation kinetics in vitro. The final objective was to investigate 
differences in protein expression between cells latently infected with MHV-76 and 
insertion virus by analysing the global protein expression profiles of the cells.  
It was hypothesised that by characterising the effects of the non-coding RNAs during 
latent infection in vitro, possible functions of these, as well as other non-coding 
RNAs would be elucidated. 
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2.1. Cell Culture techniques 
2.1.1. Maintenance of cell lines 
All cell lines were cultured in tissue flasks (Nunc, UK) at 37°C + 5% CO2. Baby 
Hamster Kidney fibroblast 21 (BHK-21) cells were maintained in Glasgow’s 
Modified Eagle’s Medium (Invitrogen, UK), containing 10% (v/v) newborn calf 
serum (Invitrogen, UK), 10% (v/v) tryptose phosphate broth (Invitrogen, UK), 2mM  
L-glutamine (Invitrogen, UK), and 100U/ml penicillin and streptomycin. NS0 and 
S11 cells were cultured in Rosewell Park Memorial Institute 1640 (RPMI-1640) 
medium (Invitrogen, UK), supplemented with 10% (v/v) fetal calf serum (Sera 
laboratories international), 2mM L-glutamine (Invitrogen, UK), and 100U/ml 
penicillin and streptomycin.  
2.1.2. Harvesting and counting cells 
BHK-21 cells were detached by trypsin treatment. Growth medium was decanted and 
cells washed with 0.02% (w/v) versene, prior to adding 0.05% (w/v) trypsin-EDTA 
(Invitrogen, UK). The trypsin was inactivated by addition of an equal volume of 
medium and the cells pelleted by centrifugation at 470 x g for 5 min at room 
temperature. NS0 and S11 cells were scraped down from the flask and pelleted by 
centrifugation at 470 x g for 5 min at room temperature. The pellet was re-suspended 
in medium and an aliquot diluted 1:1 with 0.4% (w/v) trypan blue (Sigma, UK). The 
unstained, viable cells, were counted in a haemocytometer. 
2.1.3. Cytospins 
The cells were counted, fixed in 4% (w/v) paraformaldehyde for 10 min, washed and 
re-suspended in phosphate buffered saline (PBS) to 1x105 cells/ml. Subsequently, 
200μl of cells were pelleted onto polylysine slides (VWR international) at 1000 rpm 
for 5 min using a cytospin (Shandon cytospin 2). The slides were fixed in 4% (w/v) 
paraformaldehyde for 15 min, washed in PBS and left to dry.  
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2.1.4. Transfection 
Transfection of NS0 cells was preformed using a nucleofector (Lonza, UK) with a 
pre-optimised protocol (Amaxa, Lonza, UK). NS0 cells, cultivated in RPMI-1640 
medium (Invitrogen, UK) supplemented with 10% (v/v) fetal calf serum (Sera 
laboratories international), 2mM L-glutamine (Invitrogen, UK), and 100μg/ml 
Normocin (Amaxa, Lonza, UK), were infected with viruses at a multiplicity of 
infection (MOI) of 5 plaque forming units (pfu)/cell, 4 days or 2 hours prior to 
transfection or 48 hours post transfection. For each transfection reaction 2x106 cells 
were pelleted at 90 x g at room temperature for 10 min and the medium removed. 
The cell pellet was resuspended in 100μl Nucleofector solution C (Amaxa, Lonza, 
UK) prior to the addition of 0.5μg miRNA (miScript miRNA mimics, Qiagen), 
negative small interfering RNA (siRNA) (Qiagen), or 2μg plasmid DNA and 
66.5pmol siGLO red (Thermo Scientific Dharmacon, UK). The cells were moved to 
a cuvette and transfected using programme T-005. Following transfection 500μl pre-
warmed RPMI-1640 (supplemented as above) was added to the cuvette and the cells 
transferred to a 6-well plate with 1.4ml pre-warmed medium per well, using a plastic 
pipette. The plate was incubated at 37°C with 5% CO2. The transfection efficiency 
was determined 24 hours post transfection by counting the number of red fluorescing 
cells using a fluorescent microscope. 
2.2. Virological methods 
2.2.1. Preparation of virus stocks 
BHK-21 cells were harvested as described previously, counted, and infected at a 
MOI of 0.001 pfu/cell. The virus was left to infect the cells for 1 hour at 37°C while 
shaking. The cells were subsequently incubated in T175 flasks at 3x106 cells per 
flask for around six days, until there was complete cytopatic effect (CPE). The cells 
were removed by scraping and pelleted by centrifugation at 1900 x g for 20 min at 
4°C and the pellet re-suspended in PBS, in a volume of about 1/3 of the number of 
flasks used (e.g. 10 ml for 30 flasks). The cells were homogenised in a glass dounce 
20-30 times and subsequently sonicated in an ice bath for 15 min before being 
pelleted by centrifugation at 1900 x g for 20 min at 4°C and the supernatant 
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collected. The pellet was re-suspended in 1ml of PBS and homogenised again, 
pelleted by centrifugation at 1900 x g for 20 min at 4°C and the supernatant pooled 
with the previous. The virus suspension was aliquoted and stored at -80°C. 
2.2.2. Virus titration 
BHK-21 cells were harvested as described previously and counted. The virus, at an 
unknown concentration, was ten-fold serial diluted 10-2 to 10-9 in medium, following 
which 2x106 BHK-21 cells were added to each dilution and the tube incubated for 1 
hour at 37°C while shaking. Each dilution was plated onto two 60mm Petri dishes, 
resulting in 1x106 cells per dish. Uninfected cells were plated as negative controls for 
each experiment. The plates were incubated for 4 days at 37°C + 5% CO2, following 
which the medium was decanted and the cells fixed with 10% (v/v) neutral buffered 
formaldehyde (Surgipath Europe Ltd) for 1 hour, prior to staining with 0.1% (w/v) 
toluidine blue (BDH Laboratory supplies). The plaques formed by the virus particles 
were counted by light microscope. The titre was calculated as: (no. of plaques x 
dilution)/ final dilution volume added to plate.  
For titrations of cell associated virus, 1x105 virus infected cells in 1ml medium were 
lysed by freeze thawing three times. The cells were centrifuged at 850 x g for 10 min 
at room temperature to remove cell debris, prior to serial dilution.  
2.2.3. Infection of NS0 cells for virus characterisation studies 
NS0 cells were harvested and 5x106 cells were infected with each virus at a MOI of  
5 pfu/cell, followed by incubation at 37°C for 1 hour while shaking. The cells were 
subsequently counted and 2x106 cells incubated in two T25 flasks for each virus, in 
9ml of medium. Alternatively, 3x106 cells were infected with each virus in duplicate 
and 2x106 cells incubated in T25 flasks, in 9ml of medium. A sample of the 
supernatant was frozen for titration of infectious virus and 1x105 cells in 1ml 
medium frozen for titration of cell associated virus. The cells were split as 
appropriate and the cells harvested 5 and 9 days post infection, with some or all of 
the cells taken and pelleted by centrifugation at 470 x g for 5 min at room 
temperature. A sample of the supernatant was frozen for titration of the infectious 
virus produced by the viruses. The pellet was resuspended in 3ml medium and the 
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cells counted prior to washing the cells 3 times in medium. The cells were 
subsequently counted again and 1x105 cells in 1ml medium frozen for titration of cell 
associated virus, 1x105 cells taken for infective centres, and on occasions some cells 
taken for cytospins.  
2.2.4. Infective centre assay 
50, 100, and 1000 NS0 cells were co-cultivated with 106 BHK-21 cells in 60mm 
Petri dishes in 5ml complete RPMI medium for 5 days at 37°C + 5% CO2. Following 
incubation the medium was decanted and the cells fixed with 10% (v/v) neutral 
buffered formaldehyde (Surgipath Europe Ltd) for 1 hour, before staining with 0.1% 
(w/v) toluidine blue (BDH Laboratory supplies). The infective centres formed by 
reactivating virus particles were counted by light microscope. Uninfected controls 
were included for each experiment. 
2.2.5. GFP labelled viruses 
To determine the percentage of NS0 cells infected at different MOIs, two Green 
Fluorescent Protein (GFP) labelled viruses were utilised, LHΔgfp and MHV-76GFP. 
LHΔgfp was previously constructed by co-transfection of BHK-21 cells with  
MHV-68 DNA and DNA containing a HCMV GFP cassette (Dutia et al. 2004). 
MHV-76GFP has a GFP cassette downstream of a murine PGK promoter in the left 
end of the MHV-76 genome (personal communication with Simon Talbot).  
NS0 cells were infected at a MOI of 1, 5 and 10 pfu/cell with either LHΔgfp or 
MHV-76GFP, followed by incubation at 37°C for 1 hour while shaking. The cells 
were seeded out in a 24 well plate at 1x105 cells/ well. At days 2 and 6 cells were 
harvested and cytospins made. The slides were mounted in Vectashield  
(Vector laboratories).  
2.2.6. Cloning of infected cells 
NS0 cells were infected with MHV-76 or Int9 at a MOI of 5 pfu/cell, followed by 
incubation at 37°C for 1 hour while shaking. The infected cells were subsequently 
incubated at 37°C + 5% CO2 for 5 days, when they were cloned at 0.5 cells/well in a 
96-well plate in 1ml of medium (50:50, pre-conditioned: new media). The cells were 
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given fresh medium and split appropriately. When the clones had grown to larger 
numbers, they were moved to larger plates and then flasks.  
2.2.7. Staining for lytic proteins 
Cytospins were washed in PBS and blocked with Cas block (Invitrogen, UK) for 30 
min at room temperature. The slides were incubated with primary antibody, Rabbit A 
(a polyclonal sera raised against MHV-68 lytically infected rabbit cells  
(Sunil-Chandra et al. 1992b)) diluted 1/1000 in Cas block, for 2 hours at room 
temperature. After washing the slides 2x10 min in PBS they were incubated with the 
secondary antibody, biotinylated goat anti-rabbit (Sigma, UK) diluted 1/750 in Cas 
block, for 1 hour at room temperature. The slides were washed as previously and 
incubated with streptavidin/alexa fluor 488 (Invitrogen, UK) and Topro 3 
(Invitrogen, UK) both diluted 1/1000 in PBS, for 45 min. Following another wash 
the slides were mounted in Mowiol mounting media (25% (v/v) glycerol; 10% (w/v) 
Mowiol 4-88 (Calbiochem); 50% (v/v) 200mM Tris-HCl (pH 8.5)). 
2.3. In situ hybridisation 
2.3.1. Generation of labelled RNA probe 
A digoxigenin (dig) antisense probe was constructed from a plasmid (pEH1.4) 
consisting of nucleotides 106 to 1517, covering vtRNA1-4 (Bowden et al. 1997). 
This plasmid has both T7 and SP6 promoters. 
E.coli containing the plasmid were cultured and the DNA prepared as in section 
2.4.1. The plasmid DNA was digested with HindIII and purified with a Qiaquick® 
PCR Purification kit (Qiagen), according to the manufacturer’s instructions. In brief, 
the DNA was bound to the silica-gel membrane of the column and any contaminants 
washed away. Five volumes of Buffer PBI was added to the sample, the solution 
applied to the column and the DNA bound to the membrane by centrifugation at  
10 000 x g for 60 seconds, prior to washing with Buffer PE. The DNA was eluted 
with 50μl Buffer EB and run on a 0.8% (w/v) agarose gel, to check that complete 
cleavage of the plasmid had occurred.  
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The riboprobe was in vitro transcribed by T7 RNA polymerase using the DIG RNA 
labelling kit (Roche). 1μg DNA template was mixed with 1mM each of ATP, CTP 
and GTP, 0.65mM UTP, 0.35 DIG-11-UTP, 1x Transcription buffer and 36 units T7 
polymerase, to a final volume of 20μl, and the solution incubated for 2 hours at 
37°C. The reaction was stopped by addition of 2μl 0.2M EDTA (pH 8.0). The 
labelled RNA was precipitated by addition of 1μl yeast tRNA (1mg/ml), 2.5 volumes 
of cold 100% ethanol and 0.1 volumes of 3M sodium acetate (pH 5.5), followed by 
incubation on dry ice for at least 1 hour. The RNA was subsequently pelleted by 
centrifugation at 10 000 x g for 30 min at 4°C and the supernatant removed. The 
RNA pellet was washed in cold 70% (v/v) ethanol and air dried before being 
resuspended in 45μl RNase free water. 
Alkaline hydrolysis was performed to digest the labelled probe to approximately 170 
nucleotides. The probe was incubated with 5μl 0.4M NaHCO3, 0.6M Na2CO3  
(pH 9.8) for 47 min at 60°C. The optimum time was calculated as: t = L0-Lf / (K x L0 
x Lf), where t=time, L0= initial fragment length, Lf= final fragment length and 
K=0.11. The digested probe was precipitated by addition of 2.5 volumes of cold 
100% ethanol and 0.1 volumes of 3M sodium acetate (pH 5.5), followed by 
incubation at -70°C over night. Subsequently, the RNA was pelleted by 
centrifugation at 10 000 x g for 30 min at 4°C, the pellet washed in cold 70% ethanol 
and air dried prior to being resuspended in 45μl RNase free water. 
The probe was quantified by visual comparison between serial dilutions of the probe 
to a known control. Serial dilutions of the probe at 1/10 to 1/100000 were made in 
RNase free water and the control dig-labelled neo antisense RNA was 10-fold serial 
diluted from 10μg/ml to 0.1 ng/ml. 5μl RNA was dotted onto a nylon membrane and 
left to air dry, prior to crosslinking with the auto-crosslink function on a Stratalinker 
2400 (Stratagen, UK). The membrane was washed in buffer I (0.1M maleic acid, 
0.15M NaCl, pH 7.5, 3 x 5 min), prior to blocking with buffer II (buffer I containing 
0.1% (v/v) normal sheep serum), for 30 min with constant agitation. The membrane 
was subsequently incubated with anti-dig/alkaline phosphatase (AP) conjugated 
antibody (Roche, Germany) diluted 1/5000 in buffer II, for 1 hour. The membrane 
was washed with buffer I containing 0.3% (v/v) tween-20 (3 x 5 min), followed by 
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buffer III (0.1M Tris-HCl, 0.1M NaCl, 50mM MgCl2, pH 9.5, 1 x 5 min). AP was 
detected by incubation with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium (BCIP/NBT, Sigma UK). The approximate concentration of the probe 
was determined by comparison of the colour intensity of the probe to that of the 
control.  
2.3.2. In situ hybridisation of cytospins 
NS0 cells were infected with MHV-68 at a MOI of 5 pfu/cell, followed by incubation 
at 37°C for 1 hour while shaking. The infected cells were incubated at 37°C + 5% 
CO2 for 5 days, when cytospins were made. Cytospins were washed in PBS three 
times for 10 min, prior to permeabilisation in 0.5% (v/v) Triton X-100 in PBS for 10 
min at 4°C, and rinsing in PBS three times for 10 min. The slides were subsequently 
washed in 2 x SSC for 5 min, prior to pre-hybridisation with prehybridisation buffer 
(50 % (v/v) formamide; 5 x salts (0.05M EDTA; 0.05M PIPES; 0.6M NaCl, pH 6.8), 
5 x Denhardt’s, 0.25mg/ml salmon sperm DNA (Sigma UK, boiled for 2 min at 
95°C), 0.25mg/ml yeast tRNA (Sigma, UK), 20U/ml heparin, 0.1% (w/v) sodium 
dodecyl sulphate (SDS)) for 1 hour at 55°C. The hybridisation buffer was made by 
adding 50mg/ml dextran sulphate and 200ng/ml of labelled probe to the 
prehybridisation buffer and the buffer was subsequently boiled for 2 min at 95°C 
prior to addition of 10mM DTT. The slides were incubated with the hybridisation 
buffer over night at 55°C, while covered with parafilm. Following hybridisation the 
slides were rinsed in 4 x SSC and unbound probe removed by washing with 2 x SSC 
(2 x15 min at 37°C), 1 x SSC (2 x15 min at 37°C) and 0.2 x SSC (2 x15 min at 
55°C).  
The slides were blocked in Cas block (Invitrogen, UK) for 30 min at room 
temperature and incubated with primary anti-dig antibody made in sheep (0.4ng/μl in 
Cas block, Roche) for 1.5 hours. The slides were subsequently rinsed in  
Tris-buffered saline (TBS; 3 x 15 min) and incubated for 1 hour with secondary 
biotinylated anti-sheep antibody (10ng/μl in Cas block, Vector laboratories). The 
slides were rinsed in TBS (3x15 min) and incubated for 45 min with 
streptavidin/alexa fluor 488 (Invitrogen, UK) diluted 1/1400 in TBS. The slides were 
again rinsed in TBS (3x15 min) followed by processing in 100% ethanol (2 x 5 min) 
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and xylene (2 x 3 min), prior to mounting in Vectashield mounting media for 
fluorescence with propidium iodide (Vector laboratories).  
On some occasions Mowiol mounting media (25% (v/v) glycerol; 10% (w/v) Mowiol 
4-88 (Calbiochem); 50% (v/v) 200mM Tris-HCl (pH 8.5)) was used. In that case 
Topro 3 (Invitrogen, UK) was added as a nuclear stain at 1/1000 in TBS, together 
with the alexa fluor 488. 
2.4. DNA isolation and manipulation 
2.4.1. Plasmid preps 
E. coli containing the plasmid pEH1.4 was cultured in L-Broth and 100μg/ml 
ampicillin over night at 37°C in an orbital shaker. The culture was pelleted by 
centrifugation at 3000 x g for 5 min and the DNA extracted by alkaline lysis of the 
bacteria using a QIAprep Spin Miniprep kit (Qiagen), according to the 
manufacturer’s instructions. The bacterial pellet was resuspended in 250μl Buffer P1 
and 250μl Buffer P2 was added prior to mixing by inversion of the tube, lysing the 
bacteria. 350μl of Buffer P3 was added and the solution mixed immediately by 
inversions to avoid localised precipitation of DNA. The lysed bacteria were pelleted 
by centrifugation at 17 900 x g for 10 min and the supernatant applied to a QIAprep 
spin column. The DNA was bound to the column by centrifugation at 17 900 x g for 
60 seconds and washed with Buffer PE, prior to elution with 50μl water.  
An EndoFree Plasmid Maxi Kit (Qiagen) was used according to the manufacture’s 
instructions to produce plasmid for transfection. In brief, the DNA was extracted by 
alkaline lysis and the lysate filtered through a QIA filter Maxi Cartridge. The 
endotoxins were removed by addition of buffer ER and the lysate loaded onto a 
anion exchange tip to which the plasmid DNA binds. Contaminants such as RNA 
and proteins were washed away prior to eluting the DNA. The DNA was further 
concentrated and salts removed by isopropanol precipitation. 
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2.5. RNA isolation and manipulation 
2.5.1. microRNA isolation 
Small RNAs were isolated from infected or uninfected cells with a mirVana miRNA 
isolation kit (Ambion, UK). This kit lyses the cells in a denaturing lysis solution, 
which stabilises RNA and inactivates RNases. Most cellular components are 
removed by an acid-phenol:chloroform extraction, and the solution is further purified 
by bringing the solution to 25% (v/v) ethanol and passing it through a glass-fibre 
filter. Larger RNAs are immobilised and smaller RNAs can be collected in the 
filtrate. By increasing the ethanol concentration to 55% (v/v) small RNAs become 
immobilised when passing the solution through a second glass-fibre filter. RNAs of 
≤ 200 nucleotides are then eluted with a low ionic strength solution.  
2.5.2. DNase treatment of RNA 
Contaminating DNA was removed from RNA samples by recombinant turbo  
DNA-free (Ambion, UK). 1μg of miRNA enriched RNA was treated with 3μL (6U) 
Turbo DNA free in 0.1 volume 10x Turbo DNase buffer for 1 hour at 37°C. Another 
3μL (6U) Turbo DNA free was then added and the reaction incubated at 37°C for  
1 hour. Following the DNase treatment the reaction was stopped by the addition of 
0.1 volume (at least 2 μl) inactivation reagent and the samples incubated at room 
temperature for 5 min. The inactivation reagent was pelleted by 5 min centrifugation 
at 10 000 x g and the supernatant moved to a fresh tube for RT-PCR analysis. 
2.5.3. Reverse transcription of RNA 
cDNA was generated from RNA using SuperScript™ III Reverse Transcriptase 
(Invitrogen). 8μL of DNase treated RNA was incubated with 50ng random primers 
and 1μL 10mM dNTP mix in a total volume of 13μL for 5 min at 65°C. The mixture 
was immediately chilled on ice and spun down briefly. 4μL 5x First-strand buffer, 
1μL 0.1M DTT, 1μL (40 U) RNase OUT and 1μL SuperScript III RT (200U) was 
added to the RNA/primer mix and the reaction gently mixed by pipetting. The 
reaction was subsequently incubated at room temperature for 5 min and then 50°C 
for 1 hour prior to inactivating the reaction at 70°C for 15 min. The cDNA was 
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cooled on ice before the addition of 1μL (2U) E. coli RNase H and the reaction 
incubated at 37°C for 20 min to remove RNA complementary to the cDNA. 2μL 
cDNA was used per PCR reaction. 
2.5.4. In vitro transcription of vtRNAs 
vtRNA1, 4 and 5 templates were initially annealed with T7 promoter (vtRNA1 and 
5) or forward strand (vtRNA4) by heating to 75°C for 2 min and cooling to 50°C, 
prior to addition of 1 μl 0.1M MgCl2. The vtRNAs were subsequently transcribed 
using a MEGAshortscript™ kit (Ambion), which utilises T7 polymerase to in vitro 
transcribe short transcripts. Unincorporated nucleotides were removed by Micro Bio-
spin® 30 columns (BioRad, UK), which purifies nucleic acids larger than 20 bases or 
base pairs. The vtRNAs were subsequently folded by heating to 80°C for 90 seconds, 
prior to cooling to room temperature and adding MgCl2 to a final concentration of 
20mM and placing the tubes on ice. 
2.6. Polymerase chain reaction (PCR)  
2.6.1. Standard PCR 
60-100ng template DNA was mixed with 1x PCR buffer (20mM Tris-HCl, pH8.4; 
50mM KCl, Invitrogen), 3mM MgCl2, 200μM each of dNTPs and 1μM of each 
primer, in a final volume of 50μl. The reactions were overlaid with mineral oil 
(Sigma, UK) and incubated at 94°C for 3 min. The program was paused at 80°C for 
the addition of 1 unit of Taq DNA polymerase (Invitrogen). The program continued 
with 35-40 cycles of denaturing at 94°C for 45 seconds, annealing at 51-56°C for 45 
seconds, followed by elongation for 1 min at 72°C. When all the cycles were finished 
the reactions were incubated at 72°C for 5 min and then allowed to cool down to 
room temperature. 
2.6.2. Whole cells and virus stock PCR 
20μl of cells or 1μl of virus stock was mixed with master mix containing 0.4μg/μl 
proteinase K, 1x PCR buffer (20mM Tris-HCl, pH8.4; 50mM KCl, Invitrogen), 
3mM MgCl2, 200μM each of dNTPs and 1μM of each primer, in a final volume of 
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50μl. The reactions were overlaid with mineral oil (Sigma, UK) and incubated at 
65°C for 15 min to allow the proteinase K to act, followed by 95°C for 5 min to 
inactivate the proteinase K. The program was paused at 80°C for the addition of 1 
unit of Taq DNA polymerase (Invitrogen). The program continued with 35-40 cycles 
of denaturing at 94°C for 45 seconds, annealing at 51-56°C for 45 seconds, followed 
by elongation for 1 min at 72°C. When all the cycles were finished the reactions 
were incubated at 72°C for 5 min and then allowed to cool down to room 
temperature. The reactions were run on a 1% agarose gel.  
2.6.3. qRT-PCR for miRNAs 
The levels of miRNAs in infected cells were compared using qRT-PCR, with an 
Invitrogen NCode miRNA First-Strand cDNA Synthesis Kit and Platinum SYBR 
Green qPCR SuperMix-UDG, according to a protocol optimised by Amy H Buck to 
use less of the reagents. A poly(A) tail was added to the 3’ end to increase the size of 
the miRNA, prior to reverse transcribing the miRNA using a universal RT primer. 
dsDNA was produced using a forward primer specific to the miRNA and a universal 
qPCR primer, in a PCR reaction. The levels of dsDNA produced were then 
determined using the intercalating dye SYBR green.  
Forward primers corresponding to the whole mature miRNA sequences were 
purchased from Invitrogen and resuspended to 100μM and aliquots of 1 μM made in 
PCR strips. Poly(A) tails were added to the miRNAs by incubating 4μl miRNA 
enriched RNA (section 2.5.1) with 1.25μl 5x miRNA Reaction Buffer, 0.625μl 
25mM MgCl2, 0.25μl ATP (10mM diluted 1:(1250/ng RNA used)), and 0.125μl Poly 
A Polymerase for 15 min at 37°C in a PCR machine. The universal primer was 
annealed to the polyadenylated RNA by incubating 2μl polyadenylated RNA with 
0.5μl 2x Annealing Buffer and 1.5μl 25μM Universal RT primer for 5 min at 65°C 
and chilling the reaction on ice for 1 min. The reverse transcription reaction was set 
up by adding 5μl 2x First-Strand Reaction mix and 1μl Superscript III/RNase OUT 
enzyme mix to the RNA and the tube was incubated at 50°C for 50 min before 
stopping the reaction at 85°C for 5 min. The cDNA was subsequently chilled on ice. 
5μl of the diluted forward primers for the Real Time PCR were added to wells of a 
Chapter Two  Materials and methods 
 82
96-well plate (giving a final concentration of 200nM). A Real Time mastermix was 
set up consisting of 12.5μl 2x SYBR Green qPCR Supermix UDG, 0.5μl 10μM 
Universal qPCR primer and 7μl DEPC water, for each well used. 3-5μl cDNA was 
added to the mastermix, and 20μl of the mix added to each well. The plate was spun 
down and run on a MxPro3000 Real Time PCR machine (Stratagene). The reaction 
was started by a 50°C step for 2 min and an initial denaturing step of 95°C for 2 min, 
activating the Taq polymerase. 45 cycles of amplification was performed, consisting 
of denaturing at 95°C for 15 seconds, annealing at 60°C for 15 seconds and 
extension at 72°C for 20 seconds. The reaction was finished with a 1 min 95°C step 
and a melting curve was created by measuring the fluorescence from 55°C to 95°C. 
The levels of 5S ribosomal RNA and mouse miR-16 were used to normalise the 
levels of amplified PCR product.  
2.7. Agarose gel electrophoreses 
Agarose (SeaKem®, Flowgen, UK) gels were prepared in TAE or TBE buffer at 
varying concentrations depending of the size of DNA examined. Ethidium bromide 
was added to the gel to a concentration of 0.75μg/ml. The samples were mixed with 
appropriate volume of 10 x loading buffer (0.25% (w/v) orange G; 0.15% (w/v) 
Ficoll), loaded onto the gel, and electrophoresed at 60-90V in TAE or TBE buffer, 
prior to visualisation of bands by UV transilluminator.  
2.8. Northern analysis 
2.8.1. Electrophoresis and blotting 
1μg miRNA enriched RNA was mixed with an equal volume gel loading buffer II, 
boiled for 2-5 min at 95-100°C and loaded on 15% Polyacrylamide TBE-Urea Gels 
(8M Urea). The gels were electrophoresed at 180V in TBE and the RNA transferred 
to a nylon membrane (GE healthcare) by electroblotting. A stack of 3 blotting papers 
soaked in 0.5 x TBE was placed above and below the gel/membrane (soaked in 0.5 x 
TBE) and the RNA transferred at 200mA for 30 min. Following blotting, the RNA 
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was UV crosslinked to the membrane with the auto-crosslink function on a 
Stratalinker 2400 (Stratagen UK).  
A DecadeTM marker (Ambion, UK) was used to determine the sizes of bands. A 
150nt transcript was 5’ end-labelled by T4 polynucleotide kinase and 32P-ATP, and 
cleaved to generate a set of radiolabelled markers of 100, 90, 80, 70, 60, 50, 40, 30, 
20 and 10nt. These were run alongside the samples on the gel. 
2.8.2. Prehybridisation and hybridisation 
The membrane was prehybridised with ULTRAhyb®-Oligo Hybridization Buffer 
(Ambion, UK) for 30 min at 42°C. Hybridisation was then performed by incubating 
the membrane with ULTRAhyb®-Oligo Hybridization Buffer and 10μl 32P-UTP-
labelled probe for miRNA1 over night at 42°C. Following hybridisation the 
membrane was washed three times at 42°C for 30 min with washing solution  
(2x SSC and 0.5% (w/v) SDS). The blot was wrapped in plastic film and exposed to 
x-ray film.  
2.8.3. Generation of radiolabelled probe 
The probe was generated with a mirVanaTM miRNA probe construction kit 
(Ambion). Initially, a target-specific DNA oligonucleotide template was converted to 
dsDNA with a T7 promoter. This was done by hybridising a DNA oligonucleotide 
template (corresponding to the target RNA and with a 8nt sequence complementary 
to the T7 Promoter primer) with the T7 Promoter Primer, by incubating them at 70°C 
for 5 min in hybridisation buffer and then leaving them at room temperature for  
5 min to allow for hybridisation to occur. Exo-Klenow, dNTPs and Klenow reaction 
buffer was then added and the solution incubated at 37°C for 30 min, in order to 
produce the dsDNA template. Next, a 32P-labelled antisense RNA probe was 
transcribed in vitro by incubating the dsDNA template with T7 RNA polymerase, 
ATP, CTP, GTP, 32P-UTP and transcription buffer, for 10-30 min at 37°C. The DNA 
template was then removed by DNase I treatment for 10 min at 37°C. 
Unincorporated nucleotides were removed by Micro Bio-spin® 30 columns  
(BioRad, UK), which purifies nucleic acids larger than 20 bases or base pairs. 
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2.8.4. Stripping of membranes for re-probing 
The blot was rinsed in distilled water, prior to washing twice with boiling 0.1% (w/v) 
SDS in distilled water. The blot was then washed in 6 x SCC before  
pre-hybridisation. 
2.9. Protein techniques 
2.9.1. Protein extraction 
Around 4x107 cells were washed with PBS and pelleted by centrifugation at 212 x g. 
The pellet was resuspended in 5 pellet volumes of CE buffer (10mM HEPES, 60mM 
KCl, 1mM EDTA, 0.075% (v/v) NP40, 1mM DTT, 1mM Pefa block) and incubated 
on ice for 3 min prior to centrifuging at 100-150 x g for 4 min. The cytoplasmic 
extract was removed from the pellet to a clean tube and spun at max speed for 10 min 
to pellet any nuclei. The supernatant was transferred to a clean tube and stored at  
-70°C. 
2.9.2. Protein fractionation 
A ProteoExtract® Subcellular Proteome Extraction Kit (Calbiochem, Merck UK) 
was used to extract and fractionate cellular proteins, according to the manufacturer’s 
protocol. The kit utilises the different solubilities of the cellular compartments to 
produce four different fractions of proteins (cytosolic, membrane/organelle, nuclear 
and cytoskeletal), through the addition of different extraction buffers and 
centrifugation.  
2.9.3. Protein concentrations 
The total protein concentration of protein extracts from NS0 cells was determined by 
bicinchoninic acid (BCA) Protein Assay (Pierce). In brief, this assay utilises the 
reduction of Cu2+ to Cu1+ by the peptide bonds of proteins in an alkaline solution, 
followed by the chelation of BCA with Cu1+ forming a purple-coloured product of 
which an absorbance can be measured. The amount of Cu1+ formed, and thereby the 
intensity of the colour, is directly proportional to the amount of protein in the sample.  
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0.1ml of bovine serum albumin (BSA) or sample (diluted in water, to an appropriate 
concentration range) was mixed with 2ml working reagent (50:1, reagent A:B) and 
the tubes incubated at 60°C for 30 min. After cooling to room temperature the 
absorbance of the samples was measured at 562nm. A standard curve was prepared 
by diluting BSA with the diluted sample buffer to a working range of 5-250μg/ml 
and plotting the absorbance against the concentration. The protein concentrations of 
the samples were determined by the equation produced by the Polynomial trendline 
of the standard curve. 
2.9.4. Acetone precipitation 
2-3 times sample volumes of acetone containing 60mM DTT was added to the 
sample. The sample was incubated at -20°C for 2 hours prior to centrifuging at 
12500 x g for 15 min. The pellet was washed with cold acetone containing 20mM 
DTT and spun at 12500 x g for 5 min prior to air-drying the pellet. 
2.9.5. SDS-PAGE gel 
Proteins were separated by 12% SDS- Polyacrylamide gel electrophoresis (PAGE) to 
demonstrate that the protein extracts contained numerous different proteins, prior to 
ICAT analysis. The resolving gel (12% (w/v) acrylamide (30% acrylamide/0.8% 
bisacrylamide, Severn Biotech ltd.); 375mM Tris-HCl pH 8.7; 0.1% (w/v) SDS; 
0.1% (w/v) ammonium persulphate; 0.1% (v/v) TEMED) was poured, layered with 
isobutanol and left to polymerise. The isobutanol was subsequently poured off and 
the gel rinsed with a small amount of stacking gel, prior to pouring the stacking gel 
(3.5% (w/v) acrylamide (30% acrylamide/0.8% bisacrylamide, Severn Biotech ltd.); 
144mM Tris-HCl pH 6.8; 0.1% (w/v) SDS; 0.06% (w/v) ammonium persulphate; 
0.1% (v/v) TEMED). 
Samples and 10μl prestained protein marker (broad range 6-175 kDa, Biolabs, UK) 
were mixed with 5μl sample buffer (2% (w/v) SDS; 20% (v/v) glycerol; 0.125M 
Tris-HCl pH 6.8; 0.004% (w/v) bromophenol blue; 5% (v/v) 2-mercaptoethanol) and 
boiled for 5 min before loading. Gels were run in 1x Tris-Glycine SDS  
(Severn Biotech) at 200V until the dye front had reached the bottom of the gel.  
Chapter Two  Materials and methods 
 86
The gels were stained in Coomassie blue for 1 hour (0.25% (w/v) Coomassie blue 
R250 (Sigma), 5% (v/v) acetic acid, 50% (v/v) methanol) prior to destaining (10% 
(v/v) acetic acid, 20% (v/v) methanol) over night. 
2.9.6. Digestion of proteins in solution 
10μl of protein solution was mixed with 40μl 50mM ammonium bicarbonate (ABC) 
and DTT added to a final concentration of 5mM. The sample was subsequently 
heated at 60°C for 30 min, prior to cooling to room temperature. Iodoacetamide was 
added to a final concentration of 15mM and the sample placed in the dark for 30 min, 
prior to the addition of 0.8μg trypsin and the sample incubated at 37°C for 2 hours 
for digestion.  
2.9.7. ICAT 
2.9.7.1. Cleavable ICAT ®  
To investigate differences in protein expressions between cells infected with 
different viruses, cleavable isotope-coded affinity tag labelling (cICAT) was 
performed using a cICAT Reagent Kit from Applied Biosystems. This method tags 
the cysteines with heavy or light biotin labelled isotope-coded tags (C10H17N3O3), 
with the heavy tag containing 9x 13C and the light 9x 12C, thus allowing the 
identification and quantification of individual proteins in two samples following 
mass spectrometry. The kit protocol was followed with some adjustments.  
The two protein samples were concentrated and cleaned separately by acetone 
precipitation or by using Vivaspin 500 (Sartorius group) with a molecular weight cut 
off of 3000, according to the manufacturer’s instructions. The samples were 
denatured and reduced by the addition of Denaturing buffer and Reducing reagent 
and 10 min boiling on a heat block. The proteins were labelled by either light or 
heavy ICAT reagent resuspended in acetonitrile, during a 2 hour incubation at 37°C. 
The protein samples were subsequently combined and the proteins trypsin-digested 
over night at 37°C. The resulting peptides were run through a cation-exchange 
column to wash away TCEP (reducing agent that breaks disulfide bonds), SDS and 
unused ICAT reagents. The labelled peptides were selected by utilising an avidin 
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column to bind the biotin molecule on the isotope tag. The biotin molecule was 
subsequently cleaved off the tag by drying down the sample by vacuum or freeze 
dryer and incubation for 2 hours with cleavage reagents A and B at 37°C. The 
peptides were again dried down by vacuum dryer and resuspended in 0.5% (v/v) 
acetic acid, prior to running the sample on a LC-MS/MS system (LCQDeca or LTQ, 
ThermoScientific). 
2.9.7.2. 1-D PAGE cleavable ICAT 
The 1-D PAGE cICAT is a variation of the cICAT. The protocol for 1-D PAGE 
cleavable ICAT reagent applications development kit for targeted protein ID and 
quantification (Applied Biosystems) was followed with some adjustments. Reagents 
from the cICAT kit were used.  
The two protein samples were concentrated and cleaned separately by using Vivaspin 
500 (Sartorius group) with a molecular weight cut off of 3000 MW, according to the 
manufacturer’s instructions. The samples were denatured and reduced by the addition 
of Denaturing buffer and Reducing reagent and 10 min boiling on a heat block. The 
proteins were labelled by either light or heavy ICAT reagent resuspended in 
acetonitrile, during a 2-hour incubation at 37°C. The protein samples were 
subsequently combined and the sample vacuum dried to reduce the volume prior to 
mixing with 3x loading buffer and boiling for 10 min. The sample was run on a 
1.5mm 12% SDS- Polyacrylamide gel with a 5% stacking gel at 180-200V. The gel 
was subsequently washed in distilled water and stained with Coomassie blue (Sigma) 
for about 10 min before being destained. The gel was washed in distilled water for  
1 hour prior to excising the bands and cutting them into small pieces (1x1mm), and 
storing them at -20°C. The gel pieces were subsequently washed three times in 500μl 
gel washing buffer (50% (v/v) Acetonitrile (ACN) in 100mM ABC) at room 
temperature for 20 min and dehydrated with 100μl 100% ACN for 5 min at room 
temperature, the solution removed and the gel pieces left to air-dry. The proteins 
were in-gel trypsin digested by the addition of 60μl trypsin solution (0.8μg trypsin in 
60μl 50mM ABC). The gel pieces were left to rehydrate with the trypsin solution for 
10 min and more 50mM ABC added if needed to cover the gel pieces. The gel pieces 
were left to digest over night at 32°C. The peptides were extracted by sonicating the 
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gel pieces for 20 min in a sonic ice water bath and the supernatant transferred to a 
fresh tube. A 10μl ZipTip® (Millipore, UK), that has a bed of chromatography 
media in the tip, was used to concentrate the sample using a table top centrifuge at 
144 x g. The ZipTip® was washed with 5μl 100% methanol, followed by 10μl 0.1% 
(v/v) TFA, and the sample loaded onto the ZipTip®. The bound peptides were 
washed with 2 x 10μl 0.1% (v/v) TFA and eluted with 2 x 10μl 80% (v/v) ACN in 
0.1% (v/v) TFA. The labelled peptides were purified using an avidin column 
according to the protocol, and the solution concentrated using a ZipTip® as above 
and the concentrated peptide solution dried using a vacuum dryer for 10 min. The 
biotin tag was subsequently cleaved off by the addition of cleavage reagents A and B 
and incubation for 2 hours at 37°C, and the sample vacuum dried before re-
suspension in 60μl 0.5% acetic acid. The peptides were loaded onto a ZipTip®, as 
above, eluted and dried down in a vacuum dryer prior to loading onto the  
LC-MS/MS (LCQdeca or LTQ, ThermoScientific).  
On some occasions the peptide extraction involved addition steps. Following the 
initial sonication, extraction solvent was added (50% (v/v) ACN, 0.1% (v/v) TFA) 
and the gel pieces sonicated for 20 min in a sonic ice water bath. This was repeated 
three times. In addition, on some occasions vacuum drying and freeze drying was 
used instead of the ZipTip® prior to loading the sample onto the avidin column, and 
freeze drying prior to cleaving.  
2.9.8. Mass spectrometry 
2.9.8.1. Matrix-assisted laser desorption/ionization (MALDI) 
A Voyager DE STR MALDI–TOF MS (Applied Biosystems) was used for analysis 
of some protein and peptide samples. 0.5μl of sample was spotted on to a MALDI 
plate with 0.5μl CHCA matrix (10mg/ml CHCA (Sigma), 0.3% (v/v) TFA, 50% 
(v/v) ACN) for peptides and sinapinic acid matrix (10mg/ml (Sigma), 0.3% (v/v) 
TFA, 50% (v/v) ACN) for proteins. The spots were left to air dry prior to MALDI 
analysis.  
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2.9.8.2. LC-MS/MS analysis 
A LCQdeca or LTQ (Thermo Scientific) nanoLC-MS system was used to analyse 
peptide samples.  
The LCQdeca system consisted of a Famos autosampler, Switchos column switching 
unit, Ultimate nanoLC (Dionex) and LCQdeca mass spectrometer (ThermoScientific) 
fitted with a nanoLC ESI source interfaced to the MS with a PicoTip (New 
Objective). Separation of peptides was performed at 200µl/min on a PepMap C18 
column (3µm particle size, 75µm x 15cm), monitored at 214nm and the hplc method 
controlled by Chromeleon software (Dionex). The column was equilibrated with 
solvent A (0.1% (v/v) formic acid) and eluted with a linear gradient from 0 to 70% 
solvent B (0.1 % (v/v) formic acid in 100% acetonitrile) over 45 min.  
The LTQ system consisted of an Agilent 1200 Series hplc (Agilent technologies) 
with a Kasil sealed fused silica pre-column (Next Advance) packaged to a length of 
approximately 3cm with Pursuit C18 5µm particle size (Varian), and a PicoTip 
Emitter analytical column (New Objective) packaged to a length of approximately 
20cm with Pursuit C18 5µm particle size (Varian). The column was equilibrated with 
solvent A (0.1% (v/v) formic acid in 2.5% (v/v) acetonitrile) and eluted with a linear 
gradient from 0 to 8% over 6 to 8 min; from 8 to 60% over 8 to 35 min; from 60 to 
100% over 35 to 40 min; solvent B (0.1% (v/v) formic acid, 0.025% (v/v) TFA in 
90% (v/v) acetonitrile) over 45 min at a flow rate of 5µl/min. The LTQ mass 
spectrometer (ThermoScientific) was fitted with a nanoLC-ESI source.  
For both systems data dependent acquisition was controlled by Xcalibur software and 
database searching achieved using MASCOT software (Matrix Science).  
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2.10. Stock solutions 
10x TBS buffer   100mM Tris-base 
     1500mM NaCl 
     pH 7.5 with HCl 
 
TBE buffer   0.44M Tris-base 
     0.44M Boric acid 
     12mM EDTA 
 
PBS (pH 7.4)   150mM NaCl 
     2.5mM KCl 
     10mM Na2HPO4 
     1mM KH2PO4 
 
20 x SSC    3M NaCl 
     300mM sodium citrate (pH 7.0) 
 
50 x Denhardt’s buffer 1% (w/v) Ficoll 400 
     1% (w/v) Polyvinylpyrrolidone 
     1% (w/v) Bovine serum albumin fraction V 
 
Paraformaldehyde  4% (w/v) paraformaldehyde 
     10mM NaOH 
     1 x PBS 
     pH 7.4 with 1M HCl 
     filtered through a 0.45 μm membrane filter 
 
L-broth (pH 7.5)  1% (w/v) tryptone 
     0.5% (w/v) yeast extract 
     1% (w/v) NaCl 
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2.11. Synthetic oligonucleotides used for in vitro 
transcription 




Sequence of the DNA oligonucleotide template used for making the miRNA1 probe. 
The template corresponds to the target RNA and also has a 8nt sequence 
complementary to the T7 Promoter primer, shown in red. 
vtRNA transcription 
T7 promoter  





















The T7 promoter is shown in red and the 3’ CCA coding sequence in blue.  










ORF46-F 5'- CAT GCT TAC TGC CAT TGA TCA G -3' 55°C ORF 46
ORF46-R 5'- GGT TTG GCC TTT AGT GTT CAT G -3'
vtRNA1-F 5'- TAGAGCAACAGGTCACCGATC -3' 56°C vtRNA1
vtRNA1-R 5'- TGGACCCACTTCCTCGACCAG -3' nt 146-215
70bp product
vtRNA2-F 5'- GGTAGAGCAGCGGTTCCT -3' 56°C vtRNA2
vtRNA2-R 5'- ACTCCCCCTCTCAACCA -3' nt 505-573
69bp product
vtRNA4-F 5'- GCGGCAGGCTCATC -3' 56°C vtRNA4
vtRNA4-R 5'- ATCTCAACTCTGCGTCGG -3' nt 1205-1266
62bp product
vtRNA5-F 5'- TAGAGCATCAGGCTAGTA -3' 51°C vtRNA5
vtRNA5-R 5'- CTCCACCTTTAACCAG -3' nt 1607-1669
63bp product
vtRNA8-F 5'- CCCATCCTGTTGGTT -3' 51°C vtRNA8
vtRNA8-R 5'- CGCGGGTAGCTAGTC -3' nt 5418-5471
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3.1. Aims 
The aim of this project was to investigate the functions of the viral tRNAs and 
miRNAs encoded by MHV-68. The natural deletant virus MHV-76 is useful for this 
purpose as it is missing these genes. By infecting cells with MHV-68 and MHV-76 
and comparing the phenotypes (cell numbers, percentage of reactivating virus and 
amount of infectious virus), as well as gene and protein expression, a possible 
function for the viral tRNAs and miRNAs might be found. However, MHV-76 is 
also missing the four unique genes M1-M4, meaning that any phenotype found could 
be the action of any of these proteins. M2, M3 and M4 are all important for the 
establishment of latency (Bridgeman et al. 2001; Evans et al. 2006; Geere et al. 
2006; Jacoby et al. 2002; Macrae et al. 2003; Simas et al. 2004). M2 also promotes 
reactivation (Herskowitz et al. 2005; Jacoby et al. 2002), while M1 suppresses 
reactivation from latency (Clambey et al. 2000; Evans et al. 2008). To overcome this 
MHV-76 can be utilised to construct a recombinant knock-in virus, by re-inserting 
the genes of interest into the left end of the genome without the risk of disrupting any 
viral genes. This has previously been done in this laboratory, by inserting the M4 
ORF to look at the role of the M4 gene during infection (Townsley et al. 2004), as 
well as inserting vtRNAs1-5 and miRNAs1-6 (pers commun Yvonne Ligertwood; 
Cliffe 2005). Two independent insertion viruses were made in our laboratory by 
using the recombinant cassette pL2a5, consisting of vtRNAs1-5 and miRNAs1-6 
flanked by partial M4 and ORF4 from MHV-76 and a PstI fragment of the terminal 
repeats (Figure 3.1). These viruses, named Int2 and Int9, will serve as important tools 
to investigate the functions of the non-coding RNAs, since the only difference 
between MHV-76 and the insertion viruses is the vtRNAs and miRNAs. As a control 
a revertant virus made from Int9 was constructed by recombination using a cosmid 
(cM1) covering part of the MHV-76 genome from nt115587 to nt26842  
(Macrae et al. 2001). This virus was plaque purified and analysed by Southern 
hybridisations and it was determined that the vtRNAs had been removed from the 
insertion virus and the genome reverted back to that of MHV-76 (Cliffe 2005). 
A mouse myeloma B-cell line, NS0, was used to study latent infection. MHV-68 
establishes long-term latency in B-cells in vivo and NS0 cells have been shown  


































































































Figure 3.1 Diagram showing the differences between MHV-68, MHV-76 and the 
insertion viruses (Int9 and Int2) in the left side of the genome.  
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previously to support latent infection (Sunil-Chandra et al. 1993). Prior to any major 
experiment, infection of NS0 cells was examined to ensure this provided a suitable 
model to study latent infection.  
To be able to use the insertion viruses to compare subtle differences in protein 
expression and phenotypes of virus infected cells during latent infection, a very high 
percentage of cells need to be infected. It was not known how the infectivity of BHK 
cells, on which virus titration was performed, compared to that of NS0 cells. In 
addition, it was not known if the different viruses infected the same proportion of 
cells. Therefore, the percentage of infected NS0 cells needed to be determined.  
The insertion viruses have previously been shown to express the vtRNAs during lytic 
infection by RT-PCR and the levels of expression found to be similar to that of 
MHV-68 by northern blot analysis using a probe specific for vtRNA 1-4  
(Cliffe 2005). However, it had not been confirmed that the insertion viruses express 
the vtRNAs during latent infection of NS0 cells. Further, the insertion viruses had 
not been shown to express the miRNAs. The miRNAs are known to be expressed in 
latently infected S11 cells (Pfeffer et al. 2005); however, their expression had not 
been shown in MHV-68 infected NS0 cells or during lytic infection. Hence, the 
expression of the vtRNAs and miRNAs during lytic and latent infection was 
investigated. 
3.2. Determining the percentage of infected NS0 cells 
3.2.1. GFP labelled viruses 
The initial experiment to determine the number of infected NS0 cells utilised  
GFP-labelled viruses, LHΔgfp and MHV-76GFP. LHΔgfp is a recombinant MHV-68 
virus which carries a CMV-GFP cassette in the left end of the genome resulting in a 
deletion of nt 1-3223 (Dutia et al. 2004). The MHV-76GFP virus has a GFP cassette 
downstream of a murine PGK promoter (for the house keeping gene 
phosphoglycerate kinase) in the left end of the genome (pers commun Simon Talbot).  
NS0 cells were infected with the two viruses at a MOI of 1, 5 and 10 pfu/cell and 
cytospins were made at days 2 and 6 post infection. The GFP expressing cells were 
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counted using a fluorescent microscope at 40x magnification. MHV-76GFP did not 
generate any visible fluorescence. The reason for this is unknown, though it has been 
observed previously with this virus in NS0 cells. This virus has a promoter for a 
house keeping gene that should not be affected by latency. LHΔgfp did result in 
fluorescent cells; however, at a much lower level than expected (Figure 3.2). Since 
the virus has a CMV promoter that might be shut down during latency more cells 
could be infected but are not expressing the fluorescence. The best approach would 
be to infect the cells with the wild-type virus to avoid any effects of the inserted 
cassette and promoters.  
A MOI of 10 was found to affect the cell viability and since a MOI of 5 pfu/cell has 
previously been used in published studies (Simas et al. 1999; Sunil-Chandra et al. 
1993) it was decided that this MOI would be used for future experiments.  
3.2.2. In situ hybridisation 
To detect MHV-68 infected cells within a population of cells, in situ hybridisations 
were carried out with a dig-labelled anti-sense probe consisting of nucleotides 106 to 
1517, covering vtRNA1-4. The vtRNAs are commonly used as markers for latent 
infection as they are expressed at high levels (Bowden et al. 1997). In addition, there 
are currently no antibodies for any of the latent proteins.  
NS0 cells were infected with MHV-68 at a MOI of 5 pfu/cell and at day 5 post 
infection they were harvested and cytospins made. Initially the dig-labelled probe 
was detected by anti-dig/AP conjugated antibody and BCIP/NBT (results not 
shown). However, this approach was not sufficiently sensitive and a fluorescent 
antibody was used instead which allowed the use of confocal microscopy, giving 
greater resolution. A primary sheep anti-dig antibody was used to detect the  
dig-labelled probe, followed by a secondary biotinylated anti-sheep antibody and 
streptavidin/alexa fluor 488. The slides were blocked in Cas block (Invitrogen, UK), 
as this gave the least background staining. The majority of MHV-68 infected NS0 
cells were positive for vtRNAs (Figure 3.3), meaning that they were virus infected. 
The vtRNAs appeared to localise in the cytoplasm and be peri-nuclear, which is 
consistent with previous findings in latently infected S11 cells (Cliffe 2005).  

































Figure 3.2 Percentage of NS0 cells expressing GFP, 2 and 5 days post infection with 
LHΔgfp at a MOI of 1, 5 and 10 pfu/cell. The GFP expressing cells were counted using 
a fluorescent microscope at 40x magnification.  
 
 





Figure 3.3 In situ hybridisation for vtRNAs1-4 on uninfected NS0 cells (A and C) and 
NS0 cells infected with MHV-68 at a MOI of 5 pfu/cell (B and D). The dig-labelled 
probe was detected by a primary anti-dig antibody, a secondary biotinylated antibody, 
and streptavidin/alexa fluor 488 (A and B). The cells were nuclear stained by 
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As a positive control in situ hybridisation was also carried out on S11 cells with and 
without the vtRNA probe (Figure 3.4). The S11 cells were positive for vtRNAs after 
in situ hybridisation with the probe and again the vtRNAs seemed to localise in the 
cytoplasm. There was some non-specific fluorescence around the edges of the S11 
cells even when no probe had been used for the in situ hybridisation (Figure 3.4). 
The cause of the slightly high background was found to be the secondary antibody. 
As no alternative antibody was available the antibody was titred; however, a lower 
concentration of antibody led to a loss of signal (results not shown). 
3.2.3. Cloning of infected cells 
Another method of generating a very high percentage of virus infected cells would be 
to clone infected cells. NS0 cells were infected at a MOI of 5 pfu/cell with MHV-76 
or Int9 and incubated for 5 days before being cloned at 0.5 cells/well in a 96-well 
plate. Wells with only one clone were kept growing and the cells moved to larger 
plates and eventually flasks as the cells grew in numbers. PCR was carried out to 
determine if the clones were virus infected using primers for ORF 46, a viral uracil 
DNA glycosylase (Virgin et al. 1997), and the products visualised on a 1% agarose 
gel. Of the 12 clones tested (six MHV-76 and six Int9) all were positive for viral 
DNA (Figure 3.5), indicating that a very high percent of cells are infected at a MOI 
of 5 pfu/cell.  
Although the clones would give a high number of infected cells they would not 
represent a population of cells; any phenotypes found could be a feature of that 
particular clone. Since a high percentage of infected cells could be achieved in a 
diverse population of cells, it was decided that the clones would not be used for 
further analysis. 
3.2.4. Staining for lytic proteins 
During latent infection a small number of cells will reactivate and cause a lytic 
infection. Around 3% of S11 cells and 5% of MHV-68 infected NS0 cells undergo 
spontaneous reactivation (Nash et al. 2001; Usherwood et al. 1996a). To determine 
the percentage of lytically infected cells, staining was performed using a polyclonal 
serum raised against lytically infected rabbit cells. NS0 cells were infected 




Figure 3.4 In situ hybridisation for vtRNAs1-4 on S11 cells without probe (A, C and E) 
and with probe (B, D and F). The dig-labelled probe was detected by a primary anti-dig 
antibody, a secondary biotinylated antibody, and streptavidin/alexa fluor 488 (A and 
B). The cells were nuclear stained by Topro3 (C and D), with E and F showing the alexa 









































Figure 3.5 Identifying MHV-76 and Int9 infected clones by PCR analysis with primers 
for ORF46. The PCR products were visualised on a 1% agarose gel. The size of 
molecular weight markers in bp is shown to the right. Water control (–) and viral DNA 
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with MHV-68, MHV-76, Int9, Int2 and revertant virus at a MOI of 5 pfu/cell and at 
day 5 post infection they were harvested and cytospins made. A secondary 
biotinylated anti-rabbit antibody and streptavidin/alexa fluor was used to detect the 
antibodies that had bound to viral antigens. The number of positive cells was counted 
using a fluorescent microscope at x40 magnification. 
The antibodies bound weakly to latently as well as lytically infected cells. However, 
there were clear differences, with brightly stained cells indicating lytic infection  
(Figure 3.5). The serum was raised during a lytic infection but may contain 
antibodies to antigens expressed during latent infection. However, this proved useful 
as it confirmed that a very high percentage of cells are infected at a MOI of  
5 pfu/cell. The percentage of lytically infected cells was estimated as 1% for  
MHV-68, 8% for MHV-76, and 0.1% for Int9 infected NS0 cells. 
3.3. miRNA expression 
3.3.1. Northern blot analysis 
To ensure that MHV-68 and the insertion viruses express the miRNAs during latent 
infection of NS0 cells and during lytic infection, northern blot analysis was 
performed using a probe for miRNA1.  
Small RNAs were extracted from lytically infected BHK cells and latently infected 
NS0 cells that had been mock-infected or infected with MHV-68, MHV-76, Int9 or 
revertant virus at a MOI of 5 pfu/ml for 24 hours or 5 days respectively, using a 
mirVana miRNA isolation kit (Ambion, UK), as well as from latently infected S11 
cells. The RNA was separated by electrophoresis on a 15% TBE-Urea gel, 
transferred to a nylon membrane by electroblotting, and hybridisation carried out 
using ULTRAhyb®-Oligo Hybridization Buffer (Ambion, UK) and a radiolabelled 
probe specific for miRNA1. The probe was generated using a mirVanaTM miRNA 
probe construction kit to in vitro transcribe the probe using T7 RNA polymerase. A 
DecadeTM marker (Ambion, UK) was used to determine the sizes of bands.  
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Figure 3.6 Staining of virus infected cells using a polyclonal serum raised against 
lytically infected rabbit cells. A secondary biotinylated anti-rabbit antibody and 
streptavidin/alexa fluor was used to detect the antibodies that had bound to viral 
antigens. The stained cells were visualised using a fluorescent microscope at x100 
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The northern analysis confirmed that latently infected S11 cells express miRNA1 
(Figure 3.7). It also confirmed that MHV-68 and Int9 express miRNA1 during lytic 
infection of BHK cells, while, as expected, MHV-76 and the revertant do not. In 
addition it showed that miRNA1 is expressed in NS0 cells latently infected with 
MHV-68; however, not with Int9. This was surprising as miRNA1 was expressed by 
Int9 during lytic infection.  
To confirm the lack of miRNA1 expression another northern blot analysis was 
performed on RNA from latently infected NS0 cells. The cells were infected with the 
viruses, including the second insertion virus Int2, at a MOI of 5 pfu/cell and small 
RNAs extracted 24 hours and 5 days post infection. In addition, 2μg of RNA from 
Int9 infected NS0 cells was loaded into one well, instead of the usual 1 μg, to see if 
the miRNA was expressed at a very low level. The second northern blot confirmed 
the previous result; while MHV-68 expressed miRNA1 during latent infection of 
NS0 cells both 24 hours and 5 days post infection, the insertion viruses did not 
(Figure 3.8). To further confirm this result and to examine the expression of the other 
miRNAs, a more sensitive qRT-PCR analysis was performed. 
3.3.2. qRT-PCR 
To confirm that the insertion viruses do not express miRNA1 and to determine if the 
other miRNAs are expressed, a qRT-PCR analysis for the miRNAs was performed 
using an Invitrogen NCode miRNA First-Strand cDNA Synthesis Kit and Platinum 
SYBR Green qPCR SuperMix-UDG. Using this kit a poly(A) tail was added to the 
3’ end and the miRNA reverse transcribed using a universal RT primer. dsDNA was 
produced using a forward primer specific to the miRNA and a universal qPCR 
primer in a PCR reaction. The levels of dsDNA produced were determined using the 
intercalating dye SYBR green. 
In an initial experiment small RNAs extracted from mock and MHV-68 infected NS0 
cells using a mirVana miRNA isolation kit (Ambion, UK) were used. All six 
miRNAs examined were detected in all MHV-68 infected cells and none in mock-
infected cells (Figure 3.9); however, the dissociation curve for miRNA2 was not 
good and no specific product seemed to be detected (see Appendix Figure 8.1). This 
is possibly because of the high C content of the miRNA and it was decided that this  





























Figure 3.7 Northern blot analysis of miRNA1 expression by MHV-68, MHV-76, Int9 
and revertant (Rev) viruses during lytic and latent infection. BHK cells were infected 
for 24 hours and NS0 cells for 5 days at a MOI of 5 pfu/cell and small RNAs extracted 
with a mirVana miRNA isolation kit (Ambion, UK). Hybridisation was carried out 
using ULTRAhyb®-Oligo Hybridization Buffer (Ambion, UK) and a radiolabelled 
probe specific for miRNA1. A DecadeTM marker (Ambion, UK) was used to determine 
the sizes of bands. 

























Figure 3.8 Northern blot analysis of miRNA1 expression by MHV-68, MHV-76, Int9 
and Int2 during latent infection. NS0 cells were infected for 24 hours or 5 days at a 
MOI of 5 pfu/cell and small RNAs extracted with a mirVana miRNA isolation kit 
(Ambion, UK). One well was loaded with twice as much RNA, 2μg, from Int9 infected 
NS0 cells. Hybridisation was carried out using ULTRAhyb®-Oligo Hybridization 
Buffer (Ambion, UK) and a radiolabelled probe specific for miRNA1. A DecadeTM 
marker (Ambion, UK) was used to determine the sizes of bands. 
 




Figure 3.9 qRT-PCR amplification plots for miRNA1-6 on RNA from mock (blue) and 
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miRNA could not be quantified using this method. The miRNA5 primer seemed to 
pick up some non-specific products as well (see Appendix Figure 8.1); however this 
primer was used for further analysis to see if the dissociation curve could be 
improved.  
The miRNA expression by the insertion viruses, Int9 and Int2, during latent infection 
was subsequently compared to that of MHV-68 by qRT-PCR for miRNA1, 3, 4, 5 
and 6. The relative quantity of the miRNAs was normalised against cellular 5S 
ribosomal RNA, to compensate for differences in the amount of RNA used for the 
reverse transcription. The qRT-PCR results confirmed the previous northern 
analyses; the insertion viruses express miRNA1 at very low levels during latent 
infection (Figure 3.10). In addition, miRNA3, 4, 5 and 6 were all expressed at a 
lower level than by MHV-68. This time the dissociation curve for miRNA5 was 
slightly better, but amplification of some non-specific products still occurred  
(see Appendix Figure 8.2). However, it could still be concluded that NS0 cells 
latently infected with the insertion viruses contain less of the miRNAs than MHV-68 
infected cells.  
3.4. vtRNA expression 
To ensure that the insertion viruses express the vtRNAs during latent infection,  
RT-PCR analysis was carried out on miRNA enriched RNA from mock-infected 
NS0 cells or infected with MHV-68, MHV-76, Int9, or Int2 for five days. The RNA 
was DNase treated and RT-PCR carried out using primers specific for four of the 
vtRNAs and the products visualised on a 2% agarose gel. All four vtRNAs examined 
were expressed during latency (Figure 3.11). 
3.5. Discussion 
Two insertion viruses had previously been made by inserting five of the vtRNAs and 
six of the miRNAs into the natural deletant virus MHV-76. This generated two 
viruses with the only difference from MHV-76 being the vtRNAs and miRNAs. In 
addition a revertant virus had been made by reverting the insertion virus Int9 back to 
MHV-76 genome. These were to be used to investigate the functions of the  






Figure 3.10 qRT-PCR for miRNAs. Showing the levels of miRNAs expressed by the 
insertion viruses (Int9 and Int2) relative to the expression by MHV-68. Error bars 
show the standard deviation. Values were normalised against cellular 5S ribosomal 





















































































































Figure 3.11 RT-PCR analysis showing the expression of vtRNAs1, 2, 4 and 5 from NS0 
cells latently infected with MHV-68, MHV-76, Int9, Int2 and revertant (Rev), as well as 
mock-infected cells. The RNA was DNase treated, RT-PCR carried out for the vtRNAs 
(+RT) and the products visualised on a 2% agarose gel. Control RT-PCR reactions 
without reverse transcriptase (-RT) were also carried out, as well as a water control 
(H20) for the PCR reaction.  
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non-coding RNAs. However, prior to any major studies with the viruses they needed 
to be characterised. The recombinant viruses had already been analysed by Southern 
blot analysis to confirm correct insertion of the DNA fragments into the viral genome 
of the insertion viruses and that the revertant was identical to MHV-76. The 
expression of the vtRNAs by the insertion viruses during lytic infection had also 
been confirmed (Cliffe 2005). 
To compare subtle differences in phenotypes and protein expression a large 
proportion of cells need to be infected, and the viruses need to infect a similar 
proportion of cells. The viruses were titred on BHK-21 fibroblast cells, determining 
the number of pfu per ml in the virus stocks. It was not known if the viruses had 
similar infectivity on NS0 cells. In this study it was shown that five days post 
infection at a MOI of 5 pfu/cell the viruses (MHV-68, MHV-76, Int9, Int2 and 
revertant) have all infected close to 100% of the NS0 cells, and that the cells are 
healthy and growing well following infection. 
The initial experiment using GFP-labelled viruses was unsuccessful, probably due to 
the promoters driving the GFP expression not being fully active, perhaps being  
shut-down due to chromatin remodelling during latency. However, the in situ 
hybridisations carried out for vtRNAs in MHV-68 infected NS0 cells were more 
successful. In addition to showing that close to 100% of cells were infected with 
MHV-68, the in situ hybridisation also showed that the vtRNAs appear to localise in 
the cytoplasm during latency. The vtRNA1-4 probe has previously been used for in 
situ hybridisations and has been shown to bind specifically to vtRNAs (Bowden et 
al. 1997; Cliffe 2005; Simas et al. 1999). However, since MHV-76 and the revertant 
virus do not express the vtRNAs the in situ hybridisation could not be used for all 
viruses.  
There are no antibodies available for any proteins expressed during latency; 
however, a polyclonal serum raised against lytically infected rabbit cells proved 
useful as it bound to antigens produced at low levels during latent infection. It could 
thereby be confirmed that all the viruses infect close to 100% of NS0 cells. It was 
clear that MHV-76 and the revertant virus had a higher proportion of lytically 
infected cells, while the insertion viruses had a very low number.  
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In parallel to the other experiments, virus infected clones were grown up. All the 
clones tested were virus positive, corroborating that 100% of cells are infected at a 
MOI of 5 pfu/cell. It is possible that the virus infected cells are more viable; thus 
making it more likely that the surviving clones are virus infected. However, virus 
infected cells do not increase in cell numbers compared to uninfected cells  
(see chapter four), therefore virus infection does not seem to increase cell viability. 
The clones would have been useful if a high number of infected cells could not be 
achieved through infection of NS0 cells. However, it was decided that it was better to 
use a population of infected cells, instead of a clone.  
The viruses were further characterised in regards to vtRNA and miRNA expression. 
The insertion viruses were known to express the vtRNAs during lytic infection 
(Cliffe 2005) and we confirmed by RT-PCR that the vtRNAs are expressed during 
latent infection as well. This was expected since MHV-68 expresses the vtRNAs 
during both lytic and latent infection. We corroborated that MHV-68 expresses the 
miRNAs during latent infection of S11 cells and confirmed that they are expressed in 
latently infected NS0 cells. We further showed that MHV-68 expresses the miRNAs 
during lytic infection, which was expected since the vtRNAs are expressed. This had 
not been shown at that point, but has since been published (Diebel et al. 2010). Since 
MHV-68 expresses the miRNAs during both lytic and latent infection, it was 
surprising to find that during latent infection of NS0 cells the insertion viruses do not 
express miRNA1 at detectable levels and the other miRNAs at lower levels than 
MHV-68, especially since they express miRNA1 during lytic infection.  
The lack of miRNA1 expression by the insertion viruses during latency could be 
because promoter elements needed during latent infection are missing. Eukaryotic 
tRNA genes have upstream promoter elements around -30 relative to the 
transcription initiation site that can regulate tRNA transcription (reviewed in Dieci et 
al. 2007). The insert used for making the insertion viruses consists of nt 112-1694, 
covering vtRNA1-5 and miRNA1-6. vtRNA1 starts at nt 127 and since the promoter 
regions of the vtRNA/miRNA transcripts are not fully mapped and there may be 
unknown promoter/enhancer regions, it is possible that more of the sequence should 
have been included in the insert. If this is the case the vtRNA1 expression by the 
insertion viruses would be expected to be very low as well; however, since only a 
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non-quantitative RT-PCR was performed for the expression of the vtRNAs it is not 
known if this is the case.  
The lower expression of the miRNAs by the insertion viruses during latency is 
interesting. It is possible that the presence of the non-coding RNAs affect the copy 
number of the viruses. If there are fewer copies of the viral genome, lower amounts 
of miRNAs would be expressed. Preliminary qPCR data (not shown) indicates that 
this might be the case; however, this would need to be examined further. It would be 
interesting to see if the insertion viruses also express the vtRNAs at a lower level, 
which would be expected if the deficiency is at the level of transcription, since the 
vtRNAs and miRNAs are expressed on the same transcript. In addition, it is not 
known if there is a difference in expression levels of the non-coding RNAs between 
MHV-68 and the insertion viruses during lytic infection. Perhaps the unique genes 
are needed for efficient expression of the non-coding RNAs.  
Several methods to detect and/or quantify miRNAs have been made available during 
the last few years. Initially northern blot analysis was used; however, the 
development of qRT-PCR for miRNAs has made detection more sensitive, less time 
consuming and enables large scale analysis. The initial difficulty with qRT-PCRs 
was the short miRNAs sequence, making primer design difficult. This has been 
overcome by making the miRNA larger by using stem-loop primers (Ambion), 
adding a poly(A) tail (Invitrogen), or by using LNA nucleotides that allows for 
shorter primers (Exiqon). In this study we used the Invitrogen NCode miRNA  
First-Strand cDNA Synthesis Kit and Platinum SYBR Green qPCR SuperMix-UDG. 
This kit allows for designing of a miRNA primer specific for the miRNA, while 
other kits use pre-designed primers that do not include viral miRNAs. Because the 
primer used corresponds to the whole miRNA it is difficult in some cases to obtain 
specific products and good dissociation curves as there is little sequence variation 
allowed, as seen with miRNA2 and 5. In addition, if all miRNAs are to be analysed 
in one qRT-PCR experiment it is difficult to chose an annealing temperature suitable 
for all miRNA primers. For future experiments a possible alternative would be the 
TaqMan microRNAs assay (Applied Biosystems) to which specific stem loop 
primers for MHV-68 miRNAs can be ordered.  
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The aim of this study was to characterise the vtRNA and miRNA expression profiles 
of the viruses and determine whether infection of NS0 cells provided a suitable 
model to study differences in phenotypes and protein expression during latent 
infection. In conclusion, although some differences are observed, the NS0 cells 
provide a suitable model; a very high percentage of infected cells can be achieved 
and the non-coding RNAs are expressed.  
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4.1. Aims 
The roles of the non-coding RNAs of MHV-68 during infection have not been 
extensively characterised and it is not know what their biological functions are. The 
lack of the vtRNAs, miRNAs and M1-4 seen in MHV-76 leads to an attenuated 
phenotype, with the virus being cleared more rapidly and showing a deficiency in 
establishing latency (Macrae et al. 2001). However, the unique proteins are known to 
be important during infection (see section 1.3.10). In contrast, deletion of vtRNA1-4, 
miRNAs1-7 and M1 from MHV-68 did not result in a difference in either replication 
during in vitro infection or the ability of the virus to reactivate from latency in vivo 
compared to wild type virus (Simas et al. 1998). However, this was a limited study 
investigating infection in only four mice for each virus at one time point, with 
varying results obtained between mice. In addition, the non-coding RNAs may have 
similar functions so deleting just some of them might not abolish their effect. M1 is a 
multifunctional protein and deletion of M1 has since been shown to result in an 
increase in reactivation, which is inconsistent with the above study (Clambey et al. 
2000; Evans et al. 2008).  
The insertion viruses, Int9 and Int2, provide useful tools to study the non-coding 
RNAs, since the only difference between the two insertion viruses and MHV-76 are 
the five vtRNAs and six miRNAs, and any phenotype found will be caused by these. 
However, the insertion viruses will not tell us if the phenotype is caused by the 
vtRNAs or miRNAs. A previous in vivo study showed that, like MHV-76, the 
insertion viruses are cleared more rapidly and establish latency at a lower level in the 
spleen than MHV-68 (Cliffe 2005). Since a phenotype for the insertion viruses could 
not be found in vivo, we decided to investigate the functions of the non-coding RNAs 
during latent infection in vitro.  
NS0 cells were latently infected with the different viruses at a MOI of 5 pfu/cell and 
the replication and reactivation kinetics analysed by plaque assay and infective centre 
assay.  
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4.2. Replication and reactivation kinetics 
4.2.1. Preliminary experiment 
5x106 NS0 cells were mock-infected or infected with MHV-68, MHV-76, or Int9 at a 
MOI of 5 pfu/cell for one hour and 2x106 of the infected cells incubated in T25 
flasks in duplicate for each virus, for five days. These viruses had been titrated at the 
same time on the same BHK cells. Mock lysate was used to bring the virus solutions 
to the same volume, to minimise differences in the amount of cell debris present in 
the samples. On the day of infection and five and nine days post infection, cell 
numbers and titres of cell associated virus and virus in the supernatant were 
determined. In addition, infective centre assays were performed five and nine days 
post infection, by co-cultivating latently infected NS0 cells with BHK cells, to 
determine the percentage of NS0 cells reactivating virus.  
The titres of supernatant virus and cell associated virus following adsorption for one 
hour was determined to ensure that the same pfu of each virus had been used to 
infect the cells (Figure 4.1). The cell numbers showed that the virus infection did not 
give the cells a survival advantage (as discussed for the clones in the previous 
chapter), but infection with MHV-68 and MHV-76 seemed to lead to slightly 
reduced cell numbers (Figure 4.2); however this was not observed in subsequent 
experiments (Figure 4.9). There was a significantly larger amount of virus produced 
by MHV-68 and MHV-76 compared to Int9 (Figure 4.3). This difference was also 
seen in the amount of virus present in the cells; with Int9 infected NS0 cells having 
significantly lower levels of cell associated virus (Figure 4.4). The difference became 
more apparent when looking at the percentage of cells reactivating virus; Int9 
reactivated at a significantly lower level than MHV-68 and MHV-76 (Figure 4.5). At 
five days post infection MHV-76 also reactivated at a significantly higher level than 
MHV-68 and produced significantly more virus than MHV-68 both five and nine 












Figure 4.1 Supernatant (A) and cell associated (B) virus titres (pfu/ml and pfu/105 cells) 
from NS0 cells mock-infected or infected with MHV-68, MHV-76 or Int9 at a MOI of 5 
pfu/cell, following one hour of adsorption. Each bar shows the mean of two biological 
replicates, each with two technical replicates. Error bars represent the standard 
deviation.  
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Figure 4.2 Cell numbers from NS0 cells mock-infected or infected with MHV-68, 
MHV-76 or Int9 at a MOI 5 pfu/cell, five and nine days post infection. Each bar shows 
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Figure 4.3 Supernatant virus titres (pfu/105 cells) from NS0 cells mock-infected or 
infected with MHV-68, MHV-76 or Int9 at a MOI 5 pfu/cell, five and nine days post 
infection. Each bar shows the mean of two biological replicates, each with two technical 
replicates. Error bars represent the standard deviation. * Int9 produced significantly 
less virus than MHV-68 and MHV-76 five days (p<0.025) and nine days (p<0.0025) post 
infection. * MHV-76 produced significantly more virus than MHV-68 both five 




Figure 4.4 Cell associated virus titres (pfu/105 cells) from NS0 cells mock-infected or 
infected with MHV-68, MHV-76 or Int9 at a MOI 5 pfu/cell, five and nine days post 
infection. Each bar shows the mean of two biological replicates, each with two technical 
replicates. Error bars represent the standard deviation. * Int9 infected NS0 cells had 
significantly less cell associated virus than MHV-68 and MHV-76 infected cells five 
days (p<0.025) and nine days post infection (p<0.05). * MHV-76 infected NS0 cells had 
significantly more cell associated virus than MHV-68 both five (p<0.01) and nine 














































































Figure 4.5 Percentage of NS0 cells reactivating virus, mock-infected or infected with  
MHV-68, MHV-76 or Int9 at a MOI 5 pfu/cell, five and nine days post infection. The 
percentage of cells reactivating virus was calculated by subtracting the cell associated 
virus titres from the infective centres. Each bar shows the mean of two biological 
replicates, each with two technical replicates. Error bars represent the standard 
deviation. * Int9 reactivated at a significantly lower rate than MHV-68 and MHV-76 
both five days (p<0.0025) and nine days (p<0.01) post infection. * MHV-76 reactivated 
at a higher frequency than MHV-68 five days (p<0.001) but not nine days post 
infection, as determined by Student’s t-test. 
* *
*
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4.2.2. Experiment with Int2 virus 
To confirm the reduction in reactivation seen with Int9 the experiment was repeated 
to include the second insertion virus Int2, which had been made independently of 
Int9. This time only the infective centres assay was performed five days post 
infection. The percentages of infective centres were analysed without subtracting the 
cell associated virus titre. 
The second insertion virus reactivated at the same level as Int9, strongly suggesting 
that the lower reactivation rate was due to the insert (Figure 4.6). The infective 
centres from this experiment replicated the results from the previous experiment 
(Figure 4.7). The cell associated virus titres did not have a great impact on the 
percentage of cells reactivating virus, since the same differences in reactivation 
between the viruses were observed even without subtracting the cell associated virus 
titres from the infective centres (Figure 4.5, Figure 4.7). This showed that the 
infective centres alone give a good measurement of reactivation.  
4.2.3. Experiment with revertant virus 
The replication and reactivation kinetics experiment was repeated with the revertant 
virus to confirm that the insertion viruses do reactivate at a lower level and produce 
less infectious virus. This time 3x106 NS0 cells were infected in duplicate for each 
virus (MHV-68, MHV-76, Int9, Int2 and revertant virus) at a MOI of 5 pfu/cell for 
one hour and 2x106 of the infected cells subsequently incubated in T25 flasks for five 
days. As previous, cell numbers and titres of cell associated virus and virus in the 
supernatant were determined on the day of infection and five and nine days post 
infection. Also, the percentage of cells reactivating virus was determined five and 
nine days post infection.  
The supernatant and cell associated virus titres following one hour of adsorption 
were similar for all viruses (Figure 4.8). In this experiment MHV-68 and MHV-76 
did not have lower cell numbers nine days post infection (Figure 4.9), as seen in the 
first assay. Both insertion viruses produced significantly less lytic (Figure 4.10), and 
cell associated virus (Figure 4.11), and reactivated at a significantly lower level 
(Figure 4.12) than MHV-68, MHV-76 and the revertant virus. Insertion of the  


























Figure 4.6 Percentage of infective centres from NS0 cells mock-infected or infected with  
MHV-68, MHV-76, Int9 or Int2 at a MOI 5 pfu/cell, five days post infection. Each bar 
shows the mean of two biological replicates, each with two technical replicates. Error 
bars represent the standard deviation. * Int9 and Int2 infected cells reactivated at a 
significantly lower level than MHV-68 and MHV-76 (p<0.0025). * MHV-76 reactivated 































Figure 4.7 Comparing the percentage of infective centres between the two experiments, 
five days post infection of NS0 cells mock-infected or infected with MHV-68, MHV-76, 
Int9 or Int2 at a MOI 5 pfu/cell. Each bar shows the mean of two biological replicates, 
each with two technical replicates. Error bars represent the standard deviation. ND, 











Figure 4.8 Supernatant (A) and cell associated (B) virus titres (pfu/ml and pfu/105 cells) 
from NS0 cells mock-infected or infected with MHV-68, MHV-76, Int9, Int2 or 
revertant virus (Rev) at a MOI 5 pfu/cell, following one hour of adsorption. Each bar 
shows the mean of two biological replicates, each with two technical replicates. Error 
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Figure 4.9 Cell numbers from NS0 cells, mock-infected or infected with MHV-68, 
MHV-76, Int9, Int2 or revertant virus (Rev) at a MOI 5 pfu/cell, five and nine days post 
infection. Each bar shows the mean of two biological replicates. Error bars represent 
the standard deviation.  
 
 























Figure 4.10 Supernatant virus titres (pfu/105 cells) from NS0 cells, mock-infected or 
infected with MHV-68, MHV-76, Int9, Int2 or revertant virus (Rev) at a MOI 5 
pfu/cell, five and nine days post infection. Each bar shows the mean of two biological 
replicates, each with two technical replicates. Error bars represent the standard 
deviation. * Int9 and Int2 produced significantly less virus than MHV-68, MHV-76 and 
the revertant virus both five days (p<0.01) and nine days (p<0.01) post infection.  
* MHV-76 produced significantly more virus than MHV-68 and the revertant virus five 




Figure 4.11 Cell associated virus titres (pfu/105 cells) from NS0 cells, mock-infected or 
infected with MHV-68, MHV-76, Int9, Int2 or revertant virus (Rev) at a MOI 5 
pfu/cell, five and nine days post infection. Each bar shows the mean of two biological 
replicates, each with two technical replicates. Error bars represent the standard 
deviation. * Int9 and Int2 infected NS0 cells had significantly less cell associated virus 
than MHV-68, MHV-76 and the revertant virus both five days (p<0.05) and nine days 
(p<0.001) post infection. * MHV-76 infected cells had significantly more cell associated 
virus than MHV-68 and the revertant virus five days (p<0.05) and nine days (p<0.001) 























































































Figure 4.12 Percentage of NS0 cells reactivating virus, mock-infected or infected with 
MHV-68, MHV-76, Int9, Int2 or revertant virus (Rev) at a MOI 5 pfu/cell, five and 
nine days post infection. The percentage of cells reactivating virus was calculated by 
subtracting the cell associated virus titres from the infective centres. Each bar shows 
the mean of two biological replicates, each with two technical replicates. Error bars 
represent the standard deviation. Nine days post infection the infective centres from 
MHV-76 infected cells could not be counted as there were too many on the plates.  
* Int9 and Int2 reactivated at a significantly lower level than MHV-68, MHV-76 and 
the revertant virus both five days (p<0.025) and nine days (p<0.005) post infection.  
* MHV-76 reactivated at a higher frequency than MHV-68 and the revertant virus five 
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vtRNAs and the miRNAs into the genome of MHV-76 led to a decrease in 
reactivation and production of lytic virus 10-fold or greater compared to revertant 
virus. MHV-76 reactivated at a higher rate and produced more lytic virus than both 
MHV-68 and the revertant virus (Figure 4.10, Figure 4.12).  
miRNA1 has a predicted target site in the 3’ UTR of the ORF50 gene that encodes 
the rta that is important for reactivation (Figure 4.13; pers commun Simon Talbot), 
which would be expected to lead to a reduction in ORF50 and thus a decrease in 
reactivation. However, since the insertion viruses express miRNA1 at very low levels 
during latent infection; this is unlikely to be the reason for the lower reactivation 
rates seen.  
4.2.4. In vivo reactivation kinetics 
To investigate if the lower reactivation rate seen by the insertion viruses could also 
be observed in vivo, a small study was performed where five BALB/c mice were 
infected intranasally with 4x105 pfu of MHV-76 and five with Int9. Previous in vivo 
studies had shown that Int9, like MHV-76, is cleared more rapidly than MHV-68 and 
established latency at a very low level in the spleen (Cliffe 2005); a feature that must 
therefore be because of the lack of the unique proteins M1-M4, and not the vtRNAs 
and miRNAs. However, these studies did not examine the MLN and it is possible 
that the establishment of latency is different in this location. Therefore, we 
investigated the reactivation kinetics of latently infected MLN cells. The cells were 
collected by disrupting the MLN with a scalpel, washing the cells by centrifugation 
and letting the debris settle, prior to removing the supernatant with the cells. The 
cells were counted and infective centres assays set up with 105 or 106 MLN cells. 
Although there were large variations in infectious centres between different mice, 
there did not appear to be a difference in reactivation between MHV-76 and Int9 
infected MLN cells (Figure 4.14, Figure 4.15). A larger study involving a larger 
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Figure 4.13 Showing the possible miRNA1 target sequence in the ORF50 3’ UTR. (A) 
The 3’ end of ORF50. (B) The possible binding site of miRNA1 to the ORF50 3’ UTR. 
































Figure 4.14 Infective centres per 106 MLN cells from mice infected intranasally with 




























Figure 4.15 Infective centres per 106 MLN cells from mice infected intranasally with 
4x105 pfu of MHV-76 or Int9, five mice for each virus. Showing the mean number of 
infective centres for mice infected with each virus. Error bars represent the standard 
deviation. 
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4.3. Transfection of non-coding RNAs and plasmids 
4.3.1. miRNA transfections 
The insertion viruses could not be used to distinguish whether the vtRNAs or 
miRNAs are responsible for the reduction in reactivation. Therefore, to determine if 
the miRNAs caused the reduction in reactivation, miRNAs1-6 were transfected into 
MHV-76 infected NS0 cells.  
Initially, the cells were infected with MHV-76 at a MOI of 5 pfu/cell for two hours 
prior to transfection with 0.5μg miRNA1-6 mimics (miScript miRNA mimics, 
Qiagen) or a negative siRNA and 66.5pmol siGLO red using a nucleofector. siGLO 
is a fluorescent RNA duplex that when co-transfected with miRNAs gives an 
indication of the transfection efficiency. The reactivation kinetics were analysed by 
infective centres assays 24 and 72 hours post transfection. Transfection of the 
miRNAs into MHV-76 infected cells did not lead to a change in the percentage of 
cells reactivating virus compared to the negative control; however, the transfection 
itself led to an increase in reactivation compared to untransfected cells (Figure 4.16). 
The previous reactivation experiments examined the infective centres five days post 
infection. To replicate these conditions NS0 cells were infected with MHV-76 at a 
MOI of 5 pfu/cell and the infected cells transfected with miRNAs1-6 or negative 
siRNA after four days, followed by infective centres assays after 24 hours  
(five days post infection) and 48 hours. In addition, supernatant virus titres were 
analysed. At 24 hours post transfection, miRNA transfected cells reactivated virus at 
a significantly lower level than the negative control (Figure 4.17). However, this was 
not seen at 48 hours post transfection, or in the amount of infective virus produced 
(Figure 4.18). Again, at 48 hours post transfection, negative siRNA transfected cells 
had a higher percentage of cells reactivating virus than the untransfected cells, and 
also produced a larger amount of infectious virus. 
To further investigate the difference in reactivation 24 hours post transfection of 
miRNAs, the previous experiment was repeated. This time NS0 cells infected for 
five days with Int9 was included as a control of the reactivation assay. The  





























Figure 4.16 Percentage of infective centres from MHV-76 infected NS0 cells, 
untransfected or 24 and 72 hours post transfection with negative control siRNA or 
miRNAs1-6. Each bar shows the mean of two biological replicates, each with two 
technical replicates. The transfection efficiency was around 76%. Error bars represent 
the standard deviation. * Untransfected cells had significantly (p<0.05) lower 
percentage of infective centres compared to transfected cells 72 hours post transfection, 





























Figure 4.17 Percentage of infective centres from NS0 cells latently infected with  
MHV-76 for four days, untransfected or 24 and 48 hours post transfection with 
negative control siRNA or miRNAs1-6. Each bar shows the mean of two biological 
replicates, each with two technical replicates. The transfection efficiency was around 
65%. Error bars represent the standard deviation. * miRNA transfected cells had 
significantly (p<0.01) lower percentage of infective centres compared to negative siRNA 
transfected cells 24 hours post transfection. * Untransfected cells had significantly 
lower (p<0.01) percentage of infective centres than negative siRNA transfected cells 48 




Figure 4.18 Supernatant virus titres (pfu/105 cells) from NS0 cells latently infected with 
MHV-76 for four days, 24 hours and 48 hours post transfection with negative control 
siRNA or miRNAs 1-6, or untransfected cells. Each bar shows the mean of two 
biological replicates, each with two technical replicates. The transfection efficiency was 
around 65%. Error bars represent the standard deviation. * Untransfected cells had 
significantly (p<0.05) lower percentage of infective centres compared to negative siRNA 
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transfection of miRNAs1-6 into MHV-76 infected cells did not lead to a reduction in 
reactivation at 24 hours post transfection (Figure 4.19), as seen in the previous 
experiment. Consistent with the previous experiments, the Int9 infected cells 
reactivated virus at a significantly lower level than MHV-76 infected cells. 
To confirm that the transfection led to increased miRNA levels, a qRT-PCR for 
miRNA3 was performed on small RNAs from the transfected cells. As excepted, 
untransfected or negative siRNA transfected MHV-76 infected cells did not contain 
miRNA3. miRNA transfection of MHV-76 infected NS0 cells lead to significantly 
higher levels of miRNA3 than in Int9 infected NS0 cells (Figure 4.20).  
4.3.2. Dicer 
To further investigate the role of the miRNAs in virus reactivation, the miRNA 
processing pathway was disrupted by inhibiting Dicer through transfection of a 
siRNA targeting the Dicer mRNA. Dicer is a component of the RISC loading 
complex and cleaves the pre-miRNA into small RNA duplexes approximately 22nt 
in size. By reducing the production of Dicer, the processing of new miRNAs is 
inhibited. The siRNA was transfected into NS0 cells and after 48 hours the cells were 
infected with MHV-68, MHV-76 or Int9, followed by infective centres assays  
24 hours post infection. MHV-76 infected cells were included to ensure that cellular 
miRNAs were not inhibited resulting in a change in reactivation. By waiting  
48 hours following transfection the siRNA is allowed to be processed and inhibit 
Dicer synthesis prior to infection so that viral miRNAs can not be processed. It 
should not have a major impact on the cellular miRNAs as there should still be a 
pool of these in complexes with RISC. Transfection with a siRNA against Dicer did 
not have an effect on the reactivation (Figure 4.21). To ensure that the miRNAs had 
been knocked down qRT-PCR was performed for miRNAs3 and 4 on small RNAs 
from the transfected cells. However, because of the low amounts of miRNAs present 
within Int9 infected cells, an effect of the siRNA against Dicer on viral miRNA 
levels could not be detected (Figure 4.22, Figure 4.23). Further studies are needed to 
confirm the results.  
 


























Figure 4.19 Percentage of infective centres from NS0 cells latently infected with  
MHV-76 for four days, untransfected or 24 hours post transfection with negative 
control siRNA or miRNAs1-6. Int9 infected NS0 cells were included as a control for 
reactivation. Each bar shows the mean of two biological replicates, each with two 
technical replicates. The transfection efficiency was around 36%. Error bars represent 
the standard deviation. * The Int9 infected NS0 cells reactivated virus at a significantly 
lower level (p<0.005) than MHV-76 infected cells, whether transfected or not, as 




















































Figure 4.20 Relative quantity of miRNA3 as determined by qRT-PCR, in uninfected, 
MHV-68 infected, and Int9 infected NS0 cells, and MHV-76 infected NS0 cells: 
untransfected, negative siRNA transfected or miRNA transfected. Values normalised 
against cellular mir-16 levels and expressed relative to Int9 expression levels. Error 
bars represent the standard deviation. * miRNA transfected cells had significantly 































Figure 4.21 Percentage of infective centres following transfection of a siRNA against 
Dicer. NS0 cells were transfected with siRNA and 48 hours later infected with either 
MHV-76, MHV-68 or Int9. Each bar shows the mean of two biological replicates, each 
with two technical replicates. The transfection efficiency was around 37%. Error bars 
represent the standard deviation. * Int9 infected NS0 cells reactivated virus at a 
significantly lower (p<0.005) percentage than MHV-68 and MHV-76 untransfected NS0 
cells, as determined by Student’s t-test.  
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Figure 4.22 qRT-PCR amplification plots for miRNA4. Showing uninfected cells (   ), 
MHV-68 infected cells (    ) and Int9 infected cells: untransfected (       ), negative siRNA 


























Figure 4.23 Relative quantity of miRNA3 and 4 as determined by qRT-PCR on small 
RNAs from Int9 infected NS0 cells: untransfected, negative siRNA transfected or 
miRNA transfected. Values normalised against cellular mir-16 levels and expressed 
relative to untransfected cell expression levels. Error bars represent the standard 
deviation. 
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4.3.3. ORF50 
To examine if the Int9 infected NS0 cells were capable of reactivating virus, a 
plasmid expressing the MHV-68 rta (a gift from Bahram Ebrahimi) was transfected 
into the cells. This plasmid contains the rta (ORF 50) genomic sequence fused to a 
flag sequence, under the influence of CMV promoter (Wu et al. 2001).  
NS0 cells were infected with Int9 at a MOI 5 pfu/cell for four days and the plasmid 
transfected. After 24 hours infective centres assays were performed. MHV-68 
infected NS0 cells were included as a reactivation control. Transfection of rta 
expressing plasmid did not lead to a significant increase in reactivation (p=0.06) 
compared to negative control plasmid (Figure 4.24). Again, MHV-68 infected cells 
reactivated virus at a significantly (p<0.01) higher frequency than Int9 infected cells.  
To further investigate if the lack of induction of reactivation by rta over-expression 
was due to the inability of Int9 infected cells to reactivate, the experiment was 
repeated. This time MHV-68 infected cells were transfected as well. Over-expression 
of rta in MHV-68 infected cells should lead to an increase in reactivation  
(Wu et al. 2000). This time infective centres were performed 48 hours post 
transfection as well, since over-expression of rta in S11 cells was found to lead to a 
large increase in the production of lytic virus following reactivation at this time post 
infection (Wu et al. 2000). Over-expression of rta in MHV-68 or Int9 infected cells 
did not lead to an increase in reactivation (Figure 4.25). However, the transfection 
itself stressed both MHV-68 and Int9 infected cells to reactivate virus. Due to time 
constraints this was not followed up. 
4.3.4. vtRNAs 
Since transfection of miRNAs did not have an effect on the reactivation rates of 
infected NS0 cells, expression of the vtRNAs might be the cause of the reduction in 
reactivation seen in Int9 infected NS0 cells. To investigate this further, vtRNA1 was 
in vitro transcribed, folded, and transfected into NS0 cells infected with MHV-76 for 
four days. Infective centres assays were performed 24 hours post transfection, with 
Int9 infected cells included as a control. Transfection of vtRNA1 did not lead to a 
reduction in reactivation of MHV-76 infected NS0 cells (Figure 4.26); however, the  


























Figure 4.24 Percentage of infective centres 24 hours following transfection of Int9 
infected cells with ORF50 plasmid or negative control plasmid. MHV-68 infected cells 
were included as a control of reactivation. Each bar shows the mean of two biological 
replicates, each with two technical replicates. The transfection efficiency was around 
69%. Error bars represent the standard deviation. * MHV-68 infected cells reactivated 
virus at a significantly (p<0.01) higher frequency than Int9 infected cells, whether 



























Figure 4.25 Percentage of infective centres 24 and 48 hours following transfection of 
MHV-68 or Int9 infected cells with ORF50 plasmid or negative control plasmid. Each 
bar shows the mean of two biological replicates, each with two technical replicates. The 
transfection efficiency was around 60%. Error bars represent the standard deviation. * 
MHV-68 infected untransfected cells had significantly lower reactivation rates than 
negative plasmid transfected cells 24 hours (p<0.001) and 48 hours (p<0.025). * At 48 
hours post transfection Int9 infected untransfected cells had significantly lower 
reactivation rates (p<0.0001) than negative plasmid transfected cells. * Int9 infected 
untransfected NS0 cells reactivated virus at significantly lower levels than MHV-68 
infected untransfected NS0 cells both 24 hours (p<0.000001) and 48 hours (p<0.01) post 


































Figure 4.26 Percentage of infective centres from MHV-76 infected NS0 cells, 24 hours 
post transfection with vtRNA1. Each bar shows the mean of two biological replicates, 
each with two technical replicates. The transfection efficiency was around 21%. Error 
bars represent the standard deviation. * Int9 infected cells reactivated virus at a 
significantly (p<0.001) lower level than MHV-76 infected cells, whether transfected or 



























Figure 4.27 Percentage of infective centres from MHV-76 infected NS0 cells, 24 hours 
post transfection with vtRNA1, 4 and 5. Each bar shows the mean of two biological 
replicates, each with two technical replicates. The transfection efficiency was around 
30%. Error bars represent the standard deviation. * Int9 infected cells reactivated 
virus at a significantly (p<0.0025) lower level than MHV-76 infected cells, whether 
transfected or not, as determined by Student’s t-test. 
*
*
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transfection efficiency was low, 21%. Int9 infected NS0 cells reactivated virus at a 
significantly lower level than MHV-76 infected NS0 cells.  
The vtRNAs may co-operate to reduce reactivation; therefore, the previous 
experiment was repeated but this time vtRNAs1, 4 and 5 were co-transfected into 
MHV-76 infected NS0 cells. Transfection of vtRNAs1, 4 and 5 into MHV-76 
infected NS0 cells did not lead to a reduction of reactivation (Figure 4.27). This time 
the transfection efficiency was slightly higher, around 30%. Again, Int9 infected NS0 
cells reactivated virus at a significantly lower level than MHV-76 infected NS0 cells.  
4.3.5. pL2a5 
It is possible that the vtRNAs and miRNAs co-operate and that both are needed to 
cause a reduction in reactivation. To investigate this further the plasmid used to make 
the insertion viruses, pL2a5, was transfected into infected cells. NS0 cells were 
infected with MHV-76 at a MOI of 5 pfu/cell for four days, prior to transfection with 
pL2a5 or negative control plasmid. Infective centres assays were set up 24 hours post 
transfection. Transfection of pL2a5 into MHV-76 infected NS0 cells did not led to a 
reduction in reactivation (Figure 4.28). Int9 infected NS0 cells reactivated virus at a 
significantly lower level than MHV-76 infected NS0 cells, whether transfected or 
not.  
To give the plasmid longer time to express the non-coding RNAs the previous 
experiment was repeated and infective centres performed 48 hours post transfection. 
Transfection of the pL2a5 plasmid into MHV-76 infected NS0 cells did not lead to a 
reduction in reactivation after 48 hours either (Figure 4.29). Consistent with previous 
results, Int9 infected NS0 cells reactivated virus at a significantly lower level than  
MHV-76 infected NS0 cells, whether transfected or not. 
4.4. Discussion 
In this study we showed that the introduction of vtRNAs and miRNAs into MHV-76 
causes a reduction in reactivation and production of lytic virus of latently infected 
NS0 cells, and provide evidence that this is not caused by the miRNAs.  
 



























Figure 4.28 Percentage of infective centres from MHV-76 infected NS0 cells, 24 hours 
post transfection with pL2a5. Each bar shows the mean of two biological replicates, 
each with two technical replicates. The transfection efficiency was around 66%. Error 
bars represent the standard deviation. * Int9 infected cells reactivated virus at a 
significantly (p<0.0025) lower level than MHV-76 infected cells, whether transfected or 



























Figure 4.29 Percentage of infective centres from MHV-76 infected NS0 cells, 48 hours 
post transfection with pL2a5. Each bar shows the mean of two biological replicates, 
each with two technical replicates. The transfection efficiency was around 78%. Error 
bars represent the standard deviation. * Int9 infected cells reactivated virus at a 
significantly (p<0.001) lower level than MHV-76 infected cells, whether transfected or 
not, as determined by Student’s t-test. 
*
* 
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We utilised insertion viruses, made by homologous recombination to insert the  
non-coding RNA genes into the left-end of MHV-76, to study the non-coding RNAs. 
This technique has previously been used to investigate the functions of the unique 
gene M4 (Townsley et al. 2004), and also the KSHV gene K1 (Douglas et al. 2004). 
In addition, MHV-76 was successfully rescued by recombination to generate a virus 
with growth properties indistinguishable to MHV-68 (Macrae et al. 2001). The 
technique was validated when disruption to M4 confirmed the results from the M4 
insertion virus study (Geere et al. 2006; Townsley et al. 2004). The non-coding 
RNAs of the insertion viruses are thereby expressed by their natural promoters and 
they are inserted into their original location in the genome.  
The initial replication and reactivation assays showed that the insertion virus Int9 
reactivates and replicates at a lower level than MHV-68 and MHV-76. The 
investigation of the second insertion virus Int2, made independently of Int9, 
confirmed that this was not a phenotype restricted to Int9. The revertant virus further 
confirmed the results: the decrease in reactivation and production of lytic virus 
observed with the insertion viruses was 10-fold or greater compared to revertant 
virus. Because of the rapid clearance and low levels of latency of MHV-76 and the 
insertion viruses, as well as large differences between mice, the phenotype could not 
be confirmed in vivo. A larger study involving more mice may be helpful. 
Since the only difference between the insertion viruses and MHV-76 and the 
revertant virus is the five vtRNAs and six miRNAs, these must be the cause of the 
phenotype. However, miRNA1 which has a predicted target site in the 3’ UTR of the 
viral rta (ORF50) and could be responsible for the reduction in reactivation by 
targeting the rta is expressed at very low levels by the insertion viruses during 
latency, so is not likely to affect the reactivation of the insertion viruses. To further 
investigate if the vtRNAs or miRNAs had a role in virus reactivation, miRNA 
mimics were transfected into MHV-76 infected cells. miRNA mimics are synthetic 
RNA oligonucleotides that function like the mature endogenous miRNA following 
transfection, down-regulating the target protein for up to 72 hours. Even though the 
levels of miRNA mimics, as assessed by qRT-PCR for miRNA3, were higher than 
for insertion virus infected cells, they did not cause a reduction in reactivation.  
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To further confirm that the miRNAs did not cause the reduction in reactivation, a 
siRNA against Dicer was transfected into virus infected cells. Inhibition of Dicer 
leads to a decrease in the production of mature miRNAs. However, by limiting the 
inhibition to 48 hours cellular miRNAs should not be affected. As a control MHV-76 
was included in the experiment as it does not encode any viral miRNAs. Transfection 
of a siRNA against Dicer did not lead to an increase or decrease in reactivation by 
MHV-68 or Int9 infected NS0 cells. However, the Dicer knock-down could not be 
confirmed by qRT-PCR of Int9 infected cells, since the miRNA expression is already 
low in these cells. To further confirm the results, qRT-PCR for miRNA levels in 
siRNA transfected MHV-68 infected NS0 cells or a western blot analysis looking at 
changes in the Dicer protein levels would be recommended.  
To examine if the Int9 infected NS0 cells were capable of reactivating, the rta was 
over-expressed in infected cells by transfecting a plasmid containing ORF50 under 
the influence of a CMV promoter. Over-expression of the rta using this plasmid has 
previously been found to initiate lytic replication in productively infected cells  
(Wu et al. 2001). In addition, transfection of a similar plasmid construct into S11 
cells lead to an increase in reactivation (Wu et al. 2000). In the infective centres 
assay the latently infected NS0 cells are stressed to reactivate the virus and it was 
thought that over-expression of the rta would lead to higher reactivation levels; 
however, this was not observed. The transfection itself led to an increase in 
reactivation that may have masked the effect of the rta. This increase in reactivation 
caused by the transfection was seen in several of the transfection experiments. This 
did show that Int9 infected NS0 cells are capable of reactivating. The expression 
levels of rta by the plasmid were, however, not confirmed due to time constraints. 
Since the miRNAs do not appear to be involved in the reduction of reactivation seen 
in insertion virus infected NS0 cells, it suggested that the vtRNAs are responsible. To 
further investigate this, vtRNAs were transfected into MHV-76 infected NS0 cells. 
This did not lead to a decrease in reactivation; however, since it is not known how 
the vtRNAs are processed and how they function, the transfected vtRNAs may not be 
functional vtRNAs. In addition, the transfection efficiencies achieved were quite low.  
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It is possible that expression of both the vtRNAs and miRNAs is needed to decrease 
the reactivation of infected NS0 cells. To investigate this, the plasmid used to make 
the insertion viruses was transfected into MHV-76 infected NS0 cells, but it did not 
result in a reduction in reactivation. This was not an ideal approach since the copy 
number of the plasmid was not known and the non-coding RNAs would not have 
been in the viral genome and possibly not expressed appropriately. It should be noted 
that the expression levels of the vtRNAs and miRNAs following transfection was not 
examined due to time constraints. Further work would be needed to confirm the 
results, including transfection of miRNAs and vtRNAs together.  
MHV-76 consistently reactivated at a higher level and produced more lytic virus than 
both MHV-68 and the revertant virus. The reason for this is not known. It is possible 
that the copy number of MHV-76 in the cell is higher; however, it is not known why 
the revertant would not have the same copy number since it is identical to MHV-76. 
A fresh MHV-76 virus stock could be used to see if the same phenotype is achieved. 
It may also be useful to repeat the transfection experiments using revertant virus 
infected NS0 cells. Importantly, the insertion viruses consistently reactivated at a 
much lower rate than the revertant, which is the control virus, as well as MHV-68 
and MHV-76.  
The experiment described in this chapter point to a role for the non-coding RNAs in 
virus reactivation. The miRNA transfections show that the reduction in reactivation 
is not due to the miRNAs alone, even though the miRNAs levels achieved were 
higher than in Int9 infected cells. The vtRNA transfection experiments did not 
confirm the role of the vtRNAs in viral reactivation and it is possible that the 
vtRNAs and miRNAs co-operate, which needs to be further investigated. The 
expression of the miRNAs by the insertion viruses is lower than that of MHV-68, 
and it is not known if the vtRNA levels are as well. Due to these problems a better 
approach would be to make mutations in the MHV-68 genome, which has previously 
been done to determine the functions of a number of viral genes, such as ORF 73, 
ORF50, M1 and K3 (Clambey et al. 2000; Fowler et al. 2003; Pavlova et al. 2003; 
Stevenson et al. 2002). To confirm that the vtRNAs are responsible for the reduction 
in reactivation, it would be useful to create a virus with disruption to the miRNAs 
which does not affect the processing of the vtRNAs. Since the vtRNAs and miRNAs 
Chapter Four  Investigating the functions of the non-coding RNAs 
 147
are transcribed on the same transcript and the processing of this transcript is not 
clear, it may not be possible to remove the whole miRNA. An option could be to 
mutate the seed sequences of the miRNAs. The seed sequence of the miRNA is 
usually important for target binding; however, this is not always the case and it 
would be difficult to confirm that the miRNAs actually were not functional since 
their targets are not known. Another possibility would be to disrupt the stem-loop 
structure of the vtRNAs; however, it is not know if this would affect the processing 
of the miRNAs. It may also be useful to insert only one of the vtRNA/miRNA 
transcripts into MHV-76 to investigate if the same phenotype can be achieved or if 
more than one vtRNA/miRNA transcript is necessary.  
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To investigate the functions of the non-coding RNAs, the differences in protein 
expression during latency between MHV-76 and Int9 infected cells were examined 
using cICAT. In this method the cysteines of the proteins are labelled with heavy or 
light isotope-coded tags which allows for identification and quantification of 
differentially expressed proteins using mass spectrometry. The isotope-coded tags 
are made up of C10H17N3O3, with the light tag containing 9 12C and the heavy 9 13C 
resulting in a difference of 9 amu in weight. A biotin affinity tag on the  
isotope-coded tag enables purification of labelled peptides using an avidin column, 
decreasing the complexity of the sample. The biotin tag is subsequently cleaved off, 
reducing the size of the labelled peptide and thus allowing analysis of larger 
peptides. Samples taken during the labelling to monitor the process are analysed by 
MALDI (Matrix-assisted laser desorption/ionization) mass spectrometry, while the 
final labelled sample is separated on a liquid chromatograph (LC) and analysed using 
on-line tandem mass spectrometry (MS/MS). The cICAT method is described in 
Figure 5.1. 
Mass spectrometry utilises the production of ions that are separated according to 
their mass-to-charge ratio (m/z). An ionisation source such as electrospray ionisation 
(ESI) or MALDI is used to charge the peptides, via the addition of one (MALDI) or 
more (ESI) protons. A singly charged peptide with a molecular mass of 2000 daltons 
will thus have an m/z of 2001, while a doubly charged ion will have an m/z of 1001. 
During single mass spectrometry analysis using a MALDI-TOF (Time of flight) the 
ions enter a flight tube, with the ions travelling faster towards the detector the smaller 
they are. The ions are accelerated with the same potential at the same point and time, 
and will therefore be separated by their m/z. The relative abundance of the ions is 
then plotted for each m/z value in a mass spectrum. The masses of the peaks 
generated can be matched against databases of theoretical peptides generated from 
proteins to identify the protein they originated from. A protein score is calculated for 
each protein match, which indicates the probability that the match is a random event. 






Figure 5.1 Step-by-step schematic description of the cICAT labelling. 
Sample A Sample B 
Denature and reduce 
Label with light reagent Label with heavy reagent 
Digest with trypsin 
Cation exchange column- purify 
Avidin column- purify labelled 
Analyse by mass spectrometry 
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During nanoLC-MS/MS, a reverse phase high performance liquid chromatograph 
(HPLC) separates the peptides according to polarity and they are introduced into the 
mass spectrometer. Following the single MS, ions are selected on peak intensities to 
go through a further MS. The selected ion is fragmented into product ions, usually 
through collision with a neutral gas, with b and y ions being most common  
(Figure 5.2A). The fragments are separated according to m/z, producing a MS/MS 
mass spectrum from fragments of that specific peptide (Figure 5.2B). The b and y 
ions can be identified in the spectra in Figure 5.2B by looking at differences in m/z 
values of fragment ions between the peptide labelled with light and heavy cICAT 
reagent. Since the labelled cysteine is in the far left end of this peptide, only b ions 
will be labelled and have a difference in charge in the two spectra, 9 m/z if the ion is 
singly charged and 4.5 m/z if doubly charged. The fragment masses generated are 
matched against a database of theoretical fragment masses of peptide ions of the 
same mass and an ion score reflecting the absolute probability that the match is a 
random event is calculated. The peptides identified are matched against proteins in 
the database and a protein score is derived from the ion scores, with multiple peptide 
matches for the same protein giving a high protein score and thus indicating a true 
match.  
Since the only difference between MHV-76 and Int9 is the non-coding RNAs, any 
difference in protein expression found should be caused by the vtRNAs and/or 
miRNAs. The cICAT would provide a screening method to identify proteins directly 
and indirectly affected by the non-coding RNAs. This could further be confirmed by 
western blot analysis to verify changes in protein levels, northern blot analysis to 
examine if the mRNA levels of the proteins are affected, and electric mobility shift 
assay (EMSA) to investigate if there is a direct interaction between the protein and 
the vtRNAs.  





090416_I1_Nila_ICAT #6494 RT: 41.05 AV: 1 NL: 5.44E4
T: ITMS + c NSI d Full ms2 763.46@cid35.00 [200.00-1540.00]
































090416_I1_Nila_ICAT #6509 RT: 41.13 AV: 1 NL: 4.20E4
T: ITMS + c NSI d Full ms2 767.04@cid35.00 [200.00-1545.00]


































Figure 5.2 Demonstrating the fragmentation of a peptide, showing the different 
possibilities of fragmentation (A) with b and y ions being most common, and in the 
MS/MS spectrum (B) of a Hsp90-β peptide, labelled with light (top) and heavy (bottom) 
cICAT reagent. Since the labelled cysteine is at the far left end of the peptide, only the b 
ions will be labelled and have different m/z values in the two spectra, 9 m/z if singly 

















Prior to analysing virus infected cells the technique was tested using a known 
protein, BSA, which was labelled according to the manufacturer’s protocol (section 
2.9.7.1) with some changes to the volumes used. 
Aliquots were collected at each step during the cICAT protocol and analysed by 
MALDI to monitor the process. 2.5μg BSA was denatured and reduced, and half of 
the protein solution labelled with light ICAT reagent (36μl protein + 9μl light 
reagent) and half mixed with acetonitrile as a non-labelled control (36μl protein + 
9μl acetonitrile). The proteins were trypsin digested over night at 37°C and the 
samples analysed by MALDI. The samples yielded mainly the same peptide peaks 
(Figure 5.3). Labelling of the peptides should yield peaks with m/z ratios that are 
higher than the unlabelled and not the same m/z, as was observed; however, the 
majority of the abundant peaks were BSA peptides that do not contain cysteines and 
would not be labelled (Table 5.1).  
The peptides of the cICAT labelled sample were subsequently purified using a 
cation-exchange column, which removed some of the peaks seen in the previous 
MALDI analysis (Figure 5.4). Some of these peaks could be from components of the 
denaturing buffer (SDS), reducing agent (TCEP, breaks disulfide bonds) or unused 
light cICAT reagent, which will be removed with the cation-exchange column. One 
of the most abundant peaks, a BSA peptide with an m/z of 1283, was also lost in the 
cation-exchange column. This indicated that some peptides may be lost, perhaps due 
to instability or that they do not bind or elute at the pH that was used. Labelled 
peptides were purified using an avidin column, which changed the MALDI spectrum 
with previously small peaks becoming more prominent as a results of losing some of 
the abundant non-labelled peptides and removal of salts that may interfere with the 
MALDI ionisation (Figure 5.4).  
Both the control and labelled peptide solutions were vacuum dried, prior to cleavage 
of the biotin tag of the labelled peptides, and the peptide samples subsequently dried 
using a vacuum dryer. The peptides were resuspended in 40μl 0.5% (v/v) acetic acid 










Figure 5.3 MALDI analysis of BSA peptides generated by trypsin treatment of 
unlabelled control BSA or BSA labelled with light cICAT reagent. Abundant peaks of 
possible BSA peptides that do not contain cysteines and would not be labelled are 
circled. 
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Sequence No. of cysteines Unlabelled Light
GLVLIAFSQYLQQCPFDEHVK 1 2435.24 2662.37
DAIPENLPPLTADFAEDK 0 1955.96 1955.96
HPYFYAPELLYYANK 0 1888.93 1888.93
LFTFHADICTLPDTEK 1 1850.90 2078.03
RPCFSALTPDETYVPK 1 1823.90 2051.03
MPCTEDYLSLILNR 1 1667.81 1894.94
YNGVFQECCQAEDK 2 1633.66 2087.92
ECCHGDLLECADDR 3 1578.60 2259.99
DAFLGSFLYEYSR 0 1567.74 1567.74
LKPDPNTLCDEFK 1 1519.75 1746.88
VPQVSTPTLVEVSR 0 1511.84 1511.84
DDPHACYSTVFDK 1 1497.63 1724.76
LGEYGFQNALIVR 0 1479.80 1479.80
TVMENFVAFVDK 0 1399.69 1399.69
EYEATLEECCAK 2 1388.57 1842.83
YICDNQDTISSK 1 1386.62 1613.75
ETYGDMADCCEK 2 1364.48 1818.74
SLHTLFGDELCK 1 1362.67 1589.80
TCVADESHAGCEK 2 1349.55 1803.81
HLVDEPQNLIK 0 1305.72 1305.72
HPEYAVSVLLR 0 1283.71 1283.71
ECCDKPLLEK 2 1177.56 1631.82
LVNELTEFAK 0 1163.63 1163.63
CCTKPESER 2 1052.45 1506.71
EACFAVEGPK 1 1050.49 1277.62
CCTESLVNR 2 1024.46 1478.72
SHCIAEVEK 1 1015.49 1242.62
QTALVELLK 0 1014.62 1014.62
QNCDQFEK 1 1011.42 1238.55
LVVSTQTALA 0 1002.58 1002.58
NECFLSHK 1 977.45 1204.58
DLGEEHFK 0 974.46 974.46
YLYEIAR 0 927.49 927.49
AEFVEVTK 0 922.49 922.49
DDSPDLPK 0 886.42 886.42
LCVLHEK 1 841.46 1068.59
ATEEQLK 0 818.43 818.43
LVTDLTK 0 789.47 789.47
NYQEAK 0 752.36 752.36
CCAADDK 2 725.26 1179.52
SEIAHR 0 712.37 712.37
VLASSAR 0 703.41 703.41
GACLLPK 1 701.40 928.53
AWSVAR 0 689.37 689.37
TPVSEK 0 660.36 660.36
QEPER 0 658.32 658.32
IETMR 0 649.33 649.33
CASIQK 1 649.33 876.46
AFDEK 0 609.29 609.29
VASLR 0 545.34 545.34
FWGK 0 537.28 537.28
ADLAK 0 517.30 517.30
HKPK 0 509.32 509.32
FGER 0 508.25 508.25
DTHK 0 500.25 500.25
DVCK 1 464.22 691.35  
Table 5.1 Listing the predicted BSA derived peptides, with m/z values as expected in 
the unlabelled control and labelled with light cICAT reagent. 
 










Figure 5.4 MALDI analysis of BSA derived peptides labelled with light cICAT reagent 
following cation-exchange column (pre-avidin) and after the avidin column  
(post-avidin). 
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and analysed by MALDI, and also diluted 1 in 10 and analysed on an LCQdeca 
MS/MS system. The MALDI analysis of the labelled BSA sample showed that 
cleavage of the biotin molecule (m/z 680.34) reduced the size of the peptide peaks, 
moving the peaks to the left of the spectrum (Figure 5.5). This was demonstrated by 
the most abundant peak in the post-avidin sample with an m/z of 2729 (Figure 5.4) 
that was still the most abundant peak following cleavage with an m/z of 2051  
(Figure 5.5). MALDI analysis of the control sample showed that vacuum drying and 
re-suspension in acetic acid had changed the spectrum slightly, with previously 
abundant peptides becoming less abundant (Figure 5.3, Figure 5.5). This may be 
because the abundant peptides were less stable or dissolved less well in the acetic 
acid.  
Several of the expected BSA peptide peaks (Table 5.1), labelled and unlabelled, 
could be seen among the most abundant peaks (Figure 5.5). This was confirmed 
when around 100 of the most abundant peaks from the labelled sample were 
submitted to search against the Mascot database, identifying BSA (Figure 5.6). 
Although the sample contained only BSA and trypsin, several other possible protein 
matches were listed; however, these had non-significant protein scores and were 
unlikely to be true matches. BSA was also identified when analysing the labelled 
sample on the LC-MS/MS system (Figure 5.7).  
The labelling of BSA showed that the cICAT labelling worked and the technique was 
subsequently used to analyse proteins from virus infected cells.  
5.2.2. MHV-76 vs. Int9 latently infected NS0 cells 
After successfully identifying BSA labelled by the cICAT method it was decided to 
investigate if there was a difference in protein expression between MHV-76 and Int9 
infected NS0 cells. The proteins of cells infected with MHV-76 or Int9 at a MOI of 5 
for five days were extracted and fractionated into cytosolic, membrane/organelle, 
nuclear and cytoskeletal fractions, using a ProteoExtract® Subcellular Proteome 
Extraction kit, to make the protein samples less complex. A BCA Protein Assay was 
performed to determine the protein concentrations of the samples. Since the vtRNAs 
localise mainly to the cytoplasm during latency, it was decided to use the cytosolic 
fraction for further analysis. For each sample 100μg of cytosolic proteins were  





Control: final sample 
 
 
Labelled: final sample  
 
Figure 5.5 MALDI analysis of the final BSA samples, unlabelled control or labelled 
with light cICAT reagent. The unlabelled control had been trypsin digested,  
mock-labelled, dried down by vacuum dryer and resuspended in 0.5% acetic acid. 
Showing possible BSA peptides containing cysteines (circled in red) and not containing 
cysteines (circled in green).  
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Figure 5.6 Results of the MALDI analysis of the BSA sample labelled with light cICAT 
reagent. Around 100 of the most abundant peaks were submitted to search the  
Swiss-Prot database, using Mascot software. BSA was identified with a significant 
(p<0.05) protein score of 109 that was above the threshold of 67 (as shown in the 
graph), indicating that this was a true match. Other possible protein matches did not 
have significant scores and were unlikely to be true matches.  






Figure 5.7 Results of the LC-MS/MS analysis of BSA labelled with light cICAT reagent, 
using Mascot software to search against the Swiss-Prot database. BSA was identified 
with several peptides matched to BSA, as listed.  Search parameters: Peptide mass 
tolerance ± 2 Da; Fragment mass tolerance ± 0.8 Da; missed cleavages 1.  
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acetone precipitated and resuspended in denaturing buffer and labelling performed 
according to the protocol (section 2.9.7.1). Proteins from MHV-76 infected NS0 cells 
were labelled with light and Int9 with heavy cICAT reagent. A vacuum dryer was 
used to dry down the sample prior to (nine hours) and following (20 min) cleaving of 
the biotin tag. The sample was resuspended in 60μl 0.5% (v/v) acetic acid and 
analysed on an LCQdeca MS/MS system. Only two proteins were identified, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with one peptide labelled 
with light cICAT reagent and pyruvate kinase with one peptide labelled with heavy 
cICAT reagent (results not shown).  
The MALDI analysis of samples taking during the labelling process showed that not 
many peptides were present following the trypsin digestion and after purification 
using the cation exchange and avidin columns there were few peaks with some 
background noise appearing, as shown by the less defined baseline (Figure 5.8). 
There were some peaks in the final sample following cleavage of the biotin tag, but 
also a lot of background noise, indicating low levels of peptides (Figure 5.9).  
The fact that there were few peptides present already following the trypsin digestion 
indicated that there was a problem with the protein samples. It was possible that there 
were very few different proteins present in the cytosolic fractions or that the tryptic 
digestion was not working properly. 
5.2.3. Troubleshooting protein extraction techniques 
To determine if the low number of proteins was due to the protein fractionation, the 
commercial kit was compared to a different cytoplasmic protein extraction method. 
Proteins were extracted from uninfected NS0 cells using both the ProteoExtract® 
Subcellular Proteome Extraction Kit and the cytoplasmic extraction protocol and the 
protein concentrations determined using a BCA Protein Assay. The cytoplasmic 
extraction, the different fractions from the kit, as well as the cytosolic protein 
fractions from MHV-76 and Int9 infected NS0 cells, were analysed by SDS-PAGE in 
differing amounts. The cytoplasmic extract had a higher concentration of proteins; 
however, the gel showed that although the cytosolic fraction of uninfected NS0 cells, 
as well as MHV-76 and Int9 infected, had a lower concentration of proteins they did 
contain a lot of different proteins, although at quite low concentrations (Figure 5.10). 










Figure 5.8 MALDI analysis of peptides from cytosolic proteins from MHV-76 or Int9 
infected NS0 cells labelled with light or heavy cICAT reagent, following trypsin 
digestion (post-trypsin), cation-exchange column (pre-avidin) and avidin column  
(post-avidin).  
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Figure 5.9 MALDI analysis of peptides from the final sample of cytosolic proteins from  
MHV-76 and Int9 infected NS0 cells labelled with light or heavy cICAT reagent, 
following cleavage of the biotin tag. 
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Figure 5.10 SDS-PAGE (A) showing the protein bands present in samples from NS0 
cells using the cytosolic extraction (CE) and fractionation with the ProteoExtract® 
Subcellular Proteome Extraction Kit (cytosol, membrane, nuclear and cytoskeletal 
fractions), as well as the cytosolic samples of MHV-76 and Int9 infected NS0 cells used 
previously for the cICAT assay. The different protein concentrations for the samples 
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Since the cytoplasmic extraction generated a higher concentration of different 
proteins it was decided to use this extraction protocol for the cICAT labelling. It was 
also decided to leave out protease inhibitors in the extraction protocol to avoid the 
possibility of inhibiting the trypsin. To further ensure that the cytoplasmic extraction 
buffer would not inhibit the trypsin cleavage, even without the addition of the 
protease inhibitor, and to examine the effects of acetone precipitation on the proteins, 
tryptic digestion of BSA was performed.  
BSA was dissolved in water or extraction buffer and trypsin digested in solution. In 
addition, BSA dissolved in extraction buffer was acetone precipitated prior to trypsin 
digestion. MALDI analysis of the samples showed that the trypsin digestion worked 
in the cytoplasmic extraction buffer; with several of the same peaks present as in the 
BSA digest (Figure 5.11). However, a lot of protein was lost in the acetone 
precipitation, with some of the BSA peptide peaks obtained, but at a very low signal 
with some background noise appearing. The peaks to left of the spectrum did not 
appear to be BSA peptide peaks, but could be from the extraction buffer or CHCA 
matrix. These peaks were more abundant than the BSA peaks in the acetone 
precipitated sample, showing that the levels of the BSA peptides in this sample were 
very low. 
Through these experiments it was concluded that the cytoplasmic extraction protocol 
yielded higher levels of different proteins that should enable identification of more 
proteins. In addition, the acetone precipitation was identified as a source of loss of 
proteins and an alternative method needed to be utilised. 
5.2.4. MHV-76 vs. Int9 latently infected NS0 cells- Vivaspin 
Since a lot of proteins seemed to be lost in the acetone precipitation, the cICAT 
analysis of proteins from MHV-76 and Int9 infected cells was repeated using 
Vivaspins to concentrate the proteins. NS0 cells were infected with MHV-76 or Int9 
at a MOI of 5 for five days, followed by cytoplasmic protein extraction and 
determination of protein concentration using a BCA Protein Assay. The samples 
were analysed by SDS-PAGE to ensure the presence of multiple proteins. Although  
 






BSA CE digest 
 
BSA CE precipitation digest 
 
Figure 5.11 MALDI analysis of tryptic digestions of 10μg BSA in water (BSA digest), in 
cytoplasmic extraction buffer (BSA CE digest), mixed with cytoplasmic extraction 
buffer and precipitated with acetone precipitation (BSA CE precipitation digest). The 
low signal obtained following acetone precipitation is circled. Peaks that are from the 
extraction buffer or MALDI matrix are indicated by an arrow.  
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the protein concentrations were low there were a large number of protein bands 
(Figure 5.12). 
Because of the low number of proteins identified in the previous assay, a larger mass 
of proteins were used in this experiment. For each sample 182μg of cytoplasmic 
proteins were concentrated using Vivaspins with a molecular weight cut off of 3000, 
and the assay performed according to the protocol (section 2.9.7.1) with denaturing 
buffer added to bring the volume up to 80μl. Proteins from MHV-76 infected NS0 
cells were labelled with light and Int9 with heavy cICAT reagent. The sample was 
divided into two tubes for the vacuum drying step prior to cleavage of the biotin tag 
to try and reduce the drying time; however, it still took seven hours. The second 
vacuum drying step after the cleavage took almost an hour this time. The sample was 
resuspended in 120μl 2.5% (v/v) acetic acid and analysed by MALDI and  
LC-MS/MS on an LCQdeca system.  
The LC-MS/MS analysis identified six proteins, with four having peptides labelled 
with both light and heavy cICAT reagent (Figure 5.13). This is necessary to be able 
to determine the differences in the abundance of proteins, and shows that the cICAT 
technique is working. However, many more proteins should have been identified. 
BSA was identified, indicating that in future experiments the cells need to be washed 
more rigorously prior to protein extraction, to avoid having BSA peptides 
overshadowing the other peptides. The MALDI analysis showed that the peptides 
seemed to disappear in the last step, the cleavage of the biotin tag, with a very low 
signal obtained and background noise appearing (Figure 5.14). Since this involved 
vacuum drying the sample twice, which took seven and one hour respectively, this 
was suspected as the cause of the loss of peptides.  
Utilising Vivaspins instead of acetone precipitation to concentrate the proteins prior 
to labelling did lead to identification of more proteins; however, an alternative to the 
vacuum dryer needed to be found since the long vacuum drying times appeared to 
affect the peptides. 
 
 




Figure 5.12 SDS-PAGE (A) of cytoplasmic proteins from MHV-76 and Int9 infected 
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Figure 5.13 Results of the LC-MS/MS analysis of peptides from cytosolic proteins from 
MHV-76 and Int9 infected NS0 cells labelled with light or heavy cICAT reagent, using 
Mascot software to search against the Swiss-Prot database. The identified proteins are 
listed (A) and the peptides identified for two of the proteins are shown as examples (B). 
Search parameters: Peptide mass tolerance ± 2 Da; Fragment mass tolerance ± 0.8 Da; 
missed cleavages 3. An example of a peptide identified labelled with light and heavy 
cICAT reagent is boxed.  
A 
B 










Figure 5.14 MALDI analysis of peptides from cytoplasmic proteins from MHV-76 or 
Int9 infected NS0 cells labelled with light or heavy cICAT reagent, after the avidin 
column (post-avidin) and of the final sample following vacuum drying for seven hours, 
cleavage of the biotin tag and vacuum drying for one hour. The very low signal 
obtained in the final sample is circled. 
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5.2.5. MHV-76 vs. Int9 latently infected NS0 cells- freeze-dryer 
To minimise the loss of peptides, a freeze-dryer was used instead of the vacuum 
dryer for the long drying step prior to cleaving of the biotin molecule. NS0 cells were 
infected with MHV-76 and Int9 at a MOI of 5 for five days, the cytoplasmic proteins 
extracted, and the protein concentration determined with a BCA Protein Assay. A 
large number of proteins were present in the sample as visualised by  
SDS-PAGE (Figure 5.15).  
For each sample 150μg of cytoplasmic proteins were concentrated using Vivaspins 
with a molecular weight cut off of 3000, and the assay performed according to the 
protocol (section 2.9.7.1) with denaturing buffer added to bring the volume up to 
80μl. Proteins from MHV-76 infected NS0 cells were labelled with light and Int9 
with heavy cICAT reagent. The sample was freeze-dried for four hours prior to 
cleaving of the biotin tag, and vacuum dried for 17 min following the cleaving. The 
sample was resuspended in 60μl 0.5% (v/v) acetic acid and analysed by MALDI and 
LC-MS/MS on an LCQdeca system. The MALDI analysis showed that the peptides 
were no longer lost during last step of the assay, with a high signal obtained in the 
final sample, nor during any other step of the assay (Figure 5.16, Figure 5.17). 
However, there were not as many peptide peaks as had been expected. Some pairs 
with a difference of 9 amu could still be identified in the final sample (Figure 5.17). 
The LC-MS/MS analysis identified a number of significant protein matches (Figure 
5.18); however, very few cICAT light/heavy peptide pairs. The cICAT labelling was 
working; however, only the most abundant proteins were identified.  
It was decided that the protein samples were too complex and needed to be 
fractionated prior to LC-MS/MS analysis. By analysing samples with smaller number 
of different proteins, less abundant proteins may be identified.  
 




Figure 5.15 SDS-PAGE (A) of cytoplasmic proteins from MHV-76 and Int9 infected 
NS0 cells. Also listing the protein concentrations of the two samples (B). 
MHV-76 
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Figure 5.16 MALDI analysis of peptides from cytoplasmic proteins from MHV-76 or 
Int9 infected NS0 cells labelled with light or heavy cICAT reagent, following trypsin 
digestion (post-trypsin) and cation-exchange column (pre-avidin). 
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Figure 5.17 MALDI analysis of peptides from cytoplasmic proteins from MHV-76 or 
Int9 infected NS0 cells labelled with light or heavy cICAT reagent, after the avidin 
column (post-avidin) and of the final sample following freeze-drying, cleavage of the 
biotin tag and vacuum drying. The high signal obtained in the final sample is boxed 
and cICAT pairs are circled. 
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Figure 5.18 Results of the LC-MS/MS analysis of peptides from cytosolic proteins from 
MHV-76 or Int9 infected NS0 cells labelled with light or heavy cICAT reagent, using 
Mascot software to search against the Swiss-Prot database. Listing identified proteins 
with significant protein scores. Search parameters: Peptide mass tolerance ± 2 Da; 
Fragment mass tolerance ± 1.2 Da; missed cleavages 2.  
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5.3. 1-D PAGE cICAT 
5.3.1. Assay setup 
To make the protein samples less complex an alternative of the cICAT method was 
utilised. In the 1-D PAGE cICAT method the labelled proteins are separated by  
SDS-PAGE and the gel cut into pieces to fractionate the proteins (Figure 5.19). The 
proteins are trypsin digested in the gel and the peptides extracted prior to purification 
on an avidin column and cleavage of the biotin tag. 
The 1-D PAGE cICAT protocol introduced more vacuum drying steps, something 
that had been found to be a problem previously. Therefore the effect of the vacuum 
drying on BSA peptides was examined.  
BSA was run on SDS-PAGE in different amounts (100ng, 200ng, 300ng) and the 
bands excised, washed, proteins trypsin digested, and the peptides extracted 
according to the 1-D PAGE cICAT protocol. The extraction protocol consisted of 
two parts. The gel pieces were initially sonicated for 20 min in a sonic ice water bath 
and the supernatant collected. Further extractions were then performed three times by 
addition of extraction solvent (50% (v/v) ACN, 0.1% (v/v) TFA) and sonication for 
20 min, removing the supernatant following each extraction. The supernatants 
containing the extracted peptides were pooled and vacuum dried for two hours to 
remove the ACN and TFA, prior to freeze drying over night.  
Samples were taken for MALDI analysis after the first extraction step, following the 
full extraction, and after vacuum and freeze-drying and re-suspension in 100μl and 
500μl avidin buffer. The MALDI analysis showed that the peptides were lost during 
the procedure, with most peptides obtained after the first extraction step  
(Figure 5.20). The following extractions with extraction solvent did not extract any 
further peptides, and the sample was diluted so that the peptides present initially 
could not be detected. These peptides were lost during the vacuum and  
freeze-drying. It also showed that even following the first extraction step, not many 
BSA peptide peaks were present (Figure 5.21). This could be because of the smaller 
amount of BSA used, which was chosen to replicate the amount of individual  



























Figure 5.19 Step-by-step schematic description of the 1-D PAGE cICAT protocol. 
Sample A Sample B 
Denature and reduce 
Label with light reagent Label with heavy reagent 
SDS-PAGE separation 
In-gel tryptic digestion 
Avidin column- select labelled 
Analyse by mass spectrometry 






Extract digested peptides 
Concentrate 







Figure 5.20 MALDI analysis of 100ng BSA in the vacuum drying test. Showing samples 
taken after the first and last extraction step, and following vacuum and freeze-drying 
and re-suspension in 100μl and 500μl avidin buffer.  
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1st extraction- 200ng BSA 
 




Figure 5.21 MALDI analysis of trypsin digested peptides from 200ng and 300ng BSA, 
following the first extraction step. Also showing the spectrum from a trypsin digest of 
10μg BSA from an earlier experiment for comparison.  
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proteins in the cICAT labelling. It could also be because of salts present in the 
sample affecting the MALDI analysis. 
It was concluded that the initial extraction step was sufficient to extract the peptides 
and that an alternative to the vacuum dryer needed to be found.  
5.3.2. BSA 
Following the findings in the assay setup, the 1-D PAGE cICAT protocol was tested 
with BSA, using ZipTips® instead of vacuum and freeze-drying to concentrate the 
samples during the assay, and only performing the first extraction step. The ZipTip® 
is a pipette tip with a bed of chromatography media in the end that allows for 
concentration and purification of peptides and proteins. 
10μg of BSA was denatured (10μl BSA + 40μl denaturing buffer + 1μl reducing 
agent) and labelled with light cICAT reagent. The labelled BSA was vacuum dried 
30 min to reduce the volume, run on SDS-PAGE and the band excised. There were 
two bands present on the gel, with the lighter band of smaller size probably 
consisting of unlabelled BSA. The BSA was in-gel trypsin digested and the peptides 
extracted, with only the first extraction step consisting of 20 min of sonication in a 
sonic ice water bath performed. A ZipTip® was used to concentrate the sample prior 
to purification using an avidin column and again prior to cleavage. Following 
cleavage of the biotin tag half of the sample was concentrated using a ZipTip® and 
half using a vacuum dryer for 25 min, prior to analysis by MALDI.  
The MALDI analysis showed that there were plenty of peptide peaks in the final 
sample, with the final concentrating method, vacuum drying or ZipTip®, not making 
much difference to the sample. Problems with calibration meant that although there 
was plenty of peptide peaks, BSA could not be identified when searching against the 
database. Several BSA peptide peaks (15/24 for the ZipTip® sample, Table 5.1) 
could be identified manually, as indicated by the circles in Figure 5.22, and when 
compared to the MALDI result from the previous BSA cICAT experiment it could be 
concluded that the adapted 1-D PAGE cICAT assay using ZipTips® was working.  
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Final sample: vacuum dry 
 




Figure 5.22 MALDI analysis of peptides from BSA labelled with light cICAT reagent. 
Final samples following concentration of the sample after cleavage of the biotin tag, 
using a vacuum dryer or a ZipTip®. Also showing the spectrum of BSA labelled with 
light cICAT reagent from an earlier cICAT experiment as a control. Green circles 
indicate BSA peptides and red circles probable BSA peptides.  
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5.3.3. MHV-76 vs. Int9 latently infected NS0 cells 
Following all the optimisation experiments, a definitive experiment examining the 
differences in protein expression between MHV-76 and Int9 infected NS0 cells was 
performed.  
NS0 cells were infected with MHV-76 and Int9 at a MOI of 5 for five days, the 
cytosolic proteins extracted using a ProteoExtract® Subcellular Proteome Extraction 
Kit, and the protein concentrations determined using a BCA Protein Assay. The 
extraction kit was used as this would make the protein sample less complex. 100μg 
of cytosolic proteins were concentrated using Vivaspins and the proteins labelled 
with light and heavy cICAT reagents according to the protocol (section 2.9.7.2). The 
samples were vacuum-dried for 30 min to reduce the sample volume prior to mixing 
with loading buffer and separation by SDS-PAGE. The gel strip of the lane loaded 
with labelled protein was cut into 11 pieces. The proteins were in-gel trypsin 
digested and the peptides extracted, with only the first extraction step performed. A 
ZipTip® was used to concentrate the sample prior to purification using an avidin 
column and again prior to cleavage. Following cleavage of the biotin the sample was 
concentrated using a vacuum drier, as this had not affected the peptides in the 
previous assay, and resuspended in 60μl 0.5% acetic acid. The peptides were loaded 
onto a ZipTip®, eluted, and briefly dried down in a vacuum dryer prior to analysing 
by LC-MS/MS on a LTQ. 
Initially, band 3 was further processed and the other bands stored at -20°C following 
excising from the gel. The MALDI analysis of samples taken during the assay 
showed that there were plenty of peptides present following the extraction from the 
gel piece and that there were still many peptides in the final sample; however at low 
intensities (Figure 5.23). The LC-MS/MS analysis identified three proteins with 
significant scores and several with non-significant scores when searching against 
murine proteins (Figure 5.24). The protein score is calculated from the ion scores, 
which gives the probability that the match is a random event, with higher scores 
indicating a true match. In this experiment an ion score of more than 30 (significance 
threshold 0.05) indicated identity or extensive homology. The proteins identified are 
among the more abundant in the cell.  








Figure 5.23 MALDI analysis of band 3 peptides in the 1-D PAGE cICAT assay. 
































1557.5333 1735.57171244.4470882.3565 2051.6234 2309.69491051.4417 1821.5494700.1887 2560.71252066.63861362.4890 1743.6455 1895.55441165.4616984.2304797.0791 2358.72711591.4793 2610.74802087.6046 2758.7775 3122.89761337.3974 1762.5575 1929.57751151.4226928.2246 2338.7839 3275.75592938.49841489.4452 2516.2456



































1933.66631307.4703 2214.66441541.4800804.1613 934.3390 1329.4721 2020.71201151.3838 1569.5072 1837.6315703.1256 2271.5949891.2475 1118.3687 1334.5697 1650.5389 2481.78531936.6507742.1491 2145.70911490.4958 2758.6900 2998.0161894.2704 1173.4005 1743.5581 2493.82981940.5939 2171.7337 3190.10051533.5215 3338.09881320.4732 2340.6887 2662.2446 2823.9827 3043.1930
Post-extraction 
Final sample 









Figure 5.24 Results of the LC-MS/MS analysis of peptides from cytosolic proteins from 
MHV-76 and Int9 infected NS0 cells labelled with light or heavy cICAT reagent from 
band 3, using Mascot software to search against the Swiss-Prot database. Search 
parameters: Peptide mass tolerance ± 3 Da; Fragment mass tolerance ± 0.4 Da; missed 
cleavages 3. Significant protein matches are boxed. 
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A long list of identified peptides was produced in the LC-MS/MS analysis. Since the 
software to analyse the data and identify cICAT pairs was not available, the data was 
analysed using a program developed by Mayank B. Dutia to identify peptides with 
the same sequence. Several cICAT light/heavy pairs were found (Table 5.2, Table 
5.3), with several proteins having more than one peptide pair labelled with light and 
heavy cICAT reagent. This was an improvement from the last cICAT analysis in 
which only a few pairs were identified and showed that fractionation of the sample 
improved the sensitivity of the technique. Only pairs with the same ion charge, and 
that had been cleaved at a lysine (K) or arginine (R) (the trypsin cleavage sites) were 
considered. Some peptides identified originate from the same protein, but had 
different numbers of missed cleavages. Since the probability of the missed cleavages 
would be different, these could not be considered as pairs.  
The time at which the peptides came off the LC was noted and the peptide peaks 
manually identified in the MS spectrum to determine the peak intensities. The 
peptide peak intensities were used to calculate the ratio of heavy/light  
(Int9/MHV-76) cICAT labelled peptides (Table 5.4). The analysis showed that there 
were a few differences of more than 0.4 in protein levels between MHV-76 and Int9 
infected NS0 cells. The differences observed all indicated that Int9 infected NS0 had 
higher levels of those proteins. The low ion scores and few peptides matched for 
individual proteins meant that it was difficult to be confident in some of the protein 
matches. The heat shock proteins were the protein matches that were most likely to 
be true because of the high ion and protein score; however, the proteins with lower 
protein score could still be true matches, since for many of them several peptides 
were identified. It is important to remember that the table here only lists pairs of 
labelled peptides; peptides that were labelled with only heavy or light cICAT reagent 
would still help give confidence in the protein match. It is difficult to have 
confidence in the protein matches with a protein score of 0, since these usually have 
very few peptide matches with low ion scores.  
The average ratio of the peptide pairs identified for Heat shock protein 90-beta 
(Hsp90-β) was 2.2; however, for the individual peptide pairs, the ratios were 
inconsistent (Table 5.5). The ratios of the peptides with higher scores were 0.4 and  




m/z Ion score Peptide Protein / protein score
492.11 6 K.FENLCK.L + ICAT-C (C) Heat shock protein HSP 90-beta
495.11 7 K.FENLCK.L + ICAT-C:13C(9) (C) 53
590.23 10 K.AKFENLCK.L + ICAT-C (C)
594.79 9 K.AKFENLCK.L + ICAT-C:13C(9) (C)
596.00 6 K.AKFENLCK.L + ICAT-C:13C(9) (C)
720.75 6 K.CLELFSELAEDKENYK.K + ICAT-C (C) 
723.55 2 K.CLELFSELAEDKENYK.K + ICAT-C:13C(9) (C) 
763.46 35 K.CLELFSELAEDKENYKK.F + ICAT-C (C) 
767.04 28 K.CLELFSELAEDKENYKK.F + ICAT-C:13C(9) (C) 
1147.98 18 K.CLELFSELAEDKENYKK.F + ICAT-C:13C(9) (C) 
1144.64 35 K.CLELFSELAEDKENYKK.F + ICAT-C (C) 
812.26 32 K.GPAVGIDLGTTYSCVGVFQHGK.V + ICAT-C (C) Heat shock cognate 71 kDa protein
815.59 42 K.GPAVGIDLGTTYSCVGVFQHGK.V + ICAT-C:13C(9) (C) 52
492.11 6 K.FENLCK.I + ICAT-C (C) Heat shock protein HSP 90-alpha 
495.11 7 K.FENLCK.I + ICAT-C:13C(9) (C) 46
669.78 7 K.KTKFENLCK.I + ICAT-C (C)
675.00 13 K.KTKFENLCK.I + ICAT-C:13C(9) (C) 
1151.16 34 K.CLELFTELAEDKENYKK.F + ICAT-C (C) 
1155.39 46 K.CLELFTELAEDKENYKK.F + ICAT-C:13C(9) (C) 
577.07 3 R.VPTPNVSVVDLTCR.L + ICAT-C (C) Glyceraldehyde-3-phosphate dehydrogenase
579.35 14 R.VPTPNVSVVDLTCR.L + ICAT-C:13C(9) (C) 34
864.23 34 R.VPTPNVSVVDLTCR.L + ICAT-C (C) 
865.23 27 R.VPTPNVSVVDLTCR.L + ICAT-C (C) 
869.20 27 R.VPTPNVSVVDLTCR.L + ICAT-C:13C(9) (C) 
775.24 26 R.CLYASVLTAQPR.L + ICAT-C (C) Elongation factor 2
776.90 21 R.CLYASVLTAQPR.L + ICAT-C (C) 32
779.71 17 R.CLYASVLTAQPR.L + ICAT-C:13C(9) (C) 
833.34 21 R.TFCQLILDPIFK.V + ICAT-C (C) 
837.90 11 R.TFCQLILDPIFK.V + ICAT-C:13C(9) (C) 
853.24 22 R.RCLYASVLTAQPR.L + ICAT-C (C) 
858.30 11 R.RCLYASVLTAQPR.L + ICAT-C:13C(9) (C) 
868.87 7 K.DLEEDHACIPIKK.S + ICAT-C (C) 
875.67 0 K.DLEEDHACIPIKK.S + ICAT-C:13C(9) (C) 
883.14 8 R.ETVSEESNVLCLSK.S + ICAT-C (C) 
884.17 11 R.ETVSEESNVLCLSK.S + ICAT-C (C) 
887.56 8 R.ETVSEESNVLCLSK.S + ICAT-C:13C(9) (C) 
855.94 13 R.LGDVISIQPCPDVK.Y + ICAT-C (C) Transitional endoplasmic reticulum ATPase
857.37 16 R.LGDVISIQPCPDVK.Y + ICAT-C (C) 29
861.09 12 R.LGDVISIQPCPDVK.Y + ICAT-C:13C(9) (C) 
584.18 4 K.AIANECQANFISIK.G + ICAT-C (C) 
587.71 8 K.AIANECQANFISIK.G + ICAT-C:13C(9) (C) 
1282.00 37 K.LADDVDLEQVANETHGHVGADLAALCSEAALQAIR.K + ICAT-C (C) 
1285.10 19 K.LADDVDLEQVANETHGHVGADLAALCSEAALQAIR.K + ICAT-C:13C(9) (C) 
569.28 18 K.SCQFVAVR.R + ICAT-C (C) Bifunctional aminoacyl-tRNA synthetase
574.37 22 K.SCQFVAVR.R + ICAT-C:13C(9) (C) 22
785.55 22 R.AFFPCFDTPAVK.C + ICAT-C (C) Aminopeptidase B 
790.11 3 R.AFFPCFDTPAVK.C + ICAT-C:13C(9) (C) 22
716.20 4 K.NQALFPACVLK.N + ICAT-C (C) ATP-dependent RNA helicase DDX1 
720.40 2 K.NQALFPACVLK.N + ICAT-C:13C(9) (C) 21
682.18 9 R.LQEVFGCAIR.A + ICAT-C (C) Arginyl-tRNA synthetase, cytoplasmic 
687.18 20 R.LQEVFGCAIR.A + ICAT-C:13C(9) (C) 20
901.45 13 K.IVFVPGCSVPLTIVK.S + ICAT-C (C) 
906.31 4 K.IVFVPGCSVPLTIVK.S + ICAT-C:13C(9) (C) 
623.80 16 K.CLIEILASR.T + ICAT-C (C) Annexin A6 
627.87 17 K.CLIEILASR.T + ICAT-C:13C(9) (C) 19
765.32 29 R.NTGIICTIGPASR.S + ICAT-C (C) Pyruvate kinase isozymes M1/M2 
766.10 1 R.NTGIICTIGPASR.S + ICAT-C (C) 19
767.33 32 R.NTGIICTIGPASR.S + ICAT-C (C) 
769.04 19 R.NTGIICTIGPASR.S + ICAT-C:13C(9) (C) 
770.65 24 R.NTGIICTIGPASR.S + ICAT-C:13C(9) (C) 
1697.83 18 R.DTGNLYCTGRVDR.E + ICAT-C (C) Desmocollin-2 precursor 
1706.06 1 R.DTGNLYCTGRVDR.E + ICAT-C:13C(9) (C) 18
992.22 1 K.NLFEDQNTLTSICEK.V + ICAT-C (C) Exportin-2 
997.05 17 K.NLFEDQNTLTSICEK.V + ICAT-C:13C(9) (C) 17  
Table 5.2 Peptide pairs (light/heavy) identified from band 3, showing the ion scores, 
protein matches and protein scores. Protein matches with high protein scores 
indicating true matches are in red. 
 





m/z Ion score Peptide Protein / protein score
609,18 2 K.ILDDICVAK.A + ICAT-C (C) Lysyl-tRNA synthetase 
613,49 20 K.ILDDICVAK.A + ICAT-C:13C(9) (C) 0
933,35 21 K.EICNAYTELNDPVR.Q + ICAT-C (C) 
937,52 7 K.EICNAYTELNDPVR.Q + ICAT-C:13C(9) (C) 
752,77 14 R.TLIQNCGASTIR.L + ICAT-C (C) T-complex protein 1 subunit gamma
758,00 3 R.TLIQNCGASTIR.L + ICAT-C:13C(9) (C) 0
800,72 20 K.IPGGIIEDSCVLR.G + ICAT-C (C) 
804,41 9 K.IPGGIIEDSCVLR.G + ICAT-C:13C(9) (C) 
752,33 21 R.LEDLVCDVVDR.V + ICAT-C (C) Asparaginyl-tRNA synthetase, cytoplasmic
756,54 14 R.LEDLVCDVVDR.V + ICAT-C:13C(9) (C) 0
828,55 11 R.VLVVGAGGIGCELLK.N + ICAT-C (C) SUMO-activating enzyme subunit 2
832,86 17 R.VLVVGAGGIGCELLK.N + ICAT-C:13C(9) (C) 0
728,79 3 R.GLGLSPDLVVCR.C + ICAT-C (C) CTP synthase 1
732,71 10 R.GLGLSPDLVVCR.C + ICAT-C:13C(9) (C) 0
880,56 12 R.VFANAPDSACVIGLR.K + ICAT-C (C) 6-phosphofructokinase, liver type
884,88 12 R.VFANAPDSACVIGLR.K + ICAT-C:13C(9) (C) 0
885,99 10 R.VFANAPDSACVIGLR.K + ICAT-C:13C(9) (C) 
585,21 15 QDQVCIAR + ICAT-C:13C(9) (C) G1 to S phase transition protein 1 homolog
580,09 10 QDQVCIAR + ICAT-C (C) 0
634,80 14 ALENDPDCR + ICAT-C:13C(9) (C) Plastin-2
631,96 4 ALENDPDCR + ICAT-C (C) 0
710,54 11 VIGSGCNLDSAR + ICAT-C (C) L-lactate dehydrogenase A chain
715,94 9 VIGSGCNLDSAR  + ICAT-C:13C(9) (C) 0
805,39 11 SCYDLSCHAR + 2 ICAT-C (C) Glycyl-tRNA synthetase
814,10 4 SCYDLSCHAR + 2 ICAT-C:13C(9) (C) 0
759,23 8 VVVCNLYPFVK + ICAT-C:13C(9) (C) Bifunctional purine biosynthesis protein PURH
755,93 8 VVVCNLYPFVK + ICAT-C (C) 0
591,67 5 ALCADLSPR + ICAT-C:13C(9) (C) Xaa-Pro aminopeptidase 1
588,58 0 ALCADLSPR + ICAT-C (C) 0
854,34 5 YAAMLSCLDEAIHNVTLALKR + ICAT-C (C) Arylsulfatase J precursor
857,26 2 YAAMLSCLDEAIHNVTLALKR + ICAT-C:13C(9) (C) 0
1417,70 4 IGTLLDAIICR + ICAT-C (C) TP53RK-binding protein
1426,75 2 IGTLLDAIICR + ICAT-C:13C(9) (C) 0
627,27 3 CENCGKK + 2 ICAT-C:13C(9) (C) PR domain zinc finger protein 5
619,46 1 CENCGKK + 2 ICAT-C (C) 0
573,44 3 TYGGCEGPDAMYVK + ICAT-C (C) Transcription elongation factor B polypeptide 1
577,42 3 TYGGCEGPDAMYVK + ICAT-C:13C(9) (C) 0
437,64 0 GCLGVGDNALR + ICAT-C:13C(9) (C) F-box/LRR-repeat protein 20
434,16 0 GCLGVGDNALR + ICAT-C (C) 0  
Table 5.3 Peptide pairs (light/heavy) identified from band 3 with a protein score of 0, 











pairs ID'd Ratio H/L
Heat shock protein HSP 90-beta 53 6 2.2
Heat shock cognate 71 kDa protein 52 1 0.6
Heat shock protein HSP 90-alpha 46 3 1.0
Glyceraldehyde-3-phosphate dehydrogenase 34 3 1.2
Elongation factor 2 32 7 0.9
Transitional endoplasmic reticulum ATPase 29 4 0.8
Bifunctional aminoacyl-tRNA synthetase 22 1 0.8
Aminopeptidase B 22 1 1.2
ATP-dependent RNA helicase DDX1 21 1 0.9
Arginyl-tRNA synthetase, cytoplasmic 20 2 0.8
Annexin A6 19 1 2.0
Pyruvate kinase isozymes M1/M2 19 6 1.2
Desmocollin-2 precursor 18 1 1.5
Exportin-2 17 1 0.9
Lysyl-tRNA synthetase 0 2 1.0
T-complex protein 1 subunit gamma 0 2 0.9
Asparaginyl-tRNA synthetase, cytoplasmic 0 1 1.3
SUMO-activating enzyme subunit 2 0 1 0.9
CTP synthase 1 0 1 0.9
6-phosphofructokinase, liver type 0 2 0.9
G1 to S phase transition protein 1 homolog 0 1 1.3
Plastin-2 0 1 0.7
L-lactate dehydrogenase A chain 0 1 2.0
Glycyl-tRNA synthetase 0 1 0.8
Bifunctional purine biosynthesis protein PURH 0 1 2.0
Xaa-Pro aminopeptidase 1 0 1 1.3
Arylsulfatase J precursor 0 1 1.1
TP53RK-binding protein 0 1 1.5
PR domain zinc finger protein 5 0 1 5.7
Transcription elongation factor B polypeptide 1 0 1 3.0
F-box/LRR-repeat protein 20 0 1 2.2  
 
Table 5.4 Ratios of proteins from Int9 (H) and MHV-76 (L) infected NS0 cells, from 
band 3. Ratios with differences of at least 0.4 are indicated in red. Protein matches with 
high protein scores are in red, while proteins with lower protein scores are in green, 
and proteins with a protein score of 0 are in black.  
 







m/z Ion score Intenstity Ratio H/L
492.11 6 5.33E+04 K.FENLCK.L + ICAT-C (C) 
495.11 7 3.04E+04 0.6 K.FENLCK.L + ICAT-C:13C(9) (C) 
590.23 10 2.13E+04 K.AKFENLCK.L + ICAT-C (C)
594.79 9 1.77E+05 8.3 K.AKFENLCK.L + ICAT-C:13C(9) (C)
596.00 6 2.16E+04 1.0 K.AKFENLCK.L + ICAT-C:13C(9) (C)
720.75 6 1.34E+05 K.CLELFSELAEDKENYK.K + ICAT-C (C) 
723.55 2 2.55E+05 1.9 K.CLELFSELAEDKENYK.K + ICAT-C:13C(9) (C) 
763.46 35 3.11E+05 K.CLELFSELAEDKENYKK.F + ICAT-C (C) 
767.04 28 1.22E+05 0.4 K.CLELFSELAEDKENYKK.F + ICAT-C:13C(9) (C) 
1147.98 18 8.47E+04 0.9 K.CLELFSELAEDKENYKK.F + ICAT-C:13C(9) (C) 
1144.64 35 9.89E+04 K.CLELFSELAEDKENYKK.F + ICAT-C (C) 
Heat shock protein HSP 90-beta 
 
 
Table 5.5 Rations of individual peptide pairs of heat shock protein 90-beta. Ratios with 
a difference of 0.4 or more are shown in red.  
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0.9, indicating that there was no real difference in protein levels between the 
samples. Hsp90 is a molecular chaperone and is one of the most abundant proteins in 
the cell. It is present in two isoforms (alpha and beta) and is a multifunctional protein 
involved in protein folding, degradation, and transportation, as well as signalling, and 
histone assembly, among other functions (reviewed in Csermely et al. 1998). HSP90 
is induced during stress, such as virus infection, and has been shown to be necessary 
for the replication of some viruses, such as HSV-1 (Burch and Weller 2005; Li et al. 
2004). Hsp90-β was identified as a possible vtRNA1 binding protein in an EMSA 
assay, but was thought to be a contaminant (Cliffe 2005).  
Two proteins with low protein scores had differences of more than 0.4. Annexin A6 
is a cytosolic protein that interacts with cell-membrane components (reviewed in 
Moss and Morgan 2004) and Desmocollin-2 is a transmembrane glycoprotein 
involved in cell adhesion and possibly other processes such as tumorigenesis and 
signal transduction (reviewed in Dusek et al. 2007).  
The LC-MS/MS results were also used to search against virus proteins; however, the 
only proteins identified had peptides with very low ion scores (results not shown) 
and were of no relevance to MHV-68.  
Subsequently, bands 1, 2, 4, 5, 7, 9, and 11 were processed. The LC-MS/MS analysis 
only identified three proteins with significant scores and two with low scores  
(Table 5.6). The MALDI analysis showed that there were few peptides present 
following the extraction and that those peptides were lost during the assay (data not 
shown). The reason for this is unknown, perhaps the trypsin digestion or the 
extraction of peptides from the gel bands did not work, or maybe the avidin column 
was no longer binding the labelled peptides sufficiently. 
One protein, Alpha-enolase, with a low protein score had a heavy to light ration of 
2.0, indicating that Int9 infected NS0 cells expressed more of this protein.  
Alpha-enolase, a multifunctional glycolytic enzyme, is one of the most abundant 
cytosolic proteins (reviewed in Pancholi 2001).  
Fractionation of the peptide sample by 1-D PAGE improved the sensitivity of the 
cICAT method and many light/heavy peptide pairs were identified. However, only  









pairs ID'd Ratio H/L
Fructose-bisphosphate aldolase A 37 2 0.8
Triosephosphate isomerase 32 4 0.7
Pyruvate kinase isozymes M1/M2 55 2 1.0
Beta-enolase/Alpha-enolase 25 2 1.2
Alpha-enolase 25 1 2.0
Glyceraldehyde-3-phosphate dehydrogenase 0 1 0.7
Adenosine kinase 0 1 1.1
14-3-3 protein theta 0 1 1.0
GTP-binding nuclear protein Ran 0 1 2.0
14-3-3 protein zeta/delta 0 1 0.8
DNA-(apurinic or apyrimidinic site) lyase 2 0 1 0.9
FAST kinase domain-containing protein 3 0 1 2.9
Elongation factor 2 0 1 0.8
Heat shock 70 kDa protein 4 0 1 0.8
Tubulin beta-2A chain 0 1 1.0
FK506-binding protein 4 0 1 0.7
Delta-aminolevulinic acid dehydratase 0 1 5.7
Eukaryotic initiation factor 4A-II 0 1 1.0
Short transient receptor potential channel 4 0 1 0.6
Actin-binding protein anillin 0 1 0.9  
Table 5.6 Ratios of proteins from Int9 (H) and MHV-76 (L) infected NS0 cells from, 
bands 1, 2, 4, 5, 7, 9, and 11. Ratios with differences of at least 0.4 are indicated in red. 
Protein matches with high protein scores are in red, while proteins with lower protein 
scores are in green, and proteins with a protein score of 0 are in black.  
A 
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the most abundant proteins were identified, indicating that the sample was still too 
complex and that a different fractionation method might be needed.  
5.4. Discussion 
In this chapter we aimed to analyse the functions of the non-coding RNAs by 
investigating the differences in protein expression between MHV-76 and Int9 
infected NS0 cells using the cICAT assay. This method tags the cysteine containing 
proteins and enables comparison of the levels of individual proteins in two samples. 
The cICAT and 1-D PAGE cICAT techniques have been used, for example, to 
identify biomarkers for chronic lymphocyteic leukaemia (CLL) and brain tumours, as 
well as protein changes following saline stress of yeast cells (Barnidge et al. 2005; 
Khwaja et al. 2007; Li et al. 2003). cICAT analysis of cytosolic and membrane 
protein fractions of B cells from patients with mutated or unmutated CLL identified 
nine cytosolic and four membrane proteins that had a 3-fold or greater difference in 
expression (Barnidge et al. 2005). A subset of these was confirmed by western blot 
analysis. Khwaja et al. identified 53 proteins that were differentially expressed by 
more than 1.1 or less than 0.9 when analysing cerebrospinal fluid from patients with 
two different grades of glioma and normal controls using cICAT (Khwaja et al. 
2007). Li et al. used the 1-D PAGE cICAT method to analyse protein expression 
profiles in yeast cells following saline stress. They identified over 560 proteins, 51 of 
which showed more than 2-fold difference in expression (Li et al. 2003). These 
studies show that the cICAT method is a good technique to identify changes in 
protein expression during different conditions.  
Other techniques to examine protein differences include 2D gels, SILAC and 
ITRAQ. SILAC and ITRAQ are similar methods to ICAT. In ITRAQ the N-termini 
of trypsin digested peptides are labelled with a tag. Fragmentation of this tag during 
MS/MS analysis creates a reporter ion with which the peptide abundance can be 
determined. During SILAC the cells are grown in culture with normal growth 
medium or growth medium containing a heavy amino acid that is incorporated into 
the proteins. These techniques may be better than the cICAT method; however, the 
facilities needed for these techniques were not available to us. The cICAT method 
was chosen over 2D gels since it provides a more quantitative assay. A limitation of 
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the cICAT assay is that only the cysteines are labelled; however, the advantage is 
that the biotin tag enables purification of the labelled peptides, producing a less 
complex sample. 
The initial experiment labelling BSA with light cICAT reagent worked well, with 
several labelled BSA peptides identified manually and BSA correctly identified both 
by MALDI and LC-MS/MS. The analysis of cytosolic proteins from MHV-76 and 
Int9 infected NS0 cells proved more problematic. In the first experiment only two 
proteins were identified, even though there were a large number of proteins in the 
cytosolic samples, albeit at low concentration, as shown by SDS-PAGE. It was found 
that the proteins were lost during the acetone precipitation.  
The experiment was therefore repeated using a more crude cytoplasmic protein 
extraction that yielded higher protein concentrations and Vivaspins to concentrate the 
sample instead of acetone precipitation. This time six proteins were identified in the 
LC-MS/MS analysis of the labelled peptides, four with peptides labelled with light 
and heavy cICAT reagents. The long vacuum drying steps were found to be a source 
of peptide loss and the experiment was therefore repeated using freeze-drying to 
minimise the use of the vacuum dryer. The peptides were no longer lost during the 
cICAT assay and several proteins were identified; however, not many light/heavy 
peptide pairs. The proteins identified are very abundant in the cell and after solving 
the problem of loss of proteins and peptides via acetone precipitation and vacuum 
drying, it became clear that the sample was too complex.  
To fractionate the sample and make it less complex, cytosolic proteins produced with 
the initial fractionation kit were labelled using the 1-D PAGE cICAT protocol, which 
fractionates the protein sample. This technique introduced more vacuum drying 
steps, which had proved to be a problem earlier. In addition, testing with BSA 
showed that the peptides were lost during the extraction procedure. The 1-D PAGE 
cICAT protocol was therefore tested with BSA labelled with light cICAT reagent, 
using ZipTips to concentrate the sample where possible and only performing the first 
step of the peptide extraction. The analysis generated several peptide peaks that 
could manually be identified as BSA peptides labelled with light cICAT reagent 
showing that the adapted method was working.  
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The final experiment utilised all the optimisations that had been performed. The 
initial band to be processed, band 3, generated several peptide pairs, but only three 
protein matches considered significant and 11 with protein scores above zero. The 
protein scores are calculated from the peptide scores, which are calculated to give the 
probability that the peptide match is a random event, based on the quality and 
number of fragment ions present in the MS/MS spectra.  
The average ratio of Hsp90-β was 2.2, indicating that Int9 infected NS0 cells 
produced more of this protein; however, the individual peptide pair ratios were 
inconsistent. It is possible that this protein is continuously identified because of its 
abundance in the cell. However, since Hsp90 has been found to be important for 
virus replication of e.g. HSV-1 and influenza A by interactions with the viral 
polymerases (Burch and Weller 2005; Chase et al. 2008; Li et al. 2004) and the fact 
that Hsp90-β was identified as a possible vtRNA1 interacting protein (Cliffe 2005), it 
is still an interesting protein. This could be further analyse by examining the  
Hsp90-β protein levels by western blot and possibly using Hsp90-β inhibitors such 
as Geldanamycin to examine the effect on Int9 infected NS0 cells.  
It is not clear what functions the other proteins that appear to be up-regulated in the 
presence of the non-coding RNAs, Annexin A6 and Desmocollin-2, may have during 
virus infection. Annexin A6 is a cytosolic protein that interacts with cell-membrane 
components (reviewed in Moss and Morgan 2004) and Desmocollin-2 is a 
transmembrane glycoprotein involved in cell adhesion (reviewed in Dusek et al. 
2007). The levels of these proteins would need to be confirmed by western blot 
analysis.  
The other bands analysed did not generate as many protein matches as expected. The 
reason for this is not known, but is possible that the trypsin digestion or avidin 
column were not functioning properly. Due to time constraints, this could not be 
examined further. Three proteins with protein scores considered significant were 
identified and two with lower protein scores. One of these, Alpha-enolase, a 
glycolytic enzyme, had a ratio of 2.0 indicating that the introduction of the  
non-coding RNAs led to an increase of this protein; however, this would need to be 
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confirmed by western blot analysis. Again, this protein is one of the most abundant 
in the cytosol and it is not know for what purpose it would be up-regulated.  
In this study we set out to identify differences in protein expression with and without 
the presence of the non-coding RNAs. The cICAT protocol was optimised and the  
1-D PAGE cICAT protocol subsequently optimised and used. However, the assay 
did not generate many protein matches, making it difficult to draw any conclusions 
from the data. The reason for this is not know, but it is possible that the protein 
samples were still too complex, since only the most abundant proteins were 
identified. An option would be to fractionate the sample using a cation-exchange 
column, which would generate fewer proteins in each sample and enhanced 
sensitivity. The amount of protein that is fractionated in the 1-D PAGE cICAT assay 
is limited to the amount and volume that can be loaded in the gel lane.  
As seen in this study, there are many steps in the cICAT assay at which peptides can 
be lost and the assay is dependent on the equipment that is available. The technique 
had not previously been used in the Edinburgh Protein Interaction Centre mass 
spectrometry facility and although considerable progress was made, because of time 
constraints it was not possible to achieve the aims which had been set out.  
Any difference in protein levels between MHV-76 and Int9 infected cells could be 
because of the vtRNAs and/or the miRNAs. During the time this study was 
performed, the effect of miRNAs on protein levels have usually been found to be 
quite low, with often no more than 50% and sometimes less than 30%  
down-regulation observed (Bartel 2009). This small difference in protein expression 
may be difficult to observe using a technique to examine global protein expression; 
however it has been done. Baek et al. 2008 used SILAC to find that hundreds of 
proteins are down-regulated by individual miRNAs, most with low levels of  
down-regulation. This and the fact that uncharged tRNAs and other viral non-coding 
RNAs have an effect on protein expression, warrants further analysis of changes in 
global protein levels; perhaps by including a cation-exchange column in the cICAT 
protocol to fractionate the sample, or using the ITRAQ or SILAC methods, taking 
the samples to a laboratory where these techniques are in regular use.  
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An alternative to examining global protein levels would be to examine mRNA levels 
using microarrays; however, miRNAs often do not affect the mRNA levels of the 
proteins they target. It would still be worth performing microarrays to compare 
mRNA levels of MHV-76 and Int9 infected NS0 cells, since the vtRNAs may have 
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In this study we utilised insertion viruses to investigate the functions of the  
non-coding RNAs of MHV-68, by examining growth properties and differences in 
protein expression in latently infected NS0 cells. These viruses had been made 
through recombination of the deletant virus MHV-76 and a plasmid containing five 
of the vtRNAs and six of the miRNAs, resulting in two insertion viruses with the 
only difference to MHV-76 and the revertant virus being these non-coding RNAs. 
The insertion viruses had been found to act indistinguishably to MHV-76 during  
in vivo infection, with increased clearance and low levels of latency in the spleen 
compared to MHV-68. Therefore, we sought to investigate the functions of the  
non-coding RNAs during latent infection in vitro.  
Initially, infection of the NS0 cells was investigated to ensure that this provided a 
suitable model for latency in vitro. The NS0 cell line is a murine myeloma B cell line 
that has been shown to support persistent infection (Sunil-Chandra et al. 1993). All 
viruses were found to infect close to 100% of the NS0 cells following infection for 
five days at a MOI of 5. In addition, MHV-68 infected NS0 cells expressed the 
vtRNAs and miRNAs during latent infection of NS0 cells, as in S11 cells. This 
showed that infection of NS0s provided a suitable model for latent infection. By 
examining the expression of the non-coding RNAs we also showed that MHV-68 
expresses the miRNAs during lytic infection, which had not been confirmed at that 
point. We were surprised to find that the insertion viruses expressed miRNA1 at very 
low levels during latent infection, even though it was expressed during lytic 
infection. In addition, the other miRNAs were expressed at lower levels than by 
MHV-68. The reason for this is not known, but possible explanations include: that 
promoter elements needed during latent infection are missing, the non-coding RNAs 
affect the virus copy numbers, or the unique genes are needed for efficient 
expression of the non-coding RNAs.  
The levels of expression of the vtRNAs during latent infection, as well as vtRNAs 
and miRNAs during lytic infection by the insertion viruses are not known. It would 
be interesting to examine this further, as it may help to explain the lower levels of 
miRNA expression. Since the vtRNAs are expressed on the same transcripts as the 
miRNAs, the levels of the vtRNAs would be expected to be low as well, if the 
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deficiency is at the level of transcription. However, the non-quantitative RT-PCR 
performed for the vtRNAs did not indicate any major differences in expression.  
Despite the lack of miRNA1 expression and the lower expression of the other 
miRNAs, the presence of the vtRNAs and miRNAs led to a decrease in reactivation 
and production of lytic virus. The decrease in reactivation could be seen both by 
stressing the infected cells to reactivate by infective centres assay, as well as by 
looking at spontaneous reactivation by staining for lytic proteins. The miRNAs alone 
did not seem to be responsible since transfection of miRNA mimics into MHV-76 
infected cells did not affect the reactivation rates, despite achieving higher miRNA 
levels than in insertion virus infected cells. Disruption of the miRNA biogenesis 
through transfection of a siRNA against Dicer did not have an effect either; however, 
the miRNA or Dicer knock-down was not confirmed. Transfections with the plasmid 
used to make the insertion viruses and vtRNAs were inconclusive and further 
experiments would be needed to confirm the role of the vtRNAs, or the co-operation 
between vtRNAs and miRNAs, in viral reactivation.  
It may not be the expression of the vtRNAs, but the presence of the vtRNA genes 
that is causing the reduction in reactivation. tRNA genes have been shown to 
regulate gene expression by affecting the chromatin organisation. In budding and 
fission yeast, tRNA genes have been found to act as chromatin barriers that limit the 
spread of heterochromatin into transcriptionally active regions (Biswas et al. 2009; 
Donze et al. 1999; Donze and Kamakaka 2001; Scott et al. 2006; Scott et al. 2007; 
Simms et al. 2004) and have also been shown to block enhancers or silencers from 
affecting promoters of nearby genes (Bolton and Boeke 2003; Hull et al. 1994). The 
functions of these tRNA genes are dependent on the ability of the gene to be 
transcribed; however, ectopic B-box elements not linked to functional polymerase III 
genes have also been found to act as chromatin barriers (reviewed in McFarlane and 
Whitehall 2009). In mammals SINES, believed to derive from tRNAs and containing 
B-box elements, are thought to have a similar role; an example of this is an Alu SINE 
element in transgenic mice that protects neighbouring reporter genes from 
transcriptional interference (Willoughby et al. 2000). It is not clear how the tRNA 
genes and B-box elements exert their barrier function. 
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The vtRNA genes could be acting in a similar manner to keep the area active during 
latency by acting as chromatin barriers or blocking enhancers or silencers of nearby 
genes, perhaps to regulate the transcription of the miRNAs or the unique genes. M1, 
for example, is likely to have promoter or enhancer sequences among the vtRNA 
genes (pers commun Bernadette M. Dutia). However, since the insertion viruses do 
not contain the unique genes and the miRNAs alone were found to have no effect on 
viral reactivation, these could not be the cause of the reduction in reactivation seen.  
It may be that there are sequences in the left end region that act as enhancers or 
promoters for other viral genes that may affect the reactivation, such as genes on the 
other side of the terminal repeats, since the genome circularises. In EBV LMP2 
initiates at the right end of the genome and stretches across the terminal repeats into 
the left end (Laux et al. 1988), while in KSHV, K1 and K15 both have promoter 
sequences in the terminal repeats (Bowser et al. 2002; Wong and Damania 2006). 
ORF73, whose product is essential for the establishment of latency, is known to have 
its transcription initiation site in the terminal repeats (Coleman et al. 2005), that 
perhaps is kept active due to the presence of the vtRNA genes. It would be 
interesting to examine the levels of ORF73 transcription to see if it is up-regulated in 
Int9 infected cells, as this could explain the decrease in reactivation. It is possible 
that in MHV-68 one or more of the unique genes or perhaps miRNAs act to limit 
ORF73 transcription, allowing reactivation. To investigate the possibility of the 
vtRNAs as chromatin barriers, one or more cellular tRNA genes could be inserted in 
the left-end of MHV-76 to examine if this also leads to a reduction in reactivation.  
Chromatin barriers are used in other herpesviruses to keep transcription of latency 
associated transcripts active during latency. HSV-1 has insulator-like elements  
up-stream and in the intron of the non-coding RNA LAT, that maintain chromatin 
boundaries, keeping heterochromatin (silencing) out and euchromatin (active) in. 
LAT also promotes heterochromatin on lytic promoters, which leads to lytic gene 
silencing during latency (Cliffe et al. 2009a; Wang et al. 2005b). Cellular non-coding 
RNAs have also been found to promote chromatin silencing, through recruitment of 
the Polycomb repressive complex 2 (PRC2) that methylates Lys 27 on histone H3 
(H3K27) leading to silencing. Examples of these include: RepA that is involved in  
X-chromosome inactivation, the HOX non-coding RNA HOTAIR which represses 
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transcription of the HOXD locus of transcription factors important during early 
embryonic development, and Kcnq1ot1 that confers lineage-specific silencing of the 
Kcnq1 cluster of potassium channel proteins (Pandey et al. 2008; Rinn et al. 2007; 
Zhao et al. 2008).  
Although the vtRNAs localise mainly in the cytoplasm, as seen by in situ 
hybridisations (see Chapter 3 and (Cliffe 2005), dot-blot analysis showed that 18% of 
the vtRNAs localise in the nucleoplasm during lytic infection and 19% during latent 
infection (Cliffe 2005). In addition, vtRNA1 was shown by EMSA to bind Jmjdla, a 
mouse protein of unknown function (Cliffe 2005), which has a jmjC domain. 
Proteins with jmjC domains have been found to be involved in modulation of 
heterochromatin by demethylating histones, such as H3K36, H3K9, H3K4 and 
H3K27 (reviewed in Klose and Zhang 2007; Swigut and Wysocka 2007). vtRNA1 
could act by inhibiting the demethylation activity of Jmjdla or recruiting the protein 
to promote histone demethylation. The vtRNAs may also have a function in 
recruiting chromatin modifying complexes, such as PRC2, and this could be further 
investigated by RNA immunoprecipitation. It may also be of interest to investigate 
the differences in chromatin contents on MHV-68, MHV-76 and insertion virus 
genomes by chromatin immunoprecipitations (ChIPs) to determine if there is a 
difference in the structure of the chromatin with or without the vtRNAs. 
The presence of five vtRNAs and six miRNAs led to a low level of reactivation 
(insertion viruses), while the presence of all non-coding RNAs as well as the four 
unique genes led to a higher rate of reactivation (MHV-68); however, not as high as 
the lack of all non-coding RNAs and the four unique genes (MHV-76). A possible 
explanation for this is that the non-coding RNAs and the unique genes co-operate to 
keep the virus latent and to keep the level of reactivation low enough to evade the 
immune response, but high enough to enable low level replication and spread of the 
viruses to permit long-term latency. The non-coding RNAs suppress reactivation, 
while the unique genes act to both suppress (M1) and promote (M2) reactivation 
(Clambey et al. 2000; Evans et al. 2008; Herskowitz et al. 2005; Jacoby et al. 2002). 
Without any of these genes the virus reactivates at much higher level.  
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The effect of the non-coding RNAs on protein expression could not be determined 
using the cICAT method. Despite thorough optimisation the protein samples were 
found to be too complex to detect anything but the most abundant proteins. Further 
experiments are needed to look at the differences in protein expression; however, the 
effects of the miRNAs on the protein levels may be difficult to examine, due to the 
low level of down-regulation. The fact that vtRNA1 has been found to bind to 
proteins (Cliffe 2005), as well as the functions of uncharged tRNAs and other viral 
non-coding RNAs, supports further investigation into differences in protein 
expression.  
Uncharged tRNAs as a result of amino acid starvation are involved in regulation of 
protein expression in both eukaryotic and prokaryotic cells. In bacteria binding of an 
uncharged tRNA to the ribosome stalls translation leading to lowering of the cell’s 
metabolism and over-expression of genes involved in amino acid synthesis  
(Jain et al. 2006). In addition, in gram-positive bacteria aminoacyl-tRNA synthetase 
genes and genes involved in amino acid synthesis contain T boxes to which specific 
tRNAs bind leading to termination of transcription. However, binding of an 
uncharged tRNA leads to stabilisation of an anti-terminator allowing transcription to 
proceed (Green et al. 2010). It is possible that the vtRNAs have evolved a similar 
mechanism in regulating viral genes.  
In eukaryotic cells uncharged tRNAs activate GCN2 which phosphorylates and 
inactivates eIF2, resulting in reduction in global protein synthesis, activation of 
amino acid biosynthesis genes and genes encoding aminoacyl-tRNA synthetases, and 
in mammals also regulation of gene expression at different levels (Harding et al. 
2000; Hinnebusch 2005; Jiang et al. 2004; Kilberg et al. 2005; Wek et al. 1995; 
Zhou et al. 2008). There is no evidence that the vtRNAs would function to  
down-regulate global cellular protein synthesis. Cytoplasmic protein extracts from 
MHV-76 and Int9 infected NS0 cells separated on a SDS-PAGE gel look very 
similar, with mainly the same protein bands present. Further experiments are needed 
to confirm this. 
Several viral non-coding RNAs regulate protein synthesis. The LATs reduce the 
transcription of lytic genes (Chen et al. 1997; Garber et al. 1997); the EBERs and 
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VAI prevent virus induced inhibition of protein synthesis by inhibiting PKR 
activation (Clarke et al. 1991) (Kitajewski et al. 1986; O'Malley et al. 1986); and the 
HSURs up-regulate genes associated with T-cell activation (Cook et al. 2004; Cook 
et al. 2005). 
If the vtRNAs work as chromatin barriers this would also affect the protein and 
mRNA levels. Taking all this in, the vtRNAs may have an effect on protein and/or 
mRNA levels, and it would be of interest to further examine the differences in 
protein and mRNA levels of cells infected with insertion virus and MHV-76. This 
could be done by including a cation-exchange column in the cICAT method to 
fractionate the sample, or by using ITRAQ or SILAC to examine changes in protein 
expression, and micro arrays to examine differences in mRNA levels.  
The fact that the vtRNAs are selectively packaged in the virion suggests that the 
vtRNAs are needed either in the virion particle or immediately following infection of 
the cell, perhaps regulating cellular or viral protein synthesis. It is not known if the 
miRNAs are packaged in the virion as well. 
The miRNAs did not seem to be involved in the reduction in reactivation; however, 
by comparison to other viral miRNAs, they are likely to target viral and/or cellular 
proteins such as viral proteins that are targets of the host immune response, viral 
gene regulators, regulators of apoptosis, or immunomodulators (Choy et al. 2008; 
Stern-Ginossar et al. 2007; Sullivan et al. 2005; Umbach et al. 2008). miRNA1 has a 
possible target site in the 3’UTR of ORF50, and this needs to be further investigated. 
This could be done by examining rta protein levels by western blot analysis 
following transfection of miRNA1 into MHV-76 infected NS0 cells; however, at 
present there is no antibody available to the rta. An alternative would be to transfect 
cells with a plasmid expressing the FLAG-tagged rta, and then miRNA1, to 
investigate if the rta is down-regulated by miRNA1. 
The adenovirus non-coding RNAs, VAs, share several features with the vtRNAs; 
they are transcribed by RNA polymerase III and encode miRNAs. The VAs inhibit 
the processing of cellular miRNAs by out-competing binding to the Exportin-5 
nuclear export factor and Dicer (Andersson et al. 2005; Lu and Cullen 2004). It is not 
known if the vtRNA/miRNA transcripts could have a similar effect in competing 
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with cellular miRNAs for export and processing. It is also possible that other  
non-coding RNAs may give rise to miRNAs.  
To take the current studies further, the reactivation experiments could be repeated 
with a different MHV-76 stock to see if the same increased reactivation rates seen 
with MHV-76 compared to the revertant virus is still observed. Further, the miRNA 
transfection could be repeated by transfecting revertant infected NS0 cells in stead of 
MHV-76 infected, to ensure that there is still no effect on the reactivation rates. To 
ensure that the miRNAs do not have an affect on the reactivation, the siRNA against 
Dicer transfection should be repeated and the levels of Dicer knock-down examined 
by western blot analysis and the levels of miRNAs by qRT-PCR.  
The current study shows that the presence of the non-coding RNAs in MHV-76 leads 
to a reduction in reactivation. The miRNAs alone do not have an affect on viral 
reactivation in this context; however, further studies are needed to determine the 
mechanism. To accomplish this it would be useful to examine if it is the expression 
or presence of the vtRNA genes that causes the reduction in latency, or if the 
vtRNAs and miRNAs co-operate. Virus constructs with mutations in the miRNA 
seed region in the MHV-68 genome and insertion of other tRNA genes or only one 
of the vtRNA/miRNA transcripts into the left end of MHV-76 may help to answer 
some of these questions.  
In addition the functions of the vtRNAs will need to be investigated. Previous studies 
have shown that the vtRNAs interact with proteins and it would be interesting to 
investigate if the vtRNAs bind specific proteins such as PKR, exportin-5, Dicer, or 
PRC2, as well as looking at changes in protein and mRNA levels in the presence of 
the vtRNAs. It may also be of interest to examine if the vtRNAs bind other RNAs.  
To determine the function of the miRNAs it may be useful to examine what mRNAs 
they interact with through RISC pull-down assays. It is not known how the 
vtRNA/miRNA transcripts are processed and if Drosha and Dicer are involved and 
this needs to be further investigated.  
Further investigation into the processing and functions of the vtRNAs and miRNAs 
may give an insight into not just viral non-coding RNAs but also cellular non-coding 
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8. Appendix 






Figure 8.1 qRT-PCR dissociation curves for miRNA1-6 on RNA from mock (blue) and 



































































































































Figure 8.2 qRT-PCR dissociation curves for miRNA expression by MHV-68 (red), Int9 
(green) and Int2 (grey) viruses and in mock-infected cells (blue). Showing miRNA1, 3, 
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